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 Overview of the project 
Vaccines have been vital candidate against infectious diseases, and over the past one 
hundred years have saved millions of lives. The main types of vaccines available to date are 
subunit, live attenuated, inactivated, conjugate, toxoid and recombinant DNA based 
vaccines (Tiwle 2014). While effective, each has their own inherent limitations. For example, 
subunit vaccines cannot induce long term immunity, whereas live, attenuated and 
inactivated vaccines can have a limited target range (Abhishek et al., 2016). High production 
costs make recombinant vector based vaccines unavailable to poor economies (Nascimento 
et al., 2012). Toxoid vaccines need multiple doses with adjuvants and also cause strong local 
reactions (Baxter 2007). Even though DNA vaccines have the disadvantage of being limited 
to protein antigens, they offer long term immunity inducing all arms of the immune 
responses (Khan 2013). Most DNA vaccines are effective in eliciting immune responses 
without any side effects. The main criterion for a successful DNA vaccine is to have an 
efficient delivery system which can deliver it safely to the target cells. There are several 
successful delivery systems available for DNA vaccines; however no standard system is in 
place. For vaccine trials and effective DNA vaccination, targeting antigen presenting cells 
would be important. There is an increasing demand for novel DNA vaccine delivery systems, 
mainly for the non-viral type as they are considered relatively safe. Therefore, in this proof 
of concept study two novel delivery systems 1) Solid Lipid Nanoparticles (SLNs) and 2) yeast 
transposon virus like particles (Ty-VLPs) were chosen to study their potential to carry DNA 
vaccines in vitro to dendritic cells using eGFP plasmid as the reporter plasmid. Positively 
charged SLNs were synthesised by modified solvent-emulsification method and conjugated 
XXXIII 
 
with plasmid DNA to form complexes (DNA-SLN complexes). The integrity of these 
complexes was confirmed by various agarose gel based assays. The SLN/DNA complexes 
were transfected into DC2.4 cells and analysed by flow cytometry for GFP expression. It was 
shown that there is a 10-fold increase in the transfection rate using these complexes in 
DC2.4 cells over plasmid alone and is comparable to that mediated by lipofectamine. On the 
other hand, Ty-VLPs were purified from the recombinant yeast constructed and plasmid 
DNA conjugated with them. The transfection efficiency of these complexes were analysed in 
vitro and was shown to increase compared to plasmid alone. In comparison the SLN system 
was more efficient for plasmid DNA delivery than Ty-VLPs.   
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1.1. Vaccines and their importance 
 
 The main challenge for modern science is to produce vaccines for new and persistent 
diseases. The old quote “prevention is better than cure” implies the benefit of vaccines for 
disease prevention rather than its cure. Production of a vaccine is very challenging as it 
involves the study of a pathogen, understanding the pathogenic factors causing the disease, 
development of a vaccine and finally several phases of clinical trials. This process is very time 
consuming and there is a chance of developing new strains of the pathogen before a vaccine 
is licensed, thus there is a great need for novel vaccine development strategies.  
Several diseases such as polio and measles have been successfully eradicated by vaccines. 
There has been a significant reduction in the prevalence of some infectious and other 
diseases compared to the pre-vaccinated era (Figure 1.1). A significant reduction in the 
number of disease cases due to routine childhood vaccination indicates the importance of 
vaccination in protecting against life-threatening diseases in children (Table 1.1). According to 
a 2016 report by the WHO, the global immunisation coverage for diphtheria, polio, hepatitis-B 
and measles is around 85%. The coverage for pneumococcal and rotaviruses are 31% and 19% 
respectively, which is significantly lower and is likely due to the cost of development and 
distribution of vaccines within economically disadvantaged countries, hence a cost effective 
vaccine needs to be developed to fill this gap. 
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Figure 1. 1. Percentage of decrease in the reported cases of selected dreadful diseases in the 
US due to vaccination by 2013. 
Figure adapted from (Herper 2013).  
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Table 1. 1. Importance of vaccines against diseases. 
Estimated number of illness, deaths and hospitalisations prevented by routine childhood 
immunization schedule among kids born during the Vaccines for children era in the United 
States, 1994-2013 for selected vaccine-preventable diseases 
 
Table adapted from (Haelle 2014) 
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1.2. Brief history of vaccine development 
“Variolation” is an ancient immunisation technique later named as “Vaccine” by Edward 
Jenner. The term “Variolation” was derived from the Latin word inoculare which means “to 
graft”. This involves the application of virus subcutaneously by various means into a non-
immune individual (Riedel 2005). The first report of its application in China can be dated back 
to the 10th century, followed by Turkey, England and later to Europe (Gross et al., 1998) . Even 
though it was practised since ancient ages, Edward Jenner was considered as the inventor of 
vaccination, as he was the first person to delineate the hypothesis and conduct further 
investigation with his attempt (Gross et al., 1998). Because of its huge success in eradicating 
smallpox, interest was aroused in the scientific community to explore research in this area 
and as a result various types of vaccination strategies were developed. The next milestone in 
vaccine history was when Louis Pasteur invented “live attenuated” vaccines for fowl cholera, 
rabies and anthrax (Plotkin et al., 2011). The nineteenth century experienced the heights of 
success in vaccine developments as shown in the Figure 1.2. 
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Table 1. 2. Important dates in the early vaccine development. 
Table obtained from (Gross et al., 1998) with minor modifications 
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Figure 1. 2. Brief timeline of vaccine development from the late 1970s to 2010.  
Figure adapted from (Plotkin et al., 2011). 
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1.3. Typical stages in the development of a vaccine 
The following are the most common steps involved in the production of any type of vaccine. 
1.3.1. Setting of a priority  
The foremost step is to conduct a basic survey of current available vaccines and major disease 
outbreaks with no effective vaccine. The priority can be set based on various factors such as 
health benefits and cost effectiveness using computerised tools. e.g.: (SMART Vaccines)-
“Strategic Multi-Attribute Ranking Tool for Vaccines” (Phelps et al., 2017). 
1.3.2. Conducting basic and applied research  
The basic research involves evaluation of hypotheses and strategies for a vaccines 
development. This is generally conducted by academic and government scientists with federal 
funding. The projects with potentially significant outcome may proceed further with the 
support of the private sector (Medicine et al., 1993). 
1.3.3. Clinical evaluation & Licensing 
Clinical evaluation should be conducted following guidelines provided by bodies such as the 
World Health Organisation (WHO) and US Food and Drug Administration (FDA) for obtaining a 
registered license. The vaccine needs to succeed in phase I, II and III clinical trials following its 
evaluation in laboratory animal models for its safety and protective immunogenicity before 
being licensed (Singh et al., 2016).  
1.3.4. Production & Quality control  
Finally, all licensed vaccines must be produced under strict quality control guidelines. The 
quality of each batch produced should be assured by national regulatory authorities (NRAs) 
prior to public release (WHO guidelines). The QC should conduct a complete set of tests for 
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each batch according to marketing authorisation to maintain consistency in product quality 
and ‘built-in quality’ (Metz et al., 2009). 
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1.4. Types of vaccines  
There are many different types of vaccines available to date and the main types are listed 
below. The schematic representation of vaccine evolution over the years was as shown in the 
Figure 1.3. 
 
 
 
 
Figure 1. 3 Schematic representation of the vaccine evolution in general.  
Figure adapted from (Skwarczynski et al., 2011). 
(A) Traditional vaccines utilising the whole pathogen, (B) protein-based subunit vaccine, and 
(C) subunit vaccine using a peptide.  
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1.4.1. Live attenuated vaccines 
Live attenuated vaccines were developed for both bacterial and viral diseases. They are 
generated by disabling their pathogenicity by insertional mutations or deletions of their 
genome but still allow them to replicate within their host (Lauring et al., 2010). Live 
attenuated vaccines against human viral diseases were considered successful and economic 
interventions in medical history: an example is a smallpox which was declared completely 
eradicated in the 1980s (Minor 2015). Despite the success of the live attenuated vaccines 
against polio, mumps and yellow fever, they caused considerable side effects (Lauring et al., 
2010). Interestingly, a novel reverse genetics based live attenuated vaccine for positive sense 
RNA viruses was developed, in which plasmid DNA encoding full-length RNA of a live 
attenuated virus will be introduced into the body (Pushko et al., 2016). This technique 
demonstrated successful elicitation of protective immune responses for chikungunya virus in 
mice (Tretyakova et al., 2014). The live vaccinia and rotavirus vaccines were licensed by the 
US FDA. However despite their notable success, they have been largely superseded by other 
types of vaccines due to safety implications, as live vaccines have the risk of reversion to a 
pathogenic form and are notpreferable for use in immunocompromised individuals (Strugnell 
et al., 2011). 
1.4.2. Killed/Inactivated vaccines 
The term ‘killed’ and ‘inactivated’ refers to bacteria and virus-based vaccines respectively. 
Both these types of vaccines produce antibodies to a wide range of antigens generated by 
phagocytic mediated internalisation, and is very similar to that of toxoid vaccine generated 
immunity (Baxter 2007).  
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Bacterial inactivation can be performed by various means such as chemical (glutaraldehyde, 
phenol, paraformaldehyde, alcohol, acetone or formalin) or physical (heat and UV) methods. 
The examples of commercially available bacterial and viral inactivated vaccines are whole cell 
pertussis and hepatitis-A virus vaccines (Baxter 2007). The first reported viral inactivated 
vaccine is partially inactivated rabies vaccine produced by Pasteur by culturing in rabbit spinal 
cords (Hoenig 1986). Common methods of viral inactivation involves using formaldehyde (e.g. 
picorna, flavi virus), β-propiolactone (e.g.: inactivated influenza and rabies vaccines) and H2O2 
(Schuitemaker 2015). They have the advantage of being safe and economic, but their 
parenteral administration in some cases result in harmful side effects. Oral administration is 
also not appropriate for an inactivated vaccine to elicit effective immune responses (Pace et 
al., 1998), hence effective route of administration is under investigation. However, inactivated 
influenza viral vaccine was demonstrated to be effective using subcutaneous and intramuscular 
routes of administration compared to that of intranasal administration (Budimir et al., 2013).1.4.3. 
Subunit vaccines  
Unlike attenuated or inactivated vaccines in which the whole pathogen is administered, 
subunit vaccines comprises of minimal antigenic portions of a pathogen resulting in fewer 
side effects (Abhishek et al., 2016). The antigenic portion of the pathogen may include 
polysaccharide, protein or peptide. Polysaccharide vaccines are produced against 
encapsulated bacteria such as Haemophilus influenzae sero group-B (Hib) and S. pnuemoniae 
(Lesinski et al., 2001). However, these formulations had a limited success in eliciting 
protective immune responses in young children, infants and immunocompromised patients 
(Lesinski et al., 2001). As most of the polysaccharides from these encapsulated bacteria are 
thymus-independent type 2 antigens, they induce a very limited antibody production in 
children under 2 years of age (Klouwenberg et al., 2008). Protein based subunit vaccines are 
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generally synthesised by recombinant DNA technology, e.g. Hepatitis-B surface protein 
vaccine (Liljeqvist et al., 1999). They can be delivered in vitro and in vivo by various chemical 
synthetic systems (Allahyari et al., 2016) and naturally synthesised systems, e.g. VLPs 
(Dhanasooraj et al., 2016). Virus-like particles fall into a special class of protein subunit 
vaccines as they contain repeated antigenic subunits and are able to elicit effective immune 
responses. Peptide based subunit vaccines incorporate only the immunogenic epitopes of a 
protein (Skwarczynski et al., 2016) most of which are synthetic. Synthetic peptide vaccines 
have an advantage of utilising computational methods to identify the most immunogenic part 
of the pathogen prior to its synthesis and are considered safe as they lack genetic material of 
the pathogen (Reche et al., 2014). However their delivery to the target site remains 
challenging (Reche et al., 2014). In summary, even though subunit vaccines are considered 
safe, their production is expensive and they require adjuvants for eliciting effective immune 
response.  
1.4.4. Conjugate vaccines 
Conjugate vaccines were introduced mainly to overcome the disadvantages of subunit based 
vaccines. A weakly immunogenic antigen, generally a polysaccharide, will be conjugated to a 
strongly immunogenic protein thereby increasing efficacy of the original antigen. The first 
report of this concept can be dated back to 1929 when Avery & Goebel demonstrated the 
enhancement of an immune response to S. pneumoniae type-3 polysaccharide in conjugation 
with a protein carrier (Avery et al., 1931). The capacity of conjugate vaccines to elicit 
protective immunity in infants is a major advantage over subunit vaccines (Ada et al., 2003). 
However, in case of any adverse side effects from some conjugate vaccines, there would be 
uncertainty over the compound responsible for the adverse reaction (Elliman et al., 2003). An 
example for conjugate vaccine licensed by FDA was Hib vaccine in conjugation with 
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meningococcal protein and tetanus toxoid, which displayed safe overall performance in 
comparison to Hib subunit vaccine (The US FDA, 2017). 
1.4.5. Toxoid vaccines  
Toxoid vaccines are similar to inactivated vaccines in terms of similarity in their preparation 
method. However, the toxoid vaccines involve inactivation of a pure toxin instead of a whole 
organism. They are predominantly used against bacteria which use a toxin as part of their 
pathogenic strategy. The toxoid structure mimics the native toxins, and is able to provoke the 
immune system resulting in protective immune response against toxin from pathogenic 
bacteria. The purified toxins inactivated by formalin treatment results in toxoids which are 
safe to administer into a mammalian system (Clem 2011). However, this treatment may 
change the protein’s native confirmation resulting in low levels of neutralising antibodies 
(Jones et al., 2008). Hence to overcome this, a novel method was developed, in which 
alkylation of toxin can inactivate it but preserve its native structure (Jones et al., 2008). Two 
well-known examples of toxoid vaccines are for tetanus and diphtheria. 
1.4.6. Recombinant vector vaccines 
This live vaccine category includes viruses that infect and transfer their genome to the host 
without causing any pathogenicity. The vector’s genetic material will be engineered by 
excising pathogenic genes and by introducing immunogenic antigen-encoding genes 
(Nascimento et al., 2012). Many types of bacterial and viral vectors have been modified as 
recombinant vector vaccines. The ideal recombinant vector should be non-pathogenic, able to 
receive larger fragments of foreign genes, genetically stable, safe and displaying low intrinsic 
immunity to allow boosters and be easy to produce on a large scale basis (Nascimento et al., 
2012; Souza et al., 2005). Some of the viral-based recombinant vectors include poxvirus, 
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adenovirus, alphavirus, poliovirus and herpes viruses. Most of the viral-based recombinant 
vectors have the capacity to produce antigenic proteins in large amounts eliciting both 
humoral and cellular arms of immune responses, with the ability of the virus to act itself as an 
adjuvant (Souza et al., 2005). Pre-existing immunity to most of these eradicated diseases can 
be a disadvantage. However various routes of immunisation techniques are under 
investigation to overcome this disadvantage. Most important bacterial groups used for 
recombinant vectors construction include lactobacilli, lactococci and salmonella with a 
notable success in animal models (Unnikrishnan et al., 2012).   
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1.5. DNA vaccines 
Even though many different types of vaccines are available, there is a necessity to investigate 
the efficacy of novel technologies. DNA vaccines are an advanced type, regarded as third 
generation vaccines in which plasmid DNA containing antigen-encoding genes are introduced 
into a specific tissue instead of introducing pure recombinant protein into the system. The 
current study utilised two different types of nanoparticles for DNA vaccine delivery. Therefore 
this topic will be discussed in detail as follows. 
1.5.1. Brief history of DNA vaccines 
The first generation of DNA vaccines consisted of plain plasmid constructs without any 
delivery vehicle and was generally delivered into various tissues by direct needle injection 
method during the early years. The first report of using DNA vaccine in vivo can be dated back 
to 1990, when naked plasmid DNA construct containing a reporter gene was directly injected 
into mice skeletal tissue and low amounts of reporter protein expression were observed for 
up to 2 months (Wolff et al., 1990). A stable transformation of plasmid into skin cells of mice 
by electroporation was also demonstrated (Titomirov et al., 1991). A similar approach was 
trialled by injecting a plasmid DNA encoding human growth hormone into mouse skin by gene 
gun and observed the successful production of antibodies (Tang et al., 1992). The prophylactic 
use of plasmid DNA against influenza was attempted by injecting plasmid DNA encoding viral 
antigenic protein directly into quadriceps of mice and immune protection was observed by a 
subsequent challenge (Ulmer et al., 1993). The main limitation of using naked DNA is its 
susceptibility to nuclease digestion and its negative charge reducing its interaction with the 
cell membrane, resulting in low immunogenicity (Al-Dosari et al., 2009). Hence to overcome 
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this limitation, research was focussed on improving various methods to deliver DNA vaccine 
safely to its target site.  
1.5.2. Mechanism of action of DNA vaccines 
Plasmid DNA encoding an immunogenic part of a pathogen can be introduced into somatic 
tissue or directly into antigen presenting cells depending on the targeted disease (Figure 1.4). 
The antigens encoded by a DNA vaccine can directly activate B-cells resulting in antibody 
production, and antigen presenting cells (APCs) can be activated after cross-presentation 
(indirect transfer) of antigens. The processed antigenic peptides will be presented to T cells 
via MHC-I and MHC-II after migrating to the draining lymph nodes (Xu et al., 2014). Thus DNA 
vaccines have the capacity to elicit both arms of the immune response, which is beneficial.  
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Figure 1. 4. Mechanism of action of DNA vaccines.  
Figure obtained from (Xu et al., 2014) with minor modifications. 
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1.5.3. Key barriers of DNA vaccine delivery 
Traditional methods of DNA vaccine delivery mainly involve direct injection of plasmid DNA 
into tissue and in most cases this results in very low transfection efficiency (Barry et al., 1999). 
In order to overcome the low transfection efficiency, various delivery systems were 
developed. The main pathway of DNA vaccine delivery and three important barriers which 
may inhibit delivery of a DNA vaccine through a vector are shown in Figure 1.5. An effective 
delivery system should be able to overcome all of these major barriers. The first important 
step in the successful delivery of a DNA vaccine delivery system is efficient uptake by the cell. 
The uptake of plasmid DNA can be affected by various factors such as size of plasmid DNA, 
charge of complexes and protection of DNA from extracellular nucleases (Jorritsma et al., 
2016). This can be overcome by using a suitable physical, chemical or biological agent 
(Jorritsma et al., 2016). The subsequent step is to release plasmid DNA from complexes in the 
cytoplasm and direct them to the nucleus for transcription, ultimately resulting in antigen 
expression. The released DNA should be stable enough to reach the nucleus without any 
endonuclease digestion (Luo et al., 2000). In order to achieve successful DNA vaccine delivery 
to the target site, an efficient delivery system passing these barriers needs to be developed. 
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Figure 1. 5. Schematic representation of DNA delivery pathway pointing three major 
barriers.  
Figure from (Luo et al., 2000). 
 (A) DNA–complex formation. (B) Uptake. (C) Endocytosis (endosome). (D) Escape from 
endosome. (E) Degradation (within endosome) (F) Intracellular release. (G) Degradation 
(within cytosol) (H) Nuclear targeting. (I) Nuclear entry and expression. 
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1.5.4. Methods to deliver DNA vaccines 
The convenience of DNA vaccines compared to recombinant protein based vaccines resulted 
in the invention of various types of DNA delivery methods. Second generation DNA delivery 
was favoured by various methods such as gene gun and electroporation. The third generation 
DNA vaccine delivery system included employing various delivery vehicles synthesised by 
biological and chemical means. Each method is discussed in detail as follows. 
1.5.4.1. Viral based DNA delivery 
Viral based DNA delivery is one of the most common methods to treat diseases (Nayerossadat 
et al., 2012). The concept of viral gene delivery was introduced in 1972 when a research 
group synthesised recombinant DNA by SV40 virus (Jackson et al., 1972), followed by 
utilisation of the vaccinia virus for transient gene expression (Mackett et al., 1982). The life 
cycle of a virus includes an infection phase, in which it introduces viral genetic material into its 
host cells. However in the case of viral gene delivery, an immunogenic protein encoding gene 
cassette will be packed within the viral core, ready to introduce into the host (Kay et al., 
2001). Not every virus is suitable for this kind of application and must be selected based on 
their properties. Despite having high transfection efficiency, their use is limited by their 
insertional mutagenesis capacity making them unsafe and often immunogenic (Kim et al., 
2010). However each type of viral system has its unique advantages and limitations. The most 
common types of viruses used for DNA vaccine delivery and their general advantages and 
disadvantages of each system are summarised in the Table 1.3.  
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Table 1. 3. Major types of viral systems available for gene and plasmid DNA delivery, their 
merits and demerits. 
Table adapted with minor modifications from (Jin et al., 2014) 
 
Transfection 
systems 
Advantages Disadvantages 
Adenovirus 
vectors 
Large transgene capacity (up to 
38 kb), low host specificity 
Tend to yield natural and acute 
immunologic responses, short-
term gene expression 
Adeno-
associated 
vectors 
Safety, ability to integrate into a 
specific site on chromosome 19 
with no noticeable effects 
Complicated process of vector 
production and the limited 
transgene capacity (up to 4.8 kb) 
Retroviral 
vectors 
Ability to transfect dividing cells, 
suitable for in situ treatment, 
transgene capacity of 8 kb 
Low efficiency in vivo, 
immunogenic problems, the 
inability to transfect the non-
dividing cells and the risk of 
insertion 
Lentivirus 
vectors 
High-efficiency infection of 
dividing and non-dividing cells, 
long-term stable expression, low 
immunogenicity, transgene 
capacity of 8 kb 
Difficult design and construction, 
concerns of biosafety 
Herpes 
simplex virus 
vectors 
transgene capacity of up to 150 
kb, neurotropic features 
Difficulty to keep virus action 
under control 
Poxvirus 
vectors 
High stable insertion capacity 
(more than 25 kb), simple 
construction, high expression 
levels 
Complex structure and biology, 
risk of cytotoxic effects 
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1.5.4.2. Non-viral DNA vaccine delivery methods 
1.5.4.2.1. Physical methods  
The physical methods of DNA vaccine delivery should facilitate reversible modification of cell 
membranes allowing uptake of DNA (Villemejane et al., 2009). Popular methods under this 
category include electroporation, gene gun transformation, sonoporation and 
magnetofection.  
1.5.4.2.1.1. Electroporation  
Electroporation is a one of the successful techniques which involves the application of high 
voltage electric shocks across the cells making them permeable to plasmid DNA (Potter et al., 
2003). A recent development in electroporation involves using a ‘syringe based 
microelectrode’ allowing injection of DNA followed by electroporation successfully to mouse 
brain (Nomura et al., 2016). Interestingly naked plasmid DNA was delivered to beating hearts 
of rats using electroporation with a significant gene expression within 24 h (Ayuni et al., 
2011). Remarkably, electroporation mediated DNA delivery for anthrax elicited IgG immune 
response comparable to that of the FDA approved BioThrax™ vaccine, however low 
neutralising response was observed with electroporation (Livingston et al., 2010). DNA 
vaccines were successfully delivered to lungs (Zhou et al., 2008), retina of eye (Venkatesh et 
al., 2013), skin (Medi et al., 2008) and various other tissues. Irreversible electroporation, an 
excision technique using ultra-short, high-magnitude electrical field to generate irreversible 
nanopores in the cell membrane was reported to be safe in humans, especially for the 
treatment of various types of cancers (Thomson et al., 2011; Rubinsky 2007). The major 
advantages of electroporation is its ability to be applied to a variety of cells and tissues in a 
short time, no size limit of DNA and allowance of repeated administrations (Muramatsu et al., 
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1998). However, electroporation causes significant cellular damage and is not suitable for 
some applications (Bolhassani et al., 2014). 
1.5.4.2.1.2. Gene gun (Biolistics)  
The gene gun produces high-velocity micro-projectiles to target cells, tissues and organs 
(Sanford 1988). It has been applied to deliver a plasmid DNA vaccine to live rodent brain 
tissue (Sato et al., 2000), and to mouse muscle tissue (Belperron et al., 1999) where a 
significant immune response was observed. Even though this system has the advantage of 
being fast and effective, the high cost and maintenance of the instrument limits its 
applicability in disadvantaged countries and rural areas (Leelavathi et al., 2004). The DNA 
delivery is non-specific to cells and its organelles (Leelavathi et al., 2004); hence it is not 
suitable for targeted gene delivery. Gene gun was used for the intra dermal administration of 
DNA construct encoding Fasciola hepatica glutathione S-transferase with the successful 
induction of protective immune responses (Smooker et al., 1999). 
 
1.5.4.2.1.3. Sonoporation 
The application of high-frequency sound waves to transfer DNA is a nineteenth century 
emerged technology, in which cavitation is responsible for making the cell membrane 
permeable for macromolecule uptake (Miller et al., 2002). Application of sound waves to 
deliver plasmid DNA to mammalian cells was first reported in 1987 (Fechheimer et al., 1987) 
followed by another report in 1996 (Kim et al., 1996) with gene expression detected. The 
frequency of sound waves for DNA delivery can range from low to high depending on the 
target tissue and was applied in vitro in various cell lines (Miller et al., 2002). This technique 
was applied widely to deliver DNA to muscle cells (Danialou et al., 2002). The advantage of 
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sonoporation is its non-invasiveness and its potential to deliver DNA to internal organs 
without surgery (Weiwei et al., 2013). However this method poses some disadvantages such 
as its low transfection efficiency, significant cell damage following the procedure, cell 
apoptosis induced by ultrasound contrast agents, delay in DNA synthesis and changes to 
mitochondria (Tomizawa et al., 2013).  
1.5.4.2.1.4. Magnetofection  
Magnetofection is a nanoparticle based approach developed to overcome the limitations of 
some non-viral and viral vectors such as low titre and lack of target specificity (Scherer et al., 
2002). This method involves the application of magnetic field to enhance DNA delivery. The 
target cell or tissue will be positioned between a magnetic field and DNA vectors associated 
with magnetic nanoparticles, thereby facilitating efficient transfection by natural mechanisms 
such as endocytosis rather than ballistic movement (Plank et al., 2003). This method was 
successfully applied to deliver plasmid DNA and genes to porcine kidney cells (Wang et al., 
2014), respiratory epithelial cells (Gersting et al., 2004) and melanoma cells (Prosen et al., 
2013). The greatly improved dose-response relationship is a considerable benefit over some 
other systems, but there are still many technical challenges to implement in vivo (Plank et al., 
2003).  
1.5.4.2.2. Chemical methods for DNA delivery 
Chemical methods often referred to as synthetic vectors, generally use cationic synthetic 
materials to deliver DNA vaccines. Chemical methods have been applied to transfection since 
the late 1960s to overcome the disadvantages of other available systems (Jin et al., 2014). The 
molecular structure and fine chemical properties of cationic materials such as size and surface 
potential can be fine-tuned to achieve better transfection efficiency with low toxicity (Jin et 
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al., 2014). The chemicals can be used to synthesise nanoparticles or can be complexed alone 
with DNA to deliver to cells.  
1.5.4.2.2.1. Calcium phosphate  
Calcium phosphate was introduced several decades ago to transfect nucleic acids in vitro and 
was used extensively because of its biocompatibility and simplicity in its procedure 
(Mostaghaci et al., 2016). The limitation of its low transfection efficiency still needs to be 
improved by optimising parameters such as pH of the transformation buffer and solubility in 
aqueous solution (Mostaghaci et al., 2016). An increase in transfection efficiency was 
observed by inclusion of adenovirus while co-precipitating DNA with calcium phosphate (Lee 
et al., 1999). Even though its in vitro application was reported in various cell lines (Fu et al., 
2005), in vivo application was limited for gene therapy of bone defects (Keeney et al., 2010) 
and regeneration of bone (Krebs et al., 2010). Hence this method still needs to be improved 
to apply in vivo to immune system cells. 
1.5.4.2.2.2. DEAE dextran 
DEAE, 2-diethyl-aminoethyl dextran, is a water soluble cationic polysaccharide widely utilised 
for transfection since the 1980s (Pari et al., 2004). The DEAE dextran/DNA complexes can be 
protected from cytoplasmic DNases but degraded by dextranases in vivo (Warden et al., 
1969), therefore this made them unsuitable for in vivo application until further improvements 
were made. The procedure of this method involves using DMSO, which imparts a cytotoxic 
effect on cells (Pari et al., 2004). Even though these complexes facilitate endocytosis, the 
percentage of endosomal escape is low resulting in low transfection efficiency (Warden et al., 
1969). However, this system was reported to be successful for some difficult cell lines such as 
human macrophages (Mack et al., 1998) and rat FR3T3 cells (Yang et al., 1997).  
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1.5.4.2.2.3. Cationic lipids 
The aim of using cationic chemical transfection reagents is either to complex or condense 
anionic DNA to facilitate subsequent uptake by endocytosis by immune cells (Luo et al., 2000). 
Most commonly used cationic lipids for gene delivery include DOTMA, DOTAP, DOSPA, DOGS, 
DC-chol, DMRIE and SAINT-2. The toxicity and transfection efficiency of a cationic lipid 
depends on its polar and hydrophobic domains, alkyl chain length and its saturation (Felgner 
et al., 1994; Hongtao et al., 2006). Fine tuning of their chemical structure was achieved by 
attaching ligands (You et al., 1998) or substitutions of chemical groups, mainly with 
polyethylene amine (Hsu et al., 2011; Thapa et al., ). The major limitation of cationic lipids is 
their lack in consistency while constructing liposomes and lipoplexes in some cell lines (Filion 
et al., 1998). 
1.5.4.2.2.4. Cationic polymers and dendrimers 
Cationic polymers are macromolecules consisting of repeated subunits, and are applied 
widely for gene and plasmid DNA delivery. Cationic polymers may be synthetic or biological. 
Most popular cationic polymers include polyethylene amine, poly L-lysine, imidazole-based 
polymers, chitosan, collagen and alginate (Dang et al., 2006; Merdan et al., 2002). They can be 
condensed with plasmid DNA to form ‘polyplexes’. They have the advantage of being flexible 
for tailoring according to the application and have a simple, inexpensive scale-up process 
(Merdan et al., 2002). The application of cationic polymers was successful in vitro in various 
cell lines, but there are limited reports of in vivo studies (De Smedt et al., 2000). Dendrimers 
are a new class of polymers, which are highly branched and monodisperse macromolecules 
(Klajnert et al., 2001). They can be prepared by divergent or convergent methods (Abbasi et 
al., 2014) and applied to deliver plasmid DNA to various cell lines in vitro (Eichman et al., 
2000; Merkel et al., 2009). Despite their great potential for DNA delivery, poor transfection 
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efficiency has limited their clinical application (Pack et al., 2005). Their low capability to 
escape from the endosome has been noted as a reason for their low transfection efficiency 
(Midoux et al., 2009).  
1.5.4.2.3. Biological agents for DNA delivery 
Biological agents utilise readily available native materials such as bacteria, bacteriophages, 
erythrocyte ghosts, exosomes or recombinant protein technology synthesised forms such as 
VLPs. The most commonly used biological agents for DNA delivery are depicted in Figure 1.6 
and their advantages and disadvantages are summarised in Table 1.4. 
1.5.4.2.3.1. Bactofection 
Bactofection involves using whole bacteria as a vector. Bacterial genera including Salmonella, 
Listeria and E. coli were investigated for their DNA delivery potential (Pilgrim et al., 2003; 
Wahid et al., 2007) in mammalian systems with increased transfection efficiency. The main 
limitation of using native species in bactofection is undesired interactions with host and their 
virulence factors resulting in serious side effects (Pilgrim et al., 2003). Hence to avoid this, 
attenuated and recombinant strains may need to be developed. E.coli bactofection was 
improved by a molecular engineering method by heterologous expression of  bacteriophage 
ΦX174 lysis gene-E, which resulted in enhanced gene release and induced cellular death 
(Chung et al., 2015). 
 
1.5.4.2.3.2. Bacteriophages 
Bacteriophages are a kind of viruses which infect bacteria and have been applied widely for 
gene delivery. M13 filamentous and lambda bacteriophages are the main types displaying a 
stable and efficient DNA delivery both in vitro and in vivo (March et al., 2004). The phage coat 
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protein, similar to virus-like particles, protects DNA from nucleases and can target antigen 
presenting cells (Clark et al., 2006). Despite being effective their use is limited because of 
their limited host range, and they are susceptible to rapid clearing by the immune system 
(Haq et al., 2012). 
1.5.4.2.3.3. Erythrocyte ghosts 
Erythrocytes extracted from a patient will be processed to remove cytoplasm forming 
erythrocyte ghosts (EG), which can act as a cargo to deliver drugs and plasmid DNA (Seow et 
al., 2009). Plasmid DNA loaded within EGs showed 92000-fold higher and prolonged 
expression in blood when compared to naked plasmid (Byun et al., 2004). The EGs can be 
loaded with plasmid DNA by electroporation in hypotonic medium (Byun et al., 2004). 
However the circulation time of EGs was shorter than natural RBCs and is difficult for genetic 
engineering for synthesis of targeting ligands (Byun et al., 2004).  
1.5.4.2.3.4. Exosomes 
Exosomes are nano-sized (10-40 nm) secreted membrane vesicles formed by the fusion of 
multivesicular endosomes with a cell surface (Simons et al., 2009). Their native function is to 
transfer membrane components and nucleic acids between cells and for intra-cellular 
communication (Simons et al., 2009). They have been widely applied for the successful 
delivery of small RNAs such as small interfering RNAs (siRNA) and microRNAs (miRNA) in vivo 
(Alexander et al., 2015; Alvarez et al., 2011). Because of their efficiency in RNA delivery, they 
can be a potential plasmid DNA delivery agent. Many commercial kits based on exosomes are 
available for DNA transfection. Their main advantages are their biocompatibility and their 
ability to cross the blood-brain barrier (Zhou et al., 2016). However more investigation into 
their applicability for DNA delivery is required.  
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Table 1. 4. A brief summary of advantages and disadvantages of biological agents for DNA 
vaccine delivery. 
Table adapted from (Seow et al., 2009). 
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Figure 1. 6. Production methods of biological gene delivery vehicles.  
Figure adapted from (Seow et al., 2009). 
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1.6. Virus like Particles      
Virus-like particles (VLPs) are biological agents used for DNA vaccine delivery and other 
applications. They are empty protein capsids formed by the self-assembly of overexpressed 
viral capsid proteins without any nucleic acid. VLPs were first identified in skin papillomas 
(Strauss et al., 1949), and later in blood lymphocytes of acute marecks disease (Wight et al., 
1967) and Leishmania parasites (Molyneux 1974).  
1.6.1. Production systems for VLPs 
VLPs have been investigated for their wide range of potential applications in the vaccine field. 
The primary prerequisite for the production of VLPs is to overexpress viral proteins which 
have the capacity to self-assemble into VLPs. The expression system is chosen based on the 
type and nature of the protein. For example, proteins which do not require any post 
translational modifications are expressed in the prokaryotic host, whereas those requiring 
these modifications can be produced in eukaryotic systems. Human papilloma VLPs was 
produced in Lactobacillus casei cells (Aires et al., 2006). Shrimp hematopoietic necrosis VLPs 
was produced in E coli demonstrating successful self-assembly (Hou et al., 2009). These VLPs 
can effectively enter into shrimp primary haemocytes and can deliver antivirals.  
Recombinant yeast systems were also used to produce VLPs containing heterologous proteins 
(Buckholz et al., 1991). Production of hybrid HIV-Ty VLPs containing large parts of P1 and a 
part of HIV gp120 protein, proved to be useful for preparing and evaluating HIV antigens for a 
variety of immunological purposes (Adams et al., 1987). Human papilloma virus L1 protein 
isolated from genital lesions assembled effectively into VLPs comparable to the native virus 
and can be produced in significant amounts (Kirnbauer et al., 1993) with a substitution of Asp-
202 to His of the L1 protein of native virus. This helps in developing serological assays for HPV. 
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Insect cell lines were also used to express rota virus capsid protein which assembled into VLPs 
(Crawford et al., 1994). 
1.6.2. Optimising conditions for VLP production 
Research has been done to optimise VLP vaccine production in bacterial, yeast and insect 
expression systems. Baculovirus culture conditions for producing VLPs including aeration and 
dissolved oxygen on the growth of Sf9 cells were optimised (Cruz et al., 1998). A novel 
method of production of VLPs was designed using cell suspension systems for rift valley fever 
virus (Mandell et al., 2010). A method of selective flocculation and precipitation was designed 
for scaling up of virus yield to commercial levels and observed a significant improvement in 
terms of quantity (Tsoka et al., 2000). The effects of sparging, agitation and bioreactor scale 
on cell growth, infection kinetics and productivity of VLP production at the commercial scale 
was studied (Maranga et al., 2004). These studies emphasize the importance of integrated 
strategies and engineering concepts in process development at the bioreactor stage with VLP 
vaccines. 
1.6.3. Hybrid VLPs   
Engineering of surface exposed amino acids on VLPs is also a main research area. VLPs were 
produced for adeno-associated viruses by using vp2 protein and N-terminal tagged vp3 
protein which is buried in the VLP (Hoque et al., 1999). The vp3 protein is exposed inside on 
the VLP and there is the ability to attach different drugs to the vp3 protein which can act as an 
effective vector. The production of VLPs from vp1 protein of hamster polyoma virus was 
successful (Gedvilaite et al., 2000). Some portions of these VLPs are predicted to be surface 
exposed. The fusion proteins are produced by inserting the gene coding for hepatitis-B virus 
into the vp1 gene. The resulting VLPs expose the hepatitis-B virus epitopes and elicit immune 
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responses to both polyoma virus and hepatitis B virus. This hybrid VLPs offer the flexibility to 
attach a wide range of other heterologous proteins onto the surface.  
1.6.4. Clinical trials of VLP based vaccines 
The successful licensed VLP vaccine to date is for Human papilloma virus and Hepatitis B virus 
which is being used in many countries (Gomes et al., 2017; Wang et al., 2013). Success was 
achieved in laboratory trials for many other vaccines and now clinical trials are in progress. 
Many VLP-based vaccines are at various stages of clinical trials and the chances of their 
success seem high judging from their laboratory level efficiency (Penumarthi et al., 2017). 
Interestingly, a VLP vaccine was designed for hypersensitivity (Ambuhl et al., 2007) for which 
pre-clinical and phase-1 trials were successful and this is now under further clinical trials. 
Murine polyoma virus VLPs was successfully used as gene and immune therapy tools by 
prime-boost vaccination (Ramqvist et al., 2007). Another VLP vaccine for Alzheimer disease, 
CAD106, developed by Cytos biotechnology and Novartis pharmaceuticals is currently under 
human clinical trials (Chackerian 2010). This progress indicates the efficiency of VLP based 
vaccines. 
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1.7. Ty-VLPs 
 
Ty-VLPs, yeast transposon virus-like particles of the genus Pseudovirus, family Pseudoviridae 
(Boeke et al., 1985), are natively produced in Saccharomyces. cerevisiae as transposition 
intermediates.  
1.7.1. Discovery of Ty-VLPs  
The discovery of Ty-VLPs happened in an incidental manner while investigating the killer 
character of yeast. The ‘killer character’ of yeast is a phenomenon in which one strain of 
yeast, mostly S. cerevisiae, completely inhibits the growth of other strains by secreting a 
protein consisting of a macromolecule named killer factor (Philliskirk et al., 1975). This killer 
character was proposed to be associated with VLPs encapsulating ds-RNA (Berry et al., 1972; 
Herring et al., 1974) and Ty-VLPs were thought to be responsible. S. cerevisiae killer character 
requires a killer virus and helper virus. Later studies elucidated that the L-A- virus, which is 
similar to retrovirus and Ty-VLPs in its life cycle, acts as a helper virus (Schmitt et al., 2006). 
Ty-VLPs were subsequently found to be retro transposons (Boeke et al., 1985) mainly 
functioning as transposition intermediates and as such, Ty-VLPs involvement in yeast killer 
character was disproved. The main families of viruses associated with yeast are tabulated in 
Table 1.5.   
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Table 1. 5. Families of native yeast viruses. 
Table adapted from (Reed 1991). 
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1.7.2. Types of Ty transposons in S. cerevisiae 
S. cerevisiae possesses 5 families of Ty transposons namely Ty1-Ty5 and are similar to that of 
retro elements (Krastanova et al., 2005). Ty-elements were known as one of the transposable 
elements up to 1984 and later emerged as a model for retro-elements and also as an 
important tool for molecular biologists and immunologists (Kingsman et al., 1988). Ty element 
type can be distinguished based on the length of the long terminal repeat (LTR) (Table 1.6), 
preference of their insertion sites, differences in restriction site maps and their copy number 
per haploid genome (Krastanova et al., 2005). These elements are not infectious and are 
restricted to intracellular transposition as they lack an env gene that would encode a viral 
envelope (Krastanova et al., 2005; Palmer et al., 1997). 
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Table 1. 6. Genetic organization of S. cerevisiae Ty-elements. 
Table adapted from (Jordan et al., 1999). Ty elements consist of two LTRs that flank the 
overlapping TYA and TYB ORFs. The average sizes of the LTRs and ORFs from the various Ty 
families are shown. 
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1.7.3. A Ty1 transposon 
Ty1 transposon is a repeated transposon sequence present as 35 dispersed copies in yeast 
genomes comprising 2% of the whole genome (Doolittle et al., 1980). Ty1 transposon is 
abundantly distributed within the yeast genome and hence extensively studied among the 
five types of Ty elements (Krastanova et al., 2005). 
1.7.3.1. Structure of Ty1 transposon 
Ty1 transposon belongs to copia-like elements of the LTR retro transposon super family which 
produce Ty-VLPs (Cheung et al., 2016). They have very close structural and organisational 
resemblance to the retroviral proviruses (Adams et al., 1988). Ty1 transposons are ~5.9 kb in 
size which consists of a 5.2 kb unique region called epsilon (ε) and two (LTRs), or delta regions 
(ߜ), flanking either side (Adams et al., 1994). Ty1 elements have two overlapping open reading 
frames, TYA and TYB, present in a 5.7 kb mRNA from residues 291-1572 (Kingsman et al., 
1987). These TYA and TYB ORFs are analogous to retroviral gag and pol genes (Mellor et al., 
1985) which contain an overlapping region of 38 bp (Kingsman et al., 1987) as shown in Figure 
1.7. TYA produces a 58 kDa protein, p1, by direct translation of 5.7 kb mRNA, and is further 
cleaved by proteases encoded by Ty1 to produce a cleavage product called p2, whereas TYB is 
expressed by a frame shifting process to encode a 190 kDa TYA-TYB fusion protein p3. This 
frame shifting process disregards the stop codon in the TYA ORF and shifts translation into the 
+1 reading phase of TYB (Mellor et al., 1985). The p3 protein products harbour protease (PR), 
integrase (IN) and reverse transcriptase activities as shown in Figure 1.7.  
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Figure 1. 7. Structure and organisation of Ty1 transposon.  
Figure adapted with modifications from (Roth 2000). 
(A) Ty1 transposon with 5’ and 3’ LTRs known as ߜ sequences and a ε region. (B) The full-
length Ty1 RNA (5.7 kb) produced by Ty1 transcription spans between both LTRs. (C) Genomic 
organisation and protein domains encoded by TYA and TYB, showing (D) p1 and p3 proteins 
produced after translation. The proteolytic cleavage of p3 releases PR, IN and RT, RH, and that 
of p1 releases p2. Abbreviations: CA, capsid; PR, protease; IN, integrase; RT, reverse 
transcriptase; RH, RNase-H. 
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1.7.3.2. Mechanism of the Ty1 transposition cycle 
The Ty1 transposon life cycle is the process of the insertion of these mobile genetic elements 
in a new location of the yeast genome. Transposition is a very rare event in S. cerevisiae, 
which occurs at the rate of 10-5-10-7 per Ty1 element per generation (Curcio et al., 1991). 
However the transposition rate increases with external stress conditions such as high 
temperature (Paquin et al., 1984), nitrogen starvation (Lesage et al., 2005) and DNA damage 
caused by UV radiation (Bradshaw et al., 1989). The transposition starts with reverse 
transcription of Ty1 transposon into Ty1 mRNA in the nucleus, which is then exported to the 
cytoplasm for translation (Lesage et al., 2005). Post translational protein products p1 and p3 
assemble into Ty-VLPs, which contain the p1 protein capsid encapsulating mRNA and enzymes 
required for reverse transcription (Mellor et al., 1985). These Ty-VLPs mature by the further 
processing of capsid protein and reverse transcription of its mRNA to a cDNA to form a pre-
integration complex (PIC) as shown in Figure 1.8. The actual step of transposition occurs by 
the release of cDNA from PIC, which integrates into a new location of yeast genome (Lesage 
et al., 2005). 
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Figure 1. 8. The Life cycle of S. cerevisiae Ty1 transposon depicting its transposition 
mechanism.  
Figure adapted from (Garfinkel laboratory home page; 2012) with minor modifications.  
Ty1 mRNA synthesis occurs in the nucleus and is transported to cytoplasm for translation and 
Ty-VLP assembly. Pre-integration complex (PIC) formed by the synthesis of cDNA inside Ty-
VLPs which is subsequently integrated into the yeast genome.  
http://www.bmb.uga.edu/labs/garfinkel 
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1.7.4. Structure and properties of Ty-VLPs 
Ty-VLPs are the central units of transposition in yeast and hence are called “transposisomes” 
(Kingsman et al., 1987). They are similar in structure, function and genetic composition to 
retroviral capsids (Burns et al., 1992; Roth et al., 2000). The understanding of the role of 
retroviral capsids in its pathogenesis was limited by its pleomorphic nature and difficult to 
purify in large quantities for characterisation (Burns et al., 1992). Hence, Ty-VLPs were studied 
as a model for retroviruses. Purified Ty1-VLPs are reported as true transposition 
intermediates in vitro (Eichinger et al., 1988).  
Ty-VLPs are heterogeneous in size with the majority of particles ranging from 15-50 nm, 
composed of Tya protein of 440 amino acids (Brookman et al., 1995; Burns et al., 1992). Ty-
VLPs encapsulate a 5.7 kb Ty RNA, primer, tRNA, reverse transcriptase, protease and integrase 
which are necessary for transposition (Kingsman et al., 1987). The characteristic feature of Ty-
VLPs is the presence of an electron dense central lumen representing packed RNA and 
associated enzymes (Roth 2000) as shown in the Figure 1.9. They have a calculated molecular 
weight of 14.1 MDa containing ~300 Tya subunits (Roth 2000). Despite the abundance of Ty-
transposons (~30 copies per haploid genome) in yeast, the quantity of Ty-VLPs produced is 
too low to detect by reverse transcriptase assays and electron microscopy of cell cross-
sections (Boeke et al., 1985). Hence to overcome this limitation a recombinant system over-
expressing the Tya subunit was designed in Pichia. pastoris and E. coli (Uhde-holzem et al., 
2010). The accumulation of assembled Ty-VLPs in the cytoplasm with the overexpression of Ty 
protein was revealed by TEM imaging (Mellor et al., 1985) as shown in Figure 1.10. They 
undergo a further maturation following their assembly by the cleavage of Tya subunit close to 
the C-terminus (Brookman et al., 1995). Transposition does not occur without maturation of 
these particles (Roth et al., 2000). They harbour pores on the surface which allow the entry of 
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small nucleases such as RNase-A (13.7 kDa) but not the larger nuclease such as benzonase (30 
kDa) (Al-Khayat et al., 1999; Brookman et al., 1995). The triangulation number (T-number, 
describes the icosahedral surface quasi-symmetry pattern) and size of particles which 
depends on the length of C-terminal capsid protein region (Al-Khayat et al., 1999).  
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Figure 1. 9. Transmission electron micrograph of purified Ty-VLPs.  
Figure adapted from (Roth 2000). The scale bar is 50 nm and the arrows indicate the electron 
dense central lumen within the Ty-VLPs. 
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Figure 1. 10. Electron micrographs of a cross section of S. cerevisiae cells overexpressing Tya 
protein. 
Figure adapted from (Muller et al., 1987) with minor modifications. The arrows indicate the 
location of assembly of Ty-VLPs in the cytoplasm. 
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1.7.5. Properties of Tya protein 
Tya or p1 protein is slightly basic, proline rich and phosphorylated. The PI of Tya protein is 7.8 
and shows affinity to bind DNA in a crude binding assay (Kingsman et al., 1987). Apart from 
being major structural component of Ty-VLPs, Tya protein has a regulatory role by containing 
an RNA binding domain between amino acids 346-407 allowing RNA packaging (Roth 2000). 
An immunological analysis reported that the N-terminus of Tya protein is exposed and C-
terminus is buried within the particle core (Brookman et al., 1995), therefore it is difficult to 
purify Ty-VLPs by C-terminal His-tag affinity chromatography. Fusions at the N-terminal end 
destabilize particle morphology (Brachmann et al., 1997). The amino acids 341-346 (IHAI) at 
the C-terminal are essential for Ty-VLP (Roth 2000). The calculated molecular weight of Tya 
protein is 49 kDa, which appears as 58 kDa on SDS-PAGE (Adams et al., 1987). A Tya protein 
clusters into trimers prior to their assembly into Ty-VLPs (Al-Khayat et al., 1999). 
1.7.6. TyA381-VLPs 
The Tya protein up to 381 amino acids long produces mature and homogenous particles of 40 
nm compared to that of wild-type particles containing Tya protein of 440 amino acids (Burns 
et al., 1992). Cryo-electron microscopy revealed that Tya381-VLPs contains 180-240 trimetric 
Tya subunits with T=3 or T=4 quasi-equivalent icosahedral symmetry with spikes on the 
surface (Palmer et al., 1997). They contain surface pores and RNA packaging ability similar to 
wild-type Ty-VLPs (Roth 2000). Therefore Tya381 particles were utilised for the current study 
to investigate their potential for plasmid DNA delivery.  
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1.7.7. Applications of Ty-VLPs 
1.7.7.1. Ty-VLPs as vaccines 
Hybrid Ty-VLPs produced by the insertion of antigenic portions of pathogens was the main 
application apart from being used as a model for retroviruses. Hybrid Ty-VLPs can be 
produced by the insertion of up to 72 kDa protein at the C-terminal end of the Tya subunit 
without disrupting the particle assembly (Kingsman et al., 1995). Ty-VLPs were used as an 
antigen presentation system for p24 protein of HIV which reported the elicitation of both 
cellular and humoral immune responses (Adams et al., 1994; Kingsman et al., 1988). Ty-VLPs 
were demonstrated to be an efficient subunit vaccine to deliver multiple antigens (Kingsman 
& Kingsman 1988). Ty-VLPs have native ability to carry their encapsulated mRNA, but their 
DNA delivery ability has not previously been investigated, but is considered in the current 
study. 
1.7.7.2. Other applications of Ty-VLPs 
The hybrid Ty-VLPs has other major laboratory applications such as the production of 
monoclonal and polyclonal antibodies, immunodetection reagents, and rapid screening of 
non-VLP antigens (Burns et al., 1994). 
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1.8. Solid lipid nanoparticles  
1.8.1. Development of SLNs 
Solid lipid nanoparticles (SLNs) are a lipid based nanoparticle system which has a wide range 
of applications. Lipid based nanoparticles are prominent in novel vaccine research, as most of 
the types utilise bio-compatible lipids. The three important lipid-based nanodispersed 
delivery systems are liposomes, nanoemulsions and SLNs (Figure 1.11), and the properties of 
these 3 systems vary based on their structural difference. Liposomes are artificial vesicles 
containing single or multiple bilayers of phospholipids with an aqueous inner core (Uchechi et 
al., 2014). Nanoemulsion contains a single phospholipid layer with an inner liquid-lipid core. 
Liposomes and nanoemulsions are more susceptible to microbial contamination and have less 
storage stability (Figure 1.12) as they contain a liquid core (Ekambaram et al., 2012). SLNs 
were introduced in 1991 to overcome these disadvantages by incorporating a solid lipid core 
(Muller et al., 2000). 
SLNs are submicron colloidal carriers composed of physiological lipid, dispersed in water or in 
an aqueous surfactant solution, generally in the size range of 10-1000 nm (Mukherjee et al., 
2009). SLNs can be used as colloidal drug delivery vehicles for hydrophilic and lipophilic drugs, 
nucleic acids, proteins and other macromolecules (Dolatabadi et al., 2015). SLNs have the 
advantages of being biocompatible, easy to validate and economical to scale up. Importantly, 
gaining regulatory approval is comparatively easy and straightforward (Mukherjee et al., 
2009). Therefore this platform may be desirable for vaccine delivery. 
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Figure 1. 11. Structure of main types of lipid based nanoparticles. 
 Figure adapted from (Uchechi et al., 2014). a) Liposome has an aqueous core b) 
nanoemulsion has a liquid lipid core, whereas c) SLNs has a solid lipid core. 
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Figure 1. 12. Schematic representation of the advantages of SLNs over other types of lipid 
based nanoparticles.  
Figure adapted from (Ekambaram et al., 2012). 
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1.8.2. Preparation methods for SLNs 
SLNs can be prepared by various methods, and each method has its own advantages and 
limitations as summarised in the Table 1.7. They are generally composed of 0.1-30 % (w/w) 
solid fats such as fatty acids, steroids, waxes, mono, di and triglycerides dispersed in 0.5-5% 
surfactants or water (Campani et al., 2016). The variation in composition of lipids in the 
nanoparticle formulation can influence its performance such as cationic nature and stability 
(Shah et al., 2015). Hence, composition and method of preparation should be selected based 
on the desired properties of SLNs based on their application. For example, small size SLNs can 
be synthesised by the solvent emulsification/evaporation method, whereas the cold 
homogenisation method yields large size SLNs (Garud et al., 2012). Incorporation of cationic 
lipids may facilitate effective delivery of anionic nucleic acids (Uddin 2007). Various types of 
SLNs compatible for various routes of administration were investigated both in vitro and in 
vivo, with respect to their efficiency to deliver various drugs to their target sites (Mulla et al., 
2010).  
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Table 1. 7. Advantages and disadvantages of preparation methods of SLNs. 
Table adapted from (Chaturvedi et al., 2012) 
Method Advantages Disadvantages 
Hot high 
pressure 
homogenisation 
Versatile, avoid use of organic solvent, 
easy scalability, Short production time, 
instruments easily available and no 
regulatory problems  
High temperature lead to 
degradation, conformational 
changes in protein, coalescence of 
particles, burst release due to high 
emulsifiers  
Cold high 
pressure 
homogenisation 
Minimizes thermal exposure of the drug 
but does not avoid it completely. Useful in 
temperature labile drugs or hydrophilic 
drugs  
Higher poly dispersity index  
Melt 
emulsification 
ultrasound  
No organic solvent residue, no burst 
release, high lipid concentration, Versatile, 
avoid use of organic solvent, better drug 
loading than HPH  
Metallic particle contamination, 
broader particle size  
Emulsification-
solvent 
evaporation  
Avoidance of heat during production thus 
useful for thermo labile drugs. Produce 
small size particles 
Solvent residues  
Emulsification-
Solvent diffusion  
Simple procedure, Fast drug release 
(drawback when slow release is required)  
Low lipid content, Low entrapment 
efficiency and drug loading capacity, 
organic solvent residue, Lack of scale 
up  
Micro emulsion  No need for specialized equipment and 
energy for production  
High concentrations of surfactants 
and co-surfactants, presence of large 
amounts of water in system  
Membrane 
contactor  
Simple method, Control of particle size by 
selection of process parameters, and its 
scaling-up abilities  
-  
Particle from gas 
saturated 
solution (PGSS) 
One step procedure, no need of organic 
solvent, low processing temperature 
conditions  
Frequent nozzle blockage with 
hydrophilic drugs, machinery is 
costly  
Multiple 
emulsion  
No need to melt lipids, high loading of 
hydrophilic drugs, useful for protein 
loading  
Use of solvent and surfactant  
Solvent injection  No need for high pressure 
homogenization, easy handling, fast 
production process, No need for 
specialized equipment  
Use of solvent and surfactant  
Film ultra-
sonication 
dispersion  
Simple, No need for specialized equipment  Metallic particle contamination, 
broader particle size  
Phase inversion  Useful for thermo labile drugs, avoid 
organic solvent, No need for specialized 
equipment  
-  
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1.8.3. Applications of SLNs 
SLNs offer a promising avenue for therapeutics of many diseases. SLNs were mainly used for 
controlled drug delivery apart from their applicability as non-viral gene delivery vectors 
through careful fine-tuning of their chemical composition. Cationic lipids, for example, 
provide a positive surface potential and favour binding to nucleic acids such as DNA, siRNA 
and miRNA. 
1.8.3.1. Cosmetic industry 
SLNs have been used to encapsulate molecular and particulate sunscreens to reduce their 
side effects, such as penetrating the skin and causing irritation (Muller et al., 2000). SLNs 
themselves also exhibited UV absorption capability (Wissing et al., 2001). They were also used 
as a component of occlusive (reducing water loss), skin adhesive films and topicals (Naseri et 
al., 2015). The occlusive effect of SLNs was investigated in vitro and used in various 
formulations of cosmetic creams such as day and night creams to improve their occlusive 
effect (Muller et al., 2000). 
1.8.3.2. Drug delivery 
SLNs have been used as local or systemic delivery vehicles for micro and macromolecular 
drugs using oral and pulmonary routes of administration (Naseri et al., 2015). An antibacterial 
peptide, nisin, encapsulated within SLNs showed controlled release and effective anti-
microbial effect against Listeria monocytogenes and Lactobacillus plantarum (Gonzalez 2015). 
SLNs were also investigated for their ability to deliver drugs targeting various types of cancer 
and most of these studies reported their ability to overcome multi-drug resistance in cancer 
cells with promising results in preclinical trials (Malam et al., 2009). 
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1.8.3.4. Food and agricultural industries 
SLNs were reported as suitable delivery vehicles for food bioactive compounds such as β-
carotene, lutein and lycopene (Aditya et al., 2015; Naseri et al., 2015). Another recent 
application of SLNs in agriculture is to load them with essential oils which can act as an 
effective and eco-friendly pesticide (Campos et al., 2015; Lai et al., 2006). 
1.8.3.3. Nucleic acid delivery 
SLNs are one of the important non-viral delivery system for nucleic acids such as siRNA, 
miRNA and plasmid DNA. SLNs-siRNA complexes along with PEG was reported to cross the 
blood brain barrier without any cytotoxic effect on cells (Jin et al., 2011). The miRNA delivered 
by SLNs showed an increase in survival rate of mice harbouring cancer stem cells compared to 
other delivery systems (Chen et al., 2015). SLNs alone or in combination with other 
compounds were reported to form stable complexes with plasmid DNA and deliver it safely in 
vitro for targeted gene therapy of various cancers (Apaolaza et al., 2014; Bondi et al., 2007; Yu 
et al., 2010). This indicates the efficiency of SLN formulations in the delivery of various types 
of nucleic acids. Many formulations of SLNs were investigated only for their ability to interact 
with DNA and few other systems were studied in vitro. Hence it is worthwhile investigating 
the DNA delivery ability of new SLN types. 
 
 
 
                                                                                                                                                       Chapter 1 
 
57 
 
Rationale of the study 
There are very few successful delivery systems available for DNA vaccines. Only a small 
number of veterinary DNA vaccines were approved for commercial use by 2016 (Myhr 2017) 
and none for human application. Among the various types of DNA delivery systems, non-viral 
systems were preferred as they are safe compared to that of viral based and physical 
methods. An important criterion for a DNA vaccine delivery system is to target antigen 
presenting cells of the immune system to elicit antigen specific protective immune responses. 
Particulate non-viral systems of the nano size -range are considered effective for DNA vaccine 
delivery because of their ability to be preferentially taken up by dendritic cells, which 
promotes cross presentation and robust T-cell responses. Two types of non-viral delivery 
systems a) Ty-VLPs and b) SLNs were investigated in this study for their potential to deliver 
plasmid DNA to dendritic cells (murine DC2.4 cells) in vitro. Virus like particles has been 
demonstrated to be safe and effective for a wide range of vaccine applications, as they lack 
nucleic acids which can cause pathogenicity. The native function of Ty-VLPs in yeast is to carry 
out transposition by transferring random gene fragments within the yeast cells. Their 
interaction with dsDNA was also demonstrated in vitro, so there is hope for Ty-VLPs to be 
successful in DNA vaccine delivery. Ty-VLPs production in yeast will be economical and scaling 
up of the yeast cultures is easy and time effective. Therefore production of Ty-VLPs in yeast at 
an industrial scale can be developed easily with yeast. The size of Ty-VLPs is such that they 
can be readily taken up by dendritic cells.  
Cationic lipid based nanoparticles composed of natural lipids is another recent technology 
which was successfully applied for the delivery of small nucleic acids such as siRNA and 
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miRNA. Their application for plasmid DNA delivery was less studied, and hence investigated in 
this project. Generally synthetic cationic lipids were considered toxic to cells. To overcome 
this limitation, naturally occurring lipids such as cholesterol, DOPE and DC-cholesterol were 
used in this study. The current study may be useful to develop a novel delivery system for 
DNA vaccines, which can be a basis for future DNA vaccination. All together the project deals 
with developing a novel delivery system which may be useful for delivery of a wide range of 
DNA vaccines. 
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General materials and methods 
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2.1. General laboratory procedures 
 
All the materials and methods listed in this chapter will be discussed further in the respective 
chapters wherever necessary. All the reagents utilised in the current study were of laboratory 
(analytical) grade or technical (molecular) grade. Most of these reagents were stored at room 
temperature unless otherwise specified. The reagent solutions, buffers and media were 
prepared in double distilled, deionised water (MQH2O) obtained from Millipore MilliQ® 
reverse osmosis water system (Millipore, USA). 
Sterilisation and general cleaning 
All laboratory glassware, media and solutions were sterilised by autoclaving at 121oC (15 
lbf/in2) for 20 mins. The conical flasks containing media were plugged with cotton and 
covered with aluminium foil prior to sterilisation. Autoclave tape (chemical indicator) was 
used to ensure the sterilisation process. Heat sensitive supplements such as amino acids and 
antibiotics were added to the sterilised media after cooling them to ≈50oC. Heat sensitive 
solutions and cell culture reagents were sterilised by passing them through filters with pore 
sizes of 0.22 μm or 0.45 μm. 
The glassware were soaked and washed with pyroneg detergent solution (Gallay Scientific, 
Australia) followed by cleaning them with the dish washer (Bosch). All the glassware was 
dried before using them for media and solution preparations. 
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Dispensing of solutions and reagents 
Solutions up to 10 mL were dispensed using the Finnpipette® digital pipettes (Thermo Fisher 
Scientific, USA) with capacities of 0.5 – 10 μL, 5 – 50 μL, 20 – 200 μL, 200 – 1000 μL, 1 – 5 mL, 
and 2 – 10 mL. Cell culture media was dispensed using γ-sterilised single use 10 mL glass 
pipettes attached to an electronic pipette controller (Invitrogen, USA) and measuring 
cylinders were used to dispense liquids above 10 mL volume. The pipettes were sterilised and 
calibrated for every 6 months. 
The Eppendorf microcentrifuge 5415D or MiniSpin® Plus were used to centrifuge volumes of 
1.5 mL or less and the high capacity centrifuges such as Beckman Allegra™ 21R centrifuge or 
Heraeus Multifuge 1SR centrifuge were used for volumes up to 50 mL. High speed 
centrifugation was performed using Beckman Optima L80 XP Ultracentrifuge and AvanthiTM 
J25I centrifuge. 
Solid chemicals and media components less than 2 g were weighed using Sartorius Model BP 
210 S Semi Micro analytical balance. Solids greater than 2 g were weighed using ISSCO Model 
300 balance. 
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2.2. General laboratory instruments and suppliers 
 
1010 TEM                                                                                                      JEOL, Japan 
AllegraTM 21R centrifuge                                                                            Beckman Coulter, USA 
Analytical balance (0.01-210g)                                                                 ISSCO, Australia 
Aura 2000 M.A.C. Vertical Laminar Air Flow Hood class II                  EuroClone S.P.A., Italy 
AvanthiTM J25I centrifuge                                                                           Beckman Coulter, USA 
Biological safety cabinet class II, BH2000 series                                     Clyde-Apac, Australia 
BioPhotometer UV-visible spectrophotometer                                      Eppendorf, Germany 
CanoScan LiDE 210 scanner                                                                        Canon, Japan 
Canto II cytometer                                                                                       BD biosciences, Australia 
Carbon dioxide incubator                                                                           Sanyo, Japan 
Countess® automated cell counter                                                          Life Technologies, USA 
Dry block heater                                                                                          Memmert Co., Germany 
Edelstahl Rostfrei Oven                                                                              Memmert, Germany 
Electric incinerator                                                                                     Sherwood, USA 
Electrophoresis Power Supply (Power PAC 300)                                  Bio-Rad Laboratories, USA 
Electrophoresis Unit (mini gel)                                                                Bio-Rad Laboratories, USA 
Electroporator                                                                                            Bio-Rad Laboratories, USA 
Eppendorf centrifuge                                                                                Eppendorf, Germany 
Freeze dryer                                                                                                 Operon Freeze Dryer 
Freezer -20oC and -70oC                                                                            Sanyo Co., Japan 
Fridge 4oC                                                                                                     Sanyo Co., Japan 
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GelDoc imaging system                                                                             Bio-Rad Laboratories, USA 
GStorm®PCR System                                                                                  Gene Works, Australia 
Gyratory Mixer                                                                                             Ratek, Australia 
Heraeus Multifuge 1S-R centrifuge                                                         Thermo Electron   
                                                                                                                       Corporation, USA                                  
iBlot dry gel transfer device                                                                      Life Technologies, USA 
Ice maker                                                                                                     Rinnai, Australia  
iMark microplate absorbance reader                                                     Bio-Rad Laboratories, USA 
Incubator                                                                                                     Memmert Co., Germany 
Inverted Microscope                                                                                 Olympus Corporation, USA 
Light Microscope                                                                                       Olympus Corporation, USA 
Magnetic stirrer                                                                                         Industrial equipment  
                                                                                                                       & control, Australia 
Midi gel (Wide mini-sub cell GT cell)                                                      Bio-Rad Laboratories, USA 
MiniBead beater16                                                                                   Biospec products, USA 
Mini-PROTEAN® tetra cell PAGE unit           Bio-Rad Laboratories, USA                        
MiniSpin® Plus microcentrifuge                                                               Eppendorf, Germany 
NanoDrop Lite Spectrophotometer                                                       Invitrogen, USA 
Optima L-80 XP Ultracentrifuge                                                               Beckman Coulter, USA 
Optima™ L80 XP Ultracentrifuge                                                             Beckman Coulter, USA 
Orbital shaker                                                                                              UK Labs Direct, UK 
Orbitol Incubator cum shaker                                                                  Bioline, Australia                                         
pH Lab Meter                                                                                             Metrohm, AG, Switzerland  
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Platform mixer                                                                                            Ratek, Australia 
POLARstar Omega microplate reader                                                     BMG labtech, Germany 
PowerPac 300                                                                                             Bio-Rad Laboratories, USA 
PowerPac Basic                                                                                           Bio-Rad Laboratories, USA 
Pulse controller and Gene Pulser™ apparatus                                      Bio-Rad Laboratories, USA 
QsonicaQ1375 sonicator                                                                           Invitrogen, USA 
Roller mixer                                                                                                 Ratek, Australia 
Rotary evaporator                                                                                      Heidolph, Germany 
SDS power pack 3000xi                                                                            Bio-Rad Laboratories, USA 
Semi-Micro Balance (0.001-2 g)                                                              Sartorius, Germany 
Sigma 2-6 Compact Centrifuge                                                                Sigma Centrifuges, UK 
Smooth flow- Fume cupboard                                                                Laboratory sys, Australia 
UCT ultramicrotome                                                                                  Leica, Germany 
Uv spectrophotometer                                                                             Eppendorf, Germany 
Vortex mixer                                                                                                Ratek, Australia 
Water filtration system                                                                             Merck, USA 
Waterbath                                                                                                   Ratek, Australia 
XS105 Dual Range analytical balance                                                      Mettler Toledo, Australia 
Zetasizer nano-ZS                                                                                       Malvern, UK 
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2.3. Laboratory materials, consumables and suppliers 
      
15 and 50 mL centrifuge tubes                                                                 Corning, USA.  
200-mesh Formvar/carbon coated grid                                                  ProSciTech, Australia 
Acrodisk® sterile filters (0.22 and 0.45 μm)                                           Pall, USA 
Centrifuge tubes (1.5, 2.0, 10, 50 mL)                                                     Greiner, Germany 
Centrifuge tubes (10 mL)                                                                          Sarstedt, Australia 
Countess® Cell Counting Chamber Slides                                              Life Technologies, USA 
Cryovials (1.8mL, sterile)                                                                           Iwaki, Japan 
Cuvettes for electroporation (0.1 and 0.2 cm)                                      Mol Bio Products, USA 
Dialysis membrane tubing                                                                        Spectrum Labs, USA 
Dialysis Tubing Closures (universal)                                                        Spectrum Labs, USA 
Flat bottom 96 well plate, non-sterile                                                    Nunc, Denmark 
Glass beads (425-600 μm )                                                                       Sigma Aldrich, USA  
Glass cover slips                                                                                          Mediglass, Australia 
Glass slides                                                                                                   Sail brand, China 
Microcentrifuge tubes (1.5mL, non-sterile)                                           Sarstedt, Australia  
Mini-PROTEAN® TGX™ precast gel                                                          Bio-Rad Laboratories, USA          
Nitrocellulose iBlot® Transfer Stack (mini and midi)                            Life Technologies, USA 
Parafilm                                                                                                        Interpath, Australia 
PCR tubes (flat cap, 0.2 mL)                                                                     Quantum Scientific, USA  
Petri dishes (plastic, sterile)                                                                      BioLabs, Australia  
Polypropylene gravity flow column (1 mL)                                            QIAGEN, Germany 
Spectrophotometer cuvettes (UVette®, 10 mm)                                  Eppendorf, Germany 
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Syringes, sterile (3, 5, 10 and 50 mL)                                                       Terumo, Australia 
Tissue culture cell scrappers                                                                     Invitrogen, Australia               
Tissue culture flask with filter cap (25 and 75 cm2)                             Greiner, Germany 
Tissue culture plates, sterile (6, 24 and well plates)                            Greiner, Germany           
Ultra clear centrifuge tubes (13-2 mL, open-top, thin wall)                Beckman Coulter, USA 
Vivaspin 20 diafiltration cups                                                                   Sartorius, Germany        
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2.4. Bacteria, yeast strains, plasmids and cells used 
2.4.1. Bacterial strains 
Escherichia coli DH5alpha, strain was obtained from Smooker lab. 
Table 2. 1. Genotype of bacteria used for the study. 
Bacterial strain Genotype 
 
E. coli DH5alpha 
F– Φ80lacZΔM15 Δ(lacZYAargF) U169 recA1 endA1 hsdR17 
(rK–, mK+) phoA supE44 λ– thi1 gyrA96 relA1 
 
2.4.2. Yeast strain 
S. cerevisiae strain W3031A MATa (leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-
11,15urved) was used to over express recombinant VLP subunit protein. 
2.4.3. Plasmids 
Table 2. 2. List of plasmids used. 
Plasmid name Description Source Size of plasmid 
pYEX-BX Copper inducible yeast 
expression vector 
Ian Macreadie 
laboratory, RMIT 
University 
7.1 kb 
pCDNA5frtEGFPN1 
(CAT) 
Plasmid DNA expression 
vector with EGFP 
reporter gene, AmpR 
Health Innovations 
Research Institute, 
RMIT University 
6.5 kb 
 
2.4.4. Cell lines 
DC2.4 cells-Murine dendritic cell line kindly donated from Villadangos-laboratory, The 
University of Melbourne, Australia. 
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2.5. General reagents, buffers and media 
2.5.1 General reagents and buffers 
Almost all chemicals were purchased from Sigma Aldrich, except for some which are as 
mentioned. 
Acqua instant protein stain: (Bulldog Bio Inc., USA), stored at 4°C. 
Agarose gel: (1% w/v) agarose, molecular grade (Bio-Rad-Laboratories, USA) prepared in 1 x 
TAE buffer by heating using a microwave. 
 Amino acids: 1% stock solutions were prepared in MQH2O, sterilised by autoclaving or 
filtering and stored at 4°C. Histidine (Merck, Germany), Tryptophan (Sigma Aldrich, Germany), 
Adenine (Sigma Aldrich, Germany), Leucine (Sigma Aldrich, Germany), Uracil (Sigma Aldrich, 
Germany), Methionine (BDH, USA). 
Ammonium acetate (4 M): (Sigma Aldrich, Germany) prepared in d.H2O. 
Ampicillin: (CSL, Australia) 100 mg/mL stock prepared in MQH2O, filtered through a 0.22 μm 
filter and the aliquots stored were at −20°C. Final working concentration of 100 μg/mL was 
used in the media. 
Antibody diluent (Western blotting): 1% (w/v) BSA in PBS.  
Blocking buffer (Western blotting): 5% (w/v) BSA in PBS. 
Bovine serum albumin fraction v: (Sigma-Aldrich, Germany) 1 mg/mL stock aliquots in 
MQH2O stored at −20°C. 
Bradford assay reagent: Coomassie Brilliant Blue G-250 dye-100 mg (Sigma-Aldrich, Germany) 
dissolved in 95% (v/v) ethanol-50 mL (Merck, Germany) and then mixed with 85% (v/v) 
phosphoric acid-100 mL (Chem Supply, Australia), and make up to 1 L with d.H2O, stored at 
4°C a and filtered using a 0.45 μm filter disc prior to use. 
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Buffer-A (VLP purification): HEPES/KoH (10 mM)-Weigh HEPES (Invitrogen) and adjust pH to 
pH-7.8 with 1N KoH (Sigma Aldrich, Germany), Kcl-15 mM, EDTA (10 mM), Dithiothreitol (3 
mM).             
Chemical transformation buffer: PIPES-10 mM (Sigma Aldrich, Germany), Cacl2. 2H2O-15 mM 
(Sigma Aldrich, Germany), KCl-250 mM (Sigma Aldrich, Germany) dissolved in MQH2O 
followed by adjusting pH to 6.7 with KOH (Sigma Aldrich, Germany) and MnCl2.4H2O-55 mM 
(Sigma Aldrich, Germany), aliquots stored at -20°C. 
Chloramphenicol: (Sigma-Aldrich): 34 mg/mL stock was prepared in 96% ethanol 
(Merck,Germany), filtered using a 0.22 μm filter and the aliquots stored at −20°C. The final 
working concentration used was 4 μg/mL. 
Dimethyl Sulfoxide (DMSO): (Merck, Germany). 
Ethidium bromide bath (EtBr): 6 mg EtBr (Sigma-Aldrich, Germany) dissolved in 2 L d.H2O. 
 Ethyl alcohol-99%: (Merck, Germany). 
Glycerol: 50% (v/v) (BDH, USA), sterile. 
IMAC binding buffer: 10-50 mM imidazole (Sigma-Aldrich, Germany), 0.5 M NaCl (BDH, USA), 
PBS (Oxoid, England). 
IMAC elution buffer: 0.5 M NaCl (BDH, USA), 200 mM imidazole (Sigma-Aldrich, Germany), 
PBS (Oxoid, England). 
IMAC stripping solution: 50 mM EDTA (Merck, Germany), 0.5 M NaCl (BDH, USA). 
IMAC wash buffer: 0.5 M NaCl (BDH,USA), 10-60 mM imidazole (Sigma-Aldrich, Germany), 
PBS (Oxoid, England). 
Imidazole: (Sigma-Aldrich, Germany) 2.5 M imidazole stock prepared in MQH2O, filtered 
through a 0.45 μm filter, aliquots stored at 4°C in an Al-foil wrapped storage bottle. 
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Isopropyl-β-D-thiogalactopyranoside (IPTG): (Progen, Australia) 1 M stock prepared in 
MQH2O, filtered through a 0.22 μm filter and aliquots stored at −20°C. 
Lambda (λ) DNA- pstI: (Promega, USA), digested with pstI (Promega, USA) at 37°C overnight 
and aliquots stored at −20°C. 
Lipofectamine® 2000 Transfection Reagent: (Invitrogen, USA). 
Lithium chloride-1M: (Sigma Aldrich) prepared by dissolving in MQH2O. 
Molecular grade water (MGH2O): Double distilled, RNase and DNAse free (Gibco, USA). 
Nickel sulfate (NiSO4): (BDH, USA), 0.2 M NiSO4 stock prepared, filtered through a 0.45 μm 
filter and stored at RT. 
Opti-MEM® I (Reduced Serum Medium): stored at 4°C (Gibco, USA) stored at 4°C. 
PBS/Tween: PBS (Oxoid, England) with 0.05% (v/v) Tween 20® (Sigma-Aldrich, Germany). 
Penicillin-Streptomycin (10,000 U/mL): (Gibco, USA.) aliquots stored at -20°C. 
Phenol: Chloroform: Isoamyl alcohol (25:24:1) mixture: Chloroform-9.6 mL (Merc, Germany), 
phenol-10 mL (Sigma Aldrich, USA) and iso amyl alcohol (Sigma Aldrich, USA) were mixed 
carefully in a fumehood, covered with foil and stored at 4°C. 
 Phenyl methyl sulphonyl fluoride (PMSF): Sigma Aldrich, Germany. 
Phosphate buffered saline (PBS) tablets: (Invitrogen, Australia), prepared 1x buffer by 
dissolving 1 tablet per 100 mL and stored at 4°C. (sodium chloride 0.8%, potassium chloride 
0.02%, disodium hydrogen phosphate 0.115%, potassium dihydrogen phosphate 0.02%). pH 
7.4. 
Precision Plus Protein™ Kaleidoscope™ Prestained Protein Standards: 10 μL per well (Bio-
Rad Laboratories,USA), stored at −20°C. 
Precision Plus Protein™ Unstained standard: 10 μL per well (Bio-Rad Laboratories, USA), 
stored at −20°C. 
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PrestoBlue® cell viability reagent: (Gibco, USA), stored at 4°C. 
Protease inhibitor cocktail (S. cerevisiae specific): Sigma Aldrich, Germany. 
RPMI 1640 GlutaMAX™: (Gibco, USA), stored at 4°C 
RTB buffer (VLP purification): 50 mM Tris-Hcl (pH-7.9), 1 mM EDTA,10 mM 2-
mercaptoethanol, 10% glycerol. 
SDS running buffer (10 x): Tris-HCl-3% (w/v) (Merck, Germany), glycine-14.2% (w/v). 
(Amresco, USA), SDS-1% (w/v) (Merck, Germany). 
SepharoseTM Fast Flow: (GE Healthcare, Sweden) was charged with 0.2 M nickel sulphate 
(NiSO4) solution (BDH, USA). 
Skim milk: (Bolnac Foods Limited, Australia). 
Sucrose gradients for VLPs purification: 5-45% Sucrose cushion: 5,10,1 high-grade sucrose 
(BDH Chemicals, USA) in TEN buffer. Filtered through 0.2 μm filter and stored at 4°C. 
TEN buffer-10x (VLP purification): Tris-Hcl- 10mM (Merck, Germany) , EDTA- 2mM (Merck, 
Germany), NaCl- 140mM (BDH, USA) in MQH2O and stored at 4°C. 
Tris-Acetate-EDTA (TAE) electrophoresis buffer (1x): Tris-HCl-40 mM (pH 8.0) (Merck, 
Germany), acetic acid-20 mM (Merck, Germany), EDTA 2 mM (Merck, Germany). 
Trypan blue stain: 0.4% (Life Technologies, USA). 
Uranyl acetate: (Sigma Aldrich, Germany) 1% prepared in d.H2O, filtered through 0.45 μm 
filter and aliquots stored at 4°C. 
Wash buffer (Western blotting): 1% (w/v) BSA in PBS.  
Western Blue® stabilized substrate for alkaline phosphatase: (Promega, USA). 
 Yeast lysis buffer (genomic DNA isolation): TritonX100 (2% w/v) (Sigma Aldrich, Germany), 
SDS (2% w/v) (Merck, Germany), Tris-100 mM, pH-8 (Merc, Germany), EDTA-1 mM (Merc, 
Germany) prepared in d.H2O. 
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Yeast lysis buffer (IMAC): Imidazole (10mM), Urea (8M), Tric-Hcl (50mM, Nacl (150mM).   
 β-mercaptoethanol: electrophoresis purity grade (Bio-Rad Laboratories, USA). 
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2.5.2 General media used  
All media were prepared following standard recipes at room temperature using MQH2O. The 
media was autoclaved at standard conditions (121oC, 20min) and stored at 40C until use. 
Luria-Bertani (LB) agar: Tryptone-1% (w/v) (Oxoid, England), yeast extract-0.5% (w/v) (Oxoid, 
England), NaCl-1% (w/v) (BDH, USA), bacteriological agar-1% (w/v) (Oxoid, England) dissolved 
in MQH2O. 
Luria-Bertani (LB) broth: Tryptone-1% (w/v) (Oxoid, England), yeast extract-0.5% (w/v) 
(Oxoid, England), NaCl-1% (w/v) (BDH, USA) dissolved in MQH2O. 
SOC media: yeast extract-0.5% (w/v) (Oxoid, England), Tryptone-2% (w/v) (Oxoid, England), 
NaCl-10 mM (BDH, USA), Kcl-1M (Sigma Aldrich, Germany) prepared in MQH2O and 
supplemented with 2M Mg+2 stock. 
Yeast selective media (SD Ura-): Yeast nitrogen base-0.67% (w/v) (Sigma Aldrich, USA), 
Glucose-2 % (w/v) (Oxoid, England) prepared in MQH2O, autoclaved and added Adenine-1%, 
Histidine-1%, Tryptophan-1%, Leucine-1%, Methionine-1%, Lysine-1%. 
YEPD media (yeast complete media): yeast extract-1% (w/v) (Oxoid, England), peptone-2% 
(w/v) ((Oxoid, England), Glucose-2 % (w/v) (Oxoid, England) prepared in MQH2O. 
YEPD media agar plates: yeast extract-1% (w/v) (Oxoid, England), peptone-2% (w/v) ((Oxoid, 
England), Glucose-2 % (w/v) (Oxoid, England), bacteriological agar-2% (w/v) (Oxoid, England) 
prepared in MQH2O. 
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 2.6. Restriction enzymes and other enzymes 
All the enzymes were used in their recommended supplied buffer and stored at -200C.                                       
ApaI                                                                                                               Promega, USA 
BamHI                                                                                                           New England Biolabs, USA 
Benzonase                                                                                                    Invitrogen, USA 
DNaseI                                                                                                          Promega, USA 
HindIII                                                                                                           New England Biolabs, USA 
MyTaq™ Mix                                                                                                Bioline, Australia 
Phusion High-Fidelity DNA Polymerase (2 U/μL)                                   Invitrogen, USA 
RNase-A                                                                                                        Sigma Aldrich, Germany 
SalI                                                                                                                New England Biolabs, USA 
 
2.7. Commercial kits 
All the buffers and reagents in the kits were stored and used by following the manufacturer’s 
instructions. 
QIAquick PCR Purification Kit                                                                   QIAGEN, Germany 
Bioline ISOLATE plasmid Mini kit                                                             Bioline, Australia 
PureLink® HiPure Plasmid Midiprep Kit                                                   Invitrogen, USA 
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2.8. Primers used 
All the primers were synthesised by Gene Works, Australia, supplied in lyophilised form and 
the stocks were prepared by resuspending in mol. grade water. 
Table 2. 3. List of primers used. 
Primer name Sequence 
 
TyA381His 
primers 
TyA381His 
forward 
primer 
 
5’ CTCGG ATC CAA ATGGAATCCCAACAAT3’ 
TyA381His 
reverse 
primer 
 
5’CGCGTCGACTCAATGGTGATGGTGATGGTGGGATTTGGGTTTGGTT3’ 
CUP 
promoter 
sequencing 
primers 
CUP 
forward 
primer 
 
5’CATATAGAAGTCATCGA3’ 
CUP 
reverse 
primer 
 
5’TTTGCAGCTACCACATT3’ 
T7 
promoter 
sequencing 
primers 
T7 
forward 
primer 
 
5’TAATACGACTCACTATAGGG3’ 
T7 reverse 
primer 
 
5’ GCTAGTTATTGCTCAGCGG3’ 
 
2.9. Antibodies 
Mouse anti-His IgG (storage 20°C)                                                         GE Healthcare, Sweden 
Goat anti-rabbit IgG - AP (storage 4°C)                                                  Abcam, England 
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2.10. Bacterial and yeast growth conditions 
2.10.1 Growth and storage conditions of E. coli 
E. coli DH5alpha was grown at 370C in an incubator overnight for plasmid isolation. The plates 
with transformed DH5alpha were grown at 370C for 16-18 h to observe colonies.  
2.10.2 Growth conditions of S. cerevisiae 
 A 500 mL of S. cerevisiae culture was grown at 300C, 230 rpm in 2.5 L flasks to get good 
aeration. The yeast cells containing copper inducible expression vector was grown at 280C 
after inducing protein expression. 
2.11. Bacterial and cloning methods 
2.11.1. Amplification of plasmids 
The plasmids were amplified in E. coli DH5alpha strain. A 50 ng of plasmid DNA was 
transformed to a 50 μL aliquot of competent E. coli DH5alpha cells at 2 V electric pulse using 
Bio-Rad gene pulser or chemical transformation. Then 1 mL of LB broth was added 
immediately to the transformed cells and incubated at 370C for an hour to get outgrowth of 
cells. After outgrowth, a 20 μL and 100 μL of mixture was plated on to LB agar plates with 
antibiotics specific for the plasmid. The plates were incubated at 370C for 16-18 h to observe 
transformants. A single isolated colony was inoculated in 10 mL LB broth and grown overnight 
at 370C, 200 rpm in incubator cum shaker. Then the overnight culture was used to extract the 
plasmid DNA using Bioline plasmid isolation kit. The plasmids were eluted in a 50 μL of TE 
buffer or molecular grade water and the concentration was measured using a NanoDrop Lite 
Spectrophotometer. 
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2.11.2. Plasmid isolation 
Plasmid isolation was performed using the miniprep and midiprep kits from Qiagen and 
Invitrogen respectively, following the manufacturer’s instructions. Ten millilitres of 
transformed E. coli culture grown in the presence of appropriate antibiotics was used for 
plasmid isolation. The plasmids were eluted in TE buffer provided with the kit except for the 
sample used for Sangers sequencing. The plasmids were eluted in molecular grade water for 
sequencing as the salts in TE buffer may interfere with sequencing. The plasmid samples were 
stored at -20oC in TE buffer. 
2.11.3. Preparation of chemically competent E. coli cells 
A single E. coli colony from LB plate less than 2 days old was inoculated into a 5 mL SOB 
medium and incubated overnight on a shaker at 37OC. One millilitre of this overnight culture 
was inoculated into 100 mL SOB media in 500 mL glass flask to allow good aeration and 
incubated at 260C by shaking vigorously at 230 rpm. The E. coli culture was chilled on ice for 
10 min once the optical density reached 0.55 (mid-log phase), followed by harvesting the cells 
by centrifugation at 40C for 10 min at 2500 x g. The supernatant was discarded and the cell 
pellet was resuspended gently in a 40 mL ice cold transformation buffer and incubated on ice 
for 15 min. The centrifugation was repeated again and the cell pellet was resuspended in a 
final volume of 5 mL ice cold transformation buffer followed by incubation on ice for 5 min. E. 
coli were thoroughly mixed after adding 187 μL of DMSO and incubated on ice for 5 min, the 
addition of DMSO and incubation steps was repeated. This final preparation of cells was 
aliquoted as 100 μL fractions in ice cold sterile Eppendorf tubes. The tubes were frozen 
quickly in liquid nitrogen and immediately stored at -800C. 
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2.11.4. Method of chemical transformation 
The aliquots of chemically competent E. coli cells (one aliquot per transformation) were 
slowly thawed on ice for 10 min. The cells were mixed gently by agitation of the tube and 
placed back on ice immediately. Approximately 0.5 μL pure plasmid DNA or 3 μL ligated DNA 
was added to the cells, gently mixed and incubated on ice for 15 min. Heat shock was applied 
to the cells by placing them on 420C heat block for 50 sec and then on ice for 2 min 
immediately. Finally, 900 μL of SOC media was added followed by incubation at 370C for 1 h 
by shaking vigorously. The LB plate with respective antibiotic was spread inoculated with 100 
μL of the transformed culture and incubated at 370C overnight for observing colonies. 
2.11.5. Electroporation 
Electroporation was performed using Bio-Rad Gene Pulser™ apparatus. A 50 μL aliquot of 
electrocompetent cells and 1 μL of purified plasmid or 3 μL of ligation mix were added in an 
electro cuvette and pulse of 2 kV was applied to the mixture. One millilitre of LB media was 
added immediately to the cells, incubated for 1 h at 370C and plated on LB plate with an 
appropriate antibiotic. The plates were incubated at 370C overnight for observing colonies. 
2.11.6. Restriction digestion of DNA 
Restriction digestion was performed by following the manufacturer’s instructions. ‘Double 
digest finder’ online tool from NEB labs was used to find the suitable conditions for the set of 
enzymes. Briefly, 200 ng of plasmid was used in 20 μL reaction supplemented with BSA and 1x 
cut smart buffer. The following restriction digestion reaction was used to digest eGFP plasmid 
throughout the cloning process. 
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2.11.7. Agarose gel electrophoresis 
The DNA samples (PCR products or plasmid double digests) were loaded onto 1% agarose gel 
and electrophoresis was carried out at 100 V for 60 min. After electrophoresis, the gel was 
stained in an ethidium bromide bath (3 μg/mL) and destained under slowly running tap water 
for 10-15 min to get clear background. The marker used was Lambda phage DNA digested 
with pstI. The agarose gels were observed under Bio-Rad GelDoc imaging system and 
photographs were captured. 
2.11.8. Quantification of DNA by Nanodrop 
DNA was quantified using NanoDrop Lite Spectrophotometer, by following the manufacturer’s 
instructions. Briefly, 1 μL of molecular grade water was used as a blank followed by 1 μL of 
sample. The purity of plasmid DNA was estimated based on the 260/280 ratio. 
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Table 2. 4. Restriction digestion conditions for ApaI and HindIII. 
 
 
 
 
 
 
 
 
 
 
Double digestion Reaction set up Incubation 
conditions 
 
 
ApaI and HindIII 
ApaI 
HindIII 
CutSmart buffer 
BSA 
Plasmid 
Mol grade water 
2 μL (10 U) 
1 μL (10 U) 
2 μL 
0.5 μL 
200 ng 
up to 20 μL 
 
 
Overnight at 
room 
temperature  
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2.12. Protein methods 
2.12.1. Bradford assay  
The concentration of proteins present in the sample was estimated using the Bradford assay 
(Bradford 1976). Bovine serum albumin fraction V (1mg/mL) was used as a standard stock 
solution to prepare known protein concentrations to generate a standard curve. The samples 
and standards were diluted using 0.15 M NaCl as required. A 100 μL of unknown or standard 
protein solution was mixed with 1 mL of freshly filtered Bradford reagent and incubated for 2 
min to develop the coloured reaction. Then 200 μL of each protein sample was dispensed to 
the wells of a flat-bottom 96-well plate in duplicates to measure the absorbance (595 nm) 
using the iMark™ Microplate absorbance reader. A standard curve was generated by plotting 
the absorbance of the BSA standards (Y-axis) versus concentration of the standards (x-axis). 
This standard curve was used to estimate the protein concentration of unknown samples. 
2.12.2. SDS-PAGE protein gel running 
A 4–20% Mini-PROTEAN® TGX™ Precast Protein Gels was used to load the samples. The 
protein samples (≈10 mL) were heated at 100°C for 5 min after adding 5 x SDS loading dye. 
The gel cassettes were assembled and placed inside the gel tank by following the 
manufacturer’s (Bio-Rad Laboratories, USA) instructions. The gel tank was then topped up 
with SDS-PAGE running buffer. The prepared protein samples along with the respective 
protein standards (Coomassie stain-Precision Plus Protein™ Unstained Protein Standards, 
Immunoblotting-Precision Plus Protein™ Kaleidoscope™ Prestained Protein Standards) were 
loaded into the wells and electrophoresis was performed at two different voltages, 60 V for 
30 min followed by 180 V for 70 min.  
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2.12.3. Staining SDS-PAGE gels (Acqua stain) 
An instant protein gel stain, Acqua stain (Bulldog Bio Inc., USA), was used to stain protein gels. 
Approximately 50 mL of stain was added to each gel in a plastic container and left overnight 
on a platform shaker overnight for the development of bands. The gel was then destained in 
d.H2O for 2 h to get clear background for imaging. The images were captured using a Canon 
scanner, Aus. 
2.12.4. Western blotting 
The protein bands separated by SDS-PAGE were transferred onto a nitro cellulose membrane 
(iBlot® transfer Stack) using iBlotTM Dry Blotting System-7 min following the manufacturer’s 
instructions. Briefly, the gel was placed in between the anode (bottom stack) and cathode 
(top stack attached with a nitro cellulose membrane) with a wet (with d.H2O) filter paper on 
top of the gel. The bubbles trapped underneath the gel were removed with a blotting roller 
and the device lid was closed by placing a pressure sponge. The transfer process was initiated 
using the default program which completes in 7 min. The device was disassembled to remove 
the nitrocellulose membrane transferred with protein bands. The membrane was incubated 
in blocking buffer (5% BSA) for 1 h at RT or 4°C overnight followed by incubation with 1o and 
2o antibodies for 2 h each time. The membrane was placed inside a 50 mL Falcon tube and 
rotated gently on a roller shaker during the incubation times. A wash step (2 min with TBS, 
thrice) was performed in between each incubation step to ensure the removal of unbound 
blocking agent or antibodies. The membrane was then developed with an AP-substrate. The 
reaction was stopped by washing the membrane with d.H2O. The membrane can be stored in 
TBS buffer for several days once desired band intensity was reached. 
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2.13. Tissue culture methods 
2.13.1. Growth and maintenance of DC2.4 cell line 
In vitro assays were performed with a murine dendritic cell line (DC2.4). Cell culture reagents 
were purchased from Invitrogen. DC2.4 cells were maintained in RPMI 1640 media with 1 mM 
HEPES and 2 mM L-glutamine supplemented with 10% heat inactivated foetal bovine serum 
(FBS). Cells were incubated at 37oC with a 5% CO2 humidified atmosphere and subcultured 
every 2-3 days. Cell scrapers were used to detach cells from flasks. 
2.13.2. Cytotoxicity assay  
The PrestoBlue® cell viability reagent was used to study the cytotoxic effect of different 
concentrations of test samples on DC2.4 cells in a 96 well tissue culture plate. Cells were 
seeded at a density of 5 x 104 cells per well in RPMI 1640 medium supplemented with 10% 
heat inactivated FBS and incubated overnight at 37°C in a 5% CO2 humidified atmosphere. 
Following the incubation, various concentrations of test samples suspended in 20 μL of sterile 
PBS were added to make a final volume of 120 μL media per well. Replica plates were set up 
for each time point and were incubated for up to 72 h. At the end of each time point, 12 μL of 
PrestoBlue® cell viability reagent was added to each well and incubated at 37°C for 60 min in 
the dark. A POLARstar Omega microplate reader was used to measure absorbance at 570 nm 
with 600 nm reference wavelength for normalisation during the data processing. The 0.1% 
Triton X100 and culture media served as an internal positive and untreated control, 
respectively. The dead cell dependent colour conversion (background and positive control) 
was subtracted from all the treatment groups and the cell viability percentage was calculated 
by considering untreated control cells as 100% viable.  
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2.13.3. Transfection 
DC2.4 cells were seeded in 6-well plates at a density of 3 x 105 cells per well overnight prior to 
transfection. The safe concentration of samples to apply per well was selected based on 
cytotoxicity assay data. The respective samples were added to the cells which were incubated 
in serum-free Opti-MEM media for 6 h at 37oC. Subsequently, the media was changed to 
RPMI 1640 and incubated for further 72 h before being analysed for GFP positive cells using a 
BD FACS Canto II instrument. Lipofectamine® 2000-based transfection was used as a 
reference point to evaluate the in vitro transfection efficiency of the test samples. 
2.13.4. Preparation of sample for flow cytometry analysis  
At the end of the transfection (72 h), cells were washed once with PBS and detached using cell 
scrapers. Cells were completely resuspended in 500 μL PBS and introduced into a BD FACS 
Canto II flow cytometer (BD Biosciences, San Jose, USA). The transfection efficacy was 
measured based on the count of GFP positive cells fluorescing at 525 nm. For each sample 3 
replicas were set up and a minimum of 30,000 events were collected. The average value of 
the three replicas was presented. The data was then statistically analysed using Student’s t-
test: a significant p value is ≤0.05. 
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3.1. Introduction 
There are many different types of vaccines available and each type of vaccine has their own 
advantages and disadvantages. The aim of this study is to utilise non-viral systems for DNA 
vaccine delivery using pEGFP as a reporter plasmid. The word plasmid was coined by Joshua 
Lederberg in 1952 to describe the extra chromosomal material. Since their discovery, besides 
being investigated for their function in the native environments, their application has been 
extended to use in molecular biology and various other fields. The plasmids are widely used 
for recombinant protein production in both prokaryotic (e.g. E. coli), and eukaryotic systems 
(e.g. S. cerevisiae) depending on the desired application. DNA vaccines are another advanced 
modified version of plasmids, in which an antigen encoding gene under the control of 
mammalian promoter is introduced into the plasmid (Gregersen 2001). The main components 
of a DNA vaccine are as depicted in Figure 3.1.  
DNA vaccines are bacterially derived plasmids containing a gene encoding the desired 
antigen. The expression is driven by a promoter active in mammalian cells (generally a strong 
viral promoter), a transcription terminator, and often an antibiotic resistance gene that 
facilitates the selection of bacteria maintaining the plasmid. Sites for increasing the potency 
of DNA vaccines are shown in Figure 3.1. For example, additional genes encoding cytokines or 
co-stimulatory molecules can be incorporated adjacent to the antigen gene (Liu 2003). 
Incorporation of a viral origin of replication gene has been shown to increase the potency of 
DNA vaccines. Such alterations to the plasmid can improve protein expression, leading to 
increased immune responses. 
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Figure 3. 1. Schematic representation of general components of DNA vaccines. 
Figure adapted from (Liu 2003) 
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Ty-virus-like particles are native transposons present in almost all laboratory strains of S. 
cerevisiae, harbouring 30-35 copies of TYA gene in each haploid genome (Kingsman et al., 
1981). Ty1 is more popular among Ty1-Ty5 type transposons because of its resemblance to 
retroviral transcription and hence it has been extensively studied (Al-Khayat et al., 1999). Ty1-
VLPs or Ty-VLPs are produced during transposition as intermediates which have TYa or P1 
protein as a structural unit. These Ty-VLPs are packed with Ty RNA and other enzymes 
required for transposition. The attempt to purify Ty-VLPs from wild type S. cerevisiae 
produced very low amount (data not represented here). Interestingly, in contrast to our 
observations, Capsey and his colleagues in 1990 demonstrated the ability of S. cerevisiae 
strain NCYC74 endogenous chromosomal Ty elements to direct the synthesis of high levels of 
Ty VLPs, however this was not demonstrated in any other strains. So overexpression of TYa 
protein in the recombinant system was adapted to produce Ty-VLPs. TYa protein has 440 
amino acids, but truncated TYa protein of up to 381 amino acids may be used to produce Ty-
VLPs which are more uniform in diameter and morphology in comparison to wild type 
particles (Palmer et al., 1997). The cytoplasmic environment of a recombinant system 
provides a suitable environment for the assembly of Ty-VLPs compared to the periplasm 
(Uhde-holzem et al., 2010). Although several recombinant vectors have been previously 
constructed for TYA381 expression (Burns et al., 1994), a new system was constructed for this 
current study utilising the copper-inducible expression plasmid pYEX-BX for expression in S. 
cerevisiae W303-1A strain. The C-terminus of the TYa protein is embedded in Ty-VLPs and the 
N-terminus is exposed. However, the N-terminal fusions for hybrid Ty-VLPs tend to produce 
aberrant particles (Roth 2000), so in this study a 6xHis-tag was attached at the C-terminus to 
monitor the protein monomer during the purification process. 
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The aims of the experiments performed in this chapter were as follows; 
x Extraction of the whole cell genomic DNA of S. cerevisiae W303-1A 
x Amplification of the TYA gene from the genomic DNA of S. cerevisiae by designed 
primers 
x Construction of the recombinant vector for the overexpression of theTYA381His 
protein 
x Transformation of S. cerevisiae with a TYA recombinant plasmid 
x Optimisation of parameters for Tya protein expression 
x Standardisation of the Ty-VLP purification protocol 
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3.2. Experimental methods 
3.2.1. Construction of yeast recombinant vector overexpressing Ty-VLP structural 
protein 
3.2.1.1. Construction of pYEX-BX vector 
An E. coli-yeast shuttle vector, pYEX-BX, (acquired from CSIRO) containing the copper-
inducible promoter (PCUP1) adjacent to the multiple cloning site (MCS) was employed for 
production of recombinant proteins. The plasmid includes a MCS containing five restriction 
sites, BamHI, PvuII, SalI, PstI and EcoRI, to facilitate cloning of a foreign gene expressing the 
desired protein (Figure 3.2), as well as the ampicillin resistant gene AmpR, enabling selection 
of E. coli transformants during cloning. A yeast strain auxotrophic for leucine and uracil was 
used for protein expression. Transformants were grown in the absence of leucine to express 
foreign protein and to amplify the plasmid further. The leu2d marker has a partially defective 
promoter resulting in an elevated copy number of plasmid to survive in low leucine 
concentrations.  
pYEX-BX plasmid genotype: AmpR, ori (pUC), CUP1 promoter, leu2d, URA3, ori (2μ), MCS 
(BamHI, PvuII, SalI, PstI, EcoRI). 
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Figure 3. 2. Vector map of pYEX-BX yeast copper-inducible expression vector 
Figure and supplementary information of vector adapted and modified from (Macreadie 
2007). 
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3.2.1.2 Extraction of S. cerevisiae whole genomic DNA 
Approximately 10 mL of S. cerevisiae culture was grown to saturation in a 50 mL falcon tube 
and the cells were harvested by centrifugation at 2000 x g for 5 min. Supernatant was 
discarded followed by resuspending cell pellet in 0.5 mL ultra-pure water (MQH2O). Then the 
contents were transferred to a 1.5 mL Eppendorf tube and cells pelleted by a 5 sec 
centrifugation at 14000 x g. The supernatant was discarded and the pellet was vortexed 
thoroughly to resuspend yeast cells in residual liquid. To disrupt the cells a solution of 0.2 mL 
lysis buffer, 0.2 mL phenol-chloroform-isosamyl alcohol mixture and 0.3 g acid-washed glass 
beads was added and vortexed for 4 min. Then, 0.2 mL TE (Tris-EDTA) buffer was added and 
centrifuged for 5 min to pellet the cell debris. The aqueous layer containing DNA was 
collected and 10 mL of absolute ethanol was added and mixed thoroughly by inversion to 
precipitate yeast genomic DNA. The precipitated DNA was harvested by spinning briefly for 2 
min followed by resuspension in 0.4 mL molecular grade water supplemented with 30 μL of 1 
mg/ml RNase-A and incubated at 370C water bath for 30 min. The pure genomic DNA was 
precipitated by adding 10 mL of 4 M ammonium acetate and 1 mL absolute ethanol by 
incubation on ice for 10 min. Finally, the genomic DNA was harvested by centrifuging for 2 
min. The pellet was air dried to remove residual ethanol followed by resuspending in 50 μL TE 
buffer. The sample was then stored at -200C for further use.  
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3.2.1.3. Amplification of TYA gene from yeast whole genomic DNA 
3.2.1.3.1. Designing primers for TYA381His gene 
Both forward and reverse primers were designed using ‘Clone Manager software version 7.11’ 
for amplifying the TYA gene nucleotides encoding up to 381 amino acids with a C-terminal 
6xHis tag. The TYA gene sequence specific to S. cerevisiae W303-1A was obtained from the 
Saccharomyces Genome Database (SGD). The primers were designed by incorporating a GC 
clamp and BamHI, SalI restriction sites at 5’ and 3’ ends respectively for directional cloning 
into plasmids. The melting temperature of primers was above 400C. The primers were 
manufactured by ‘GeneWorks’.  
3.2.1.3.2. Preparation of primers for PCR 
Primers were supplied in lyophilised state from the manufacturer with a specified amount in 
nanomoles. The samples were dissolved in molecular biology grade water to a concentration 
of 100 mM, and further diluted to 10 pmol concentration ready to use in a PCR reaction. The 
primers were aliquoted and stored at -200C until use. 
3.2.1.3.3. Optimisation of PCR parameters for amplification of TYA381His gene 
from whole genomic DNA of S. cerevisiae 
The PCR conditions were optimised for both MyTaqTM DNA polymerase (for detection during 
cloning) and proof reading Phusion® High-Fidelity DNA Polymerase (for cloning). About 50-
100 ng of DNA template was used in a 50 μL PCR reaction. In order to get the best PCR 
product, the annealing temperature was optimised by performing a gradient PCR. The 
temperature ranges of 45-500C (450C, 45.90C, 47.80C and 49.90C) were selected for MyTaq™ 
DNA polymerase and the range of 50-550C (500C, 51.20C, 52.80C and 54.80C) were applied for 
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Phusion£ polymerase. PCR products were analysed on 1% agarose gels and the optimum 
conditions resulting in high quality amplification were selected. 
3.2.1.4. Cloning of amplified TYA381His gene into pYEX-BX plasmid 
The amplified TyA381His was cloned into the multiple cloning site downstream of the CUP1 
promoter as shown in Figure 3.3. The series of steps for the cloning process is as follows; 
3.2.1.4.1. Amplification and isolation of plasmids 
The pYEX-BX plasmid was used for overexpression of recombinant TYA381His protein in this 
study. The plasmid was transformed into competent E. coli DH5α and plated out on LB agar 
plate containing ampicillin. The amplification of plasmids was performed following standard 
protocols (section 2.11.1). The resultant transformants were inoculated in LB broth with 
ampicillin and grown overnight at 370C. Plasmid isolation was performed using Bioline 
plasmid miniprep kits following the manufacturer’s instructions. The purified plasmid 
concentration was measured by a Thermo Scientific nanolite spectrophotometer using 
MQH2O as a blank. The isolated plasmids were stored in 1x TE buffer at -200C. 
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Figure 3. 3. Schematic representation of pYEX-BX+TYA381His construct.  
The TyA381His gene was cloned between the unique BamHI and SalI restriction sites in the 
MCS. The size of plasmid along with the insert is 8.3 kb. The plasmid map was made using 
Snapgene software. 
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3.2.1.4.2. Double restriction enzyme digestion 
The identity of the plasmid was confirmed by performing vector specific double digestion 
using BamHI+SalI under the following conditions shown in Table 3.1. The enzyme set was 
selected based on nucleotide sequence data of the plasmid. Approximately 100 ng of plasmid 
was digested with BamHI+SalI and analysed on 1% agarose gel. The pYEX-BX plasmid was 
expected to produce a 7074 bp linear fragment after BamHI+SalI restriction digestion. 
3.2.1.4.3. Generating sticky ends 
The PCR product for TYA381His and pYEX-BX plasmid were digested with BamHI+SalI using 
parameters mentioned in the Table 3.1 to generate compatible sticky ends. These sticky ends 
were generated to aid in directional cloning and confirmed by analysing the digested 
fragments on 1% agarose gel. 
3.2.1.4.4. Ligating TYA381His gene into pYEX-BX plasmid 
Double digested products were cleaned to remove digested nucleotides and restriction 
enzymes using Qiagen PCR clean up kit by following the manufacturer’s instructions. Ligation 
was performed with the molar ratio of insert: vector as 1:3. The following equation was 
applied to calculate the amount of insert required for ligation by using 50 ng of vector in a 
single ligation reaction. 
݊݃݋݂݅݊ݏ݁ݎݐ ൌ ݊݃݋݂ݒ݁ܿݐ݋ݎ ൈ ܭܾݏ݅ݖ݁݋݂݅݊ݏ݁ݎݐܭܾݏ݅ݖ݁݋݂ݒ݁ܿݐ݋ݎ ൈ ݉݋݈ܽݎݎܽݐ݅݋
݅݊ݏ݁ݎݐ
ݒ݁ܿݐ݋ݎ 
            
Ligation was performed using T4 DNA ligase (New England Biolabs) using optimised 
parameters as shown in Table 3.2. The Eppendorf tube containing ligation mix was floated on 
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water at 16°C in an insulated box and the setup was incubated overnight at 4°C. After 
overnight incubation the ligation reaction was terminated by storing at -20°C until use. 
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Table 3. 1. Restriction double digestion parameters used to cleave pYEX-BX yeast expression 
vector. 
Double digestion Reaction set up Incubation 
conditions 
 
 
BamHI and SalI 
BamHI 
SalI 
CutSmart buffer 
BSA 
Plasmid 
Mol grade water 
1 μL (10 U) 
1 μL (10 U) 
2 μL          
0.5 μL 
200 ng 
-up to 20 μL 
 
 
370C for 2 h 
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Table 3. 2. Ligation reaction set up and conditions for insertion of TyA381His into pYEX-BX 
vector. 
Optimised conditions to insert the TyA381His gene into the pYEX-BX plasmid are described 
above. The total volume of reaction was 20 μL with 50 ng vector and the amount of insert was 
calculated to achieve 1:3 molar ratio.  
 
 
 
 
 
 
 
 
 
Reaction set up Incubation 
conditions 
pYEX-BX 
TYA381His 
T4 DNA ligase 
10 x ligase buffer 
Molecular grade water 
50 ng 
24.6 ng 
1 μL 
2 μL 
up to 20 μL 
 
 
 
Overnight at 16°C to 
4 °C 
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3.2.1.5. Transformation and selection of clones 
 Chemically competent E. coli DH5α cells used for transformation were prepared and 
transformed with (pYEX-BX + TYA381His) ligation mix by following standard protocols (section 
2.11.3 & 2.11.4) Approximately 2 μL of ligation mix was used for transformation and cells 
were plated onto selective LB plates with ampicillin, incubated 16-18 h at 37°C.  
The positive clones were selected using miniprep and double digestion approach. Selected 
numbers of colonies from the LB-amp plate were grown overnight in LB broth containing 
ampicillin, followed by miniprep and double digestion with BamHI+SalI to confirm the 
presence of the insert.  
3.2.1.6. Nucleotide sequencing of construct to confirm the presence of insert 
Positive clones were selected using double digestion strategy and were further subjected to 
sequencing to confirm successful directional cloning of TYA381His gene into the MCS of the 
pYEX-BX plasmid.  
3.2.1.6.1. Primer design 
 Copper-inducible promoter (CUP1) specific primers were designed using ‘Clone Manager 
version 7.11’ to facilitate sequencing of the gene inserted within MCS of the pYEX-BX plasmid. 
Care was taken while designing the primers to obtain a melting temperature above 500C. 
Primers were synthesised from Geneworks and delivered in lyophilised form. The primers 
were resuspended in molecular grade water to a concentration of 100 mM, and further 
diluted to 10 pmol prior to addition in a PCR reaction.  
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3.2.1.6.2. Preparation of sample for sequencing 
Sequencing was performed by the Australian Genome Research Facility (AGRF), Melbourne 
VIC, by Sanger’s method using a ‘Life Technologies AB3730xl 96-capillary sequencer’. Samples 
were prepared following AGRF instructions. Plasmid was isolated in MQH2O instead of TE 
buffer at the final step of the miniprep. The quality of plasmid was confirmed by running on 
agarose gel and ensuring an OD260/OD280 of 1.8 to 2. Approximately 1 mg of plasmid sample 
was mixed with 10 pmol of forward and reverse primers in separate Eppendorf tubes for 
submission to AGRF.  
3.2.1.6.3. Analysis of sequencing data ‘in silico’ 
Sequencing data was generated from both forward and reverse orientations of CUP1 
promoter. A contig was prepared manually using nucleotide sequencing data generated from 
forward and reverse primers and translated using the ExPASy translate tool. Data was 
analysed further using the following databases as indicated in Table 3.3. 
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Table 3. 3. List of databases and software used for ‘in silico’ analysis from nucleotide 
sequencing data. 
 
 
 
 
 
Database Purpose Reference 
Basic Local Alignment 
Search Tool (BLAST) 
To identify the encoded gene by 
querying a nucleotide database 
https://blast.ncbi.nlm.ni
h.gov/Blast.cgi#768828
779 
ExPASy ¾ To translate into protein 
sequence and confirm the 
presence of a C-terminal 6xHis-
tag 
¾ To calculate PI value and 
theoretical molecular weight 
http://web.expasy.org/t
ranslate/ 
 
http://web.expasy.org/c
ompute_pi/ 
Protein calculator 
(Innovagen) 
To calculate molecular weight, PI value 
and net charge of a protein 
http://pepcalc.com/prot
ein-calculator.php 
SCRATCH protein 
predictor (Omics 
group) 
To calculate the probability of 
disulphide bond formation 
http://www.ics.uci.edu/
~baldig/scratch/explana
tion.html 
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3.2.2. Introducing recombinant vector into S. cerevisiae and optimising parameters 
for protein overexpression 
Construction of a recombinant vector in a cloning host E. coli precedes transformation into 
expression host S. cerevisiae in order to express the targeted protein.  
3.2.2.1. Transformation and selection of positive clones of S. cerevisiae harbouring 
(pYEX-BX + TYA381His) vector 
3.2.2.1.1. Growing S. cerevisiae for transformation  
A fresh YEPD (1% Yeast Extract, 2% Peptone, and 2% Dextrose) agar plate was inoculated with 
a fresh overnight grown S. cerevisiae W303-1A and incubated at 300C for 2 days for dense 
growth. 
3.2.2.1.2. Transformation procedure 
An EZ-YeastTM transformation kit (Mp Biomedicals, Ohio) was used for yeast transformation 
following the manufacturer’s instructions. S. cerevisiae was patch streaked on agar media and 
grown for several days at 30°C until patches appeared dense. Approximately 3-4 mm size 
patches were resuspended in 125 μL of EZ-Transformation solution followed by the addition 
of 2 μg of plasmid DNA and 5 μL of carrier DNA. The cells were mixed thoroughly with the 
contents using vortex mixer and incubated at 42°C for 30 min. Then the mixture was spread 
inoculated on selective plates without uracil and incubated at 300C for at least 3-4 days to 
observe transformants.  
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3.2.2.1.3. Selection of transformants 
3.2.2.1.3.1. Auxotrophic selection 
S. cerevisiae transformants were screened for the presence of (pYEX-BX + TYA381His) plasmid 
using a selective plate lacking uracil. Phenotypic testing was performed further to confirm the 
phenotype of transformants based on their auxotrophic requirements.  
3.2.2.1.3.2. Phenotypic test 
The transformed colonies from selective plates were resuspended in 100 μL sterile MQH2O 
and 5 μL of the suspension was then spotted onto individual selective plates lacking single 
auxotrophic amino acid. The potential transformants with the recombinant plasmid were 
expected to grow on plates without uracil and leucine, as the constructs contained URA3 and 
LEU2 genes. 
3.2.2.1.4. Storage and recovery of transformants 
S. cerevisiae harbouring (pYEX-BX + TYA381His) can be stored in 40% glycerol for up to a year. 
Overnight culture of freshly transformed S. cerevisiae was used to prepare glycerol stocks and 
1 mL aliquots stored at -800C. The glycerol stocks were recovered by growing them in 50 mL 
selective media overnight at 300C and scaled up to 500 mL for the induction of protein 
expression. 
3.2.2.2. Optimising parameters for overexpression of TYA381His monomer 
3.2.2.2.1. Optimising Western blotting for improved detection  
Ty-VLPs were composed of TYA381His protein containing a C-terminal 6xHis tag which is 
buried internally. Thus, to monitor Ty-VLPs throughout the purification process, Western 
blotting was performed followed by denaturing the particles with SDS. However the Western 
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blotting performed resulted in very faint bands for TYA381His protein, and was subsequently 
optimised for the sensitive detection of expressed protein monomer. 
3.2.2.2.1.1. Preparation of whole cell protein of yeast for Western blot analysis 
The expression of TYA381His protein was monitored by running the whole cell lysates on SDS-
PAGE (section 2.12.2) and subsequently analysed by Western blotting using anti-6xhis 
antibody (section 2.12.4). Whole cell lysates from copper-induced S. cerevisiae was prepared 
by an improved lithium acetate (LiAc) method (Zhang et al., 2011). Briefly, cells were pre-
treated with 2 M LiAc for 5 min on ice and harvested by a short spin. The same step was 
repeated with 0.4 M NaOH followed by resuspending the pellet in 100 μL SDS-loading buffer 
and boiled for 5 min. The cell debris was removed by centrifugation and supernatant 
containing yeast whole proteins was stored at -800C until analysed by SDS-PAGE. 
3.2.2.2.1.2. Optimisation of parameters for Western blotting  
Western blotting was performed under a range of conditions by varying concentrations of 10 
and 20 antibodies (1/5000 and 1/10,000 dilutions), incubation time and blocking agents (BSA 
and skim milk). About 50 μL of whole cell protein was separated by SDS-PAGE at standard 
conditions and transferred on to a nitrocellulose membrane using Bio-Rad iBlot® 7-Minute 
Blotting System. The nitrocellulose membrane with transferred protein was subjected to 
different conditions of immuno-probing for optimization of its reaction with the alkaline 
phosphate substrate. The optimized conditions were adapted for further Western blotting to 
detect the TyA381His protein.  
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3.2.2.2.2. Optimising overexpression of TYA381His protein by copper induction 
The optimal concentration of copper required for induction of TYA381His overexpression was 
determined by using various volumes of CuSO4. The toxic effect of various concentrations of 
CuSO4 was also investigated on (pYEX-BX +TYA381His) containing S. cerevisiae W303-1A using 
non-transformed S. cerevisiae as a control.  
3.2.2.2.3. Optimising copper concentration and expression time 
One millilitre glycerol stock of recombinant yeast overexpressing TYA381His protein 
(3.2.2.1.4) was inoculated in 50 mL SD Ura- media (synthetic defined media lacking uracil) and 
incubated overnight by shaking at 230 rpm at 300C. The overnight culture was then used to 
inoculate 500 mL SD Ura- media and grown up to log phase (0.D600 = 1). The samples were 
then induced with various concentrations of copper sulphate (0.1 mM-0.5 mM) and allowed 
for protein expression for 2 h. Post induction protein expression time was also optimised to 
achieve maximum protein concentration at selected time points (1, 2, 3, and 4 h). 
3.2.2.2.4. Investigating toxic effect of TYA381His protein and copper on 
recombinant S. cerevisiae growth 
SD Ura- plates prepared with Phytagar£ containing various concentrations of CuSO4 (0.1 mM-
0.5 mM) were used. The pYEX-BX plasmid transformed yeast was set up as negative control. 
Overnight cultures of S. cerevisiae transformed with plain pYEX-BX plasmid and (pYEX-BX + 
TyA381His) construct were serial diluted up to 10-7 and 5 μL spot of each dilution was applied 
on to all the plates and incubated at 300C for 2 days. The visual growth density compared to 
negative control was used to estimate the toxic effect of copper and expressed protein on 
recombinant yeast growth.  
 
                                                                                                                                                       Chapter 3 
107 
 
3.2.3. Standardizing Ty-VLP purification protocol 
Selection of a suitable purification method is an important aspect while purifying VLPs as their 
structure should remain intact and stable to use them for future applications. Three different 
protocols for the purification of Ty-VLPs were selected for comparison of yield and ease of 
purification. The procedure for each method is outlined in Table 3.4. The samples were 
collected at each purification step and analysed by Western blotting using anti-6xHis 
antibodies. 
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Table 3. 4. Various methods for purification of Ty-VLPs 
RTB buffer method Buffer-A method TEN buffer method 
Thaw (S. cerevisiae W303-1A+TYA381His) cell pellet, resuspend in Buffer-A with protease 
inhibitors and glass beads and vortex until 90% lysis 
 
Centrifuge clarified 
supernatant at 25000 x g for 
2 h 
 
 
Pellet resuspended in 3 mL 
RTB buffer and loaded onto 
10-50% sucrose gradients 
and centrifuged at 25000 x g 
for 14 h 
 
 
Fractions were collected and 
analysed by Western blot 
 
 
Fractions containing protein 
were pooled and dialysed 
overnight against TEN buffer 
at 40C 
 
Filtered by 0.2 μm filter, 
concentrated by 
Vivaspin£20 and aliquots 
stored at -200C 
 
Clarified supernatant loaded 
on to 20-70% sucrose 
gradients and centrifuge at 
115604 x g for 3.15 h at 40C 
 
 
Collect 1 mL fractions and 
analysed by Western blotting 
 
Dilute the pooled fractions 
positive for TYA381His protein, 
centrifuge at 18000 x g for 
3.30 h 
 
 
Remove the supernatant 
carefully without disturbing 
the pellet and resuspend the 
pellet in 150 μL TEN buffer 
 
 
Aliquot the purified Ty-VLPs, 
store at -200C 
 
Clarified supernatant loaded 
on to 2 mL 60 % sucrose 
cushion and spin at 100000 x 
g for 1 h 
 
Collected cushion was 
dialyse overnight and 
centrifuged at 13000 x g for 
20 min 
 
Supernatant was loaded on 
to 5-60 % sucrose gradient 
and centrifuge at 53000 x g 
for 6 h 
 
Sucrose fractions containing 
VLPs were removed with a 
syringe, dialysed overnight 
 
Dialysate was centrifuged at 
13000 x g for 20 min 
followed by filtering through 
0.2 μm filter 
 
Sample was concentrated 
and run through sephacryl-
500 column at flow rate of 
16 mL per hour 
 
 
Fractions with Ty-VLPs 
identified by Western 
blotting 
(Muller et al., 1987) (Luschnig et al., 1995) (Burns et al., 1994) 
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3.3. Results 
3.3.1. Construction of (pYEX-BX + TYA381His) vector 
3.3.1.1. Amplification of TYA381His gene from yeast whole genomic DNA 
The S. cerevisiae W303-1A whole genomic DNA was successfully isolated by the phenol 
chloroform extraction method and subsequently used in a PCR reaction to amplify the 
TYA381His gene. PCR parameters were successfully optimized for MyTaqTM and Phusion£ 
DNA polymerases. Gradient PCR at high temperature (56-650C) for both enzymes resulted in 
non-specific amplification (data not shown here), and so low temperature ranges were used 
in subsequent experiments. MyTaq™ polymerase yielded a high amount of quality product at 
an annealing temperature of 49.90C compared to other ranges (Figure 3.4). Phusion£ DNA 
polymerase amplification resulted in high yield at gradient temperature ranges 50-550C with 
the exception of 500C (Figure 3.5). Out of these, an annealing temperature of 51.20C was 
selected for amplification by Phusion£ polymerase as it was close to the melting temperature 
of the primer set. The optimised PCR conditions using the G-storm PCR thermocycler are as 
represented in Table 3.5. 
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Table 3. 5. Optimised parameters for amplification of TyA381His gene by PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage of PCR MyTaq™ DNA 
polymerase 
Phusion£ DNA 
polymerase 
Initial denaturation 98°C, 2 min (1 
cycle) 
98°C for 30 sec 
(1 cycle) 
 
PCR 
amplification 
No of cycles 30 25 
Denaturation 98°C, 30 sec 98°C, 10 sec 
Annealing 49.9°C, 30 sec 51.2°C, 30 sec 
Extension 72°C, 1 min 72°C for, sec 
Final extension 72°C, 5 min 72°C, 5 min 
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Figure 3. 4. Agarose gel analysis of TYA381His gene amplified by gradient PCR using 
MyTaq™ DNA polymerase. 
 -Lane M: Phage Lambda DNA digested with PstI, -Lane 1-4: PCR products obtained at 
annealing temperatures of 450C, 45.90C, 47.80C and 49.9 0C respectively 
 
 
 
 
 
                                                                                                                                                       Chapter 3 
112 
 
 
 
 
 
 
 
Figure 3. 5. Optimisation of PCR conditions for TYA381His gene amplification by proof 
reading Phusion£ DNA polymerase from whole S. cerevisiae W3031A DNA. 
-Lane M: Phage Lambda DNA digested with PstI, -Lane 1-4: Annealing temperatures of 500C, 
51.20C, 52.80C and 54.80C respectively 
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3.3.1.2. Purification of yeast expression plasmid 
pYEX-BX plasmid was purified using a miniprep kit and the concentration was measured using 
a NanoDrop spectrophotometer. The identity of the plasmid was confirmed by performing 
double digestion with BamHI+SalI enzymes followed by sizing the digested products on a 1% 
agarose gel. As these two enzymes recognition sites were present within the multiple cloning 
site the plasmid generated a single linear DNA fragment of 7.1 kb (lane 1 in Figure 3.6) as 
expected. Another expected DNA fragment of 100 bp was not visualised on the gel due to its 
very low molecular weight. However, the 7.1 kb linear fragment corresponds to the pYEX-BX 
plasmid. 
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Figure 3. 6. Double digestion of pYEX-BX plasmid with BamHI+SalI restriction enzymes. 
-M: Lambda DNA double digested with PstI, -Lane 1: pYEX-BX plasmid double digested with 
BamHI+SalI 
 
 
 
                                                                                                                                                       Chapter 3 
115 
 
3.3.1.3. Inserting amplified TYA381His into the pYEX-BX plasmid 
TYA381His gene was designed by incorporating a C-terminal 6xHis tag and BamHI, SalI 
restriction enzyme sites at 5’ and 3’ ends respectively. PCR conditions were optimised using 
proof reading Phusion£ DNA polymerase and MyTaq™ DNA polymerase. The agarose gel 
analysis of BamHI+SalI double digested pYEX-BX plasmid and TYA381-His fragment resulted in 
the expected fragment sizes of 7.1 kb and 1.1 kb respectively (Figure 3.7a, lane 1 & 2). These 
two fragments were ligated, and transformed into E. coli DH5α. The isolated plasmids from 4 
clones were screened for the presence of the insert by double digestion using BamHI+SalI. 
Plasmids from two clones showed the presence of 1167 bp TYA381His insert (Figure 3.7b, lane 
3 and 5). These two constructs were sequenced further with a CUP1 promoter primer pair to 
confirm the presence of the insert in the correct orientation.  
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Figure 3. 7. a) Pre-ligation products and b) positive clone screening of pYEX-BX+TYA381-His 
construct. 
-Lane 1: TYA381-His double digested with BamHI+SalI, -Lane 2: pYEX-BX plasmid double 
digested with BamHI+SalI, -Lane 3 to 6: Screening of double digested plasmids isolated from 
E. coli transformed with pYEX-BX+TYA381-His 
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3.3.1.4. ‘In silico’ analysis of (pYEX-BX + TYA381His) construct 
Alignment of the nucleotide sequence of the insert against standard entries in the BLAST 
database showed 98% identity with nucleotide sequence encoding the S. cerevisiae gag-pol 
fusion protein (Tya protein). Analysing both CUP1 forward and reverse primer generated data 
indicated the presence of the insert in correct orientation. The protein BLAST of translated 
contig sequence (manually prepared from sequencing data) against known TYA381His 
sequence showed 100% identity (Figure 3.8). The theoretical molecular weight was estimated 
to be 43.6 kb and the isoelectric point value is 6.83. The presence of disulphide bonds was 
analysed by an online software “SCRATCH protein predictor”. This revealed the possibility of 
formation of 2 disulphide bonds between the cysteine residues at position 18 and 43, and 310 
and 331 respectively. 
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Figure 3. 8. Nucleotide sequencing data analysis of (pYEX-BX + TYA381His) construct. 
a) Contig prepared using forward and reverse primer sequencing data, b) Translated 
contig using ExPASy, c) Standard Protein BLAST of the translated contig 
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3.3.2. Transformation of S. cerevisiae with recombinant vector and optimising 
overexpression parameters 
 3.3.2.1. Transformation of yeast with (pYEX-BX + TYA381His) vector 
The pYEX-BX+TYA381 copper-inducible yeast expression construct was transformed 
successfully into S. cerevisiae W303-1A using an EZ-yeast transformation kit. Phenotypic 
testing showed that S. cerevisiae W303-1A transformed with pYEX-BX+TYA381-His construct 
was growing on the plates lacking leucine due to the presence of the plasmid harbouring LEU2 
and URA3 auxotrophic markers. Non-transformed S. cerevisiae, however, were unable to 
grow in the absence of uracil and leucine (Figure 3.9). This indicated the successful 
introduction of recombinant plasmid into S. cerevisiae.  
3.3.2.2. TYA381His monomer expression optimisation 
3.3.2.2.1. Optimising Western blotting for protein detection 
A series of Western blotting parameters such as 10 and 20 antibody concentrations, incubation 
time and blocking agents were investigated for sensitive detection. Out of these parameters, 
blocking agents have the most significant effect on sensitivity of detection by Western 
blotting. Band intensity and sharpness were improved significantly with the use of BSA as 
blocking agent when compared to skim milk, and thus was incorporated into the protocol for 
further experiments. A faint band of 52.7 kDa was observed with skim milk, whereas a very 
dark, sharp band of the same size was observed with BSA as blocking agent (Figure 3.10). 
Even though the calculated molecular weight (43.6 kDa) is different from its apparent 
molecular weight (52.7kDa), it concurs with the data demonstrated previously (Palmer et al., 
1997). Based on this observation BSA was used as blocking agent for repeating the Western 
blotting.  
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3.3.2.2.2. Optimising parameters for TYA381His protein expression 
pYEX-BX is a copper-inducible yeast expression vector. The optimum copper concentration 
required for TYA monomer expression was successfully determined to achieve the maximum 
yield. The post-induction time required to achieve high protein yield was also successfully 
optimised. 
The intensity of the protein band indicated that the maximum yield was observed with 0.3 
mM induced S. cerevisiae expression system. The amount of protein was reduced in 0.4 mM 
and 0.5 mM CuSO4 induced sample (Figure 3.11). Even though Western blotting is a semi-
quantitative method, the optimum concentration of CuSO4 required for maximal TYA381His 
protein yield was estimated as 0.3 mM for an expression time of 2 h.  
The optimal time point to achieve maximum protein expression was further determined. 
Whole cell protein was extracted from samples collected at various time points after 
induction (0, 1, 2, 3 and 4 h) and analysed by Western blotting (Figure 3.12). Western blotting 
showed a gradual increase in protein expression from 0 to 4 h. Thus, the optimal expression 
time after induction was determined to be 4 h, although it is possible that longer times (not 
tested) may have further increased yield.  
The toxic effect of expressed protein along with various copper concentrations was 
investigated. As shown in the Figure 3.13, the cell growth was neither affected by copper 
concentrations ranging from 0 to 0.5 mM, nor by the presence of the expressed protein.  
These observations indicated that the safe copper concentration required for maximal protein 
yield in S. cerevisiae TYA381His overexpression system is 0.3 mM copper induction for 4 h.  
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3.3.2.2.3. Optimised protein expression protocol 
The following protocol with optimised parameters was used for rest of the study. Glycerol 
stock aliquots of S. cerevisiae transformed with (pYEX-BX + TYA381His) were recovered by 
inoculating into 50 mL SD Ura- media and incubated at 300C, 230 rpm shaking overnight. The 
culture was then scaled up to 500 mL in a baffled Erlenmeyer flask and grown to get an O.D600 
value of 1. Then the protein expression was induced with 0.3 mM CuSO4 and allowed to 
express for 4 h. Cells were harvested by centrifugation at 3500 x g for 20 min in 500 mL 
polypropylene bottles using an Avanti J-26XP centrifuge. Cold solutions were used for 
harvesting and washing the cells. The pellet was transferred to a 50 mL falcon tube after 
resuspending in 5 mL MilliQ H2O and centrifuged at 3500 x g for 5 min. The washing steps 
were repeated twice followed by washing once with TEN buffer containing protease 
inhibitors. The pellet obtained after these wash steps were stored at -200C until use.  
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Figure 3. 9. Phenotypic test of S. cerevisiae W303-1A transformed with pYEX-BX+TYA381-His 
construct on selective plates.  
The deficient amino acid or nucleobase in the selective plates was represented on each plate 
(e.g. His- indicates lack of histidine) and ‘Comp’ reflects complete media. (a) Phenotypic test 
with transformed S. cerevisiae and (b) Phenotypic test with non-transformed S. cerevisiae 
a) 
b) 
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Figure 3. 10. Optimisation of Western blotting for detection of TyA381His. 
-Lane 1: TYA381His sample at 4 h copper induction blocked with 5% skim milk, - Lane 2: 
TYA381His sample at 4 h copper induction and blocked with 5% BSA  
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Figure 3. 11. Whole cell lysates of recombinant S. cerevisiae induced with various 
concentrations of copper. 
M-KaleidoscopeTM prestained protein marker, Lane 1-5 are whole cell lysates of recombinant 
yeast induced with 0.1 to 0.5 mM copper respectively 
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Figure 3. 12. Western blotting of optimum time point determination for expression of 
TyA381His protein. 
-M: KaleidoscopeTM prestained protein marker, -Lane 1 to 5 are 0-4 h W303-1A + (pYEX-BX 
+ TYA381-His) clone whole cell lysate after copper induction 
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Figure 3. 13. Assay to investigate the toxic effect of copper and expressed TyA381His 
protein on S. cerevisiae growth. 
-a) to f) are SD Ura- plates with 0-0.5 mM CuSO4 respectively. Each plate was inoculated with 
10-1 to 10-7 dilution spots (from left to right) of S. cerevisiae transformed with (pYEX-BX + 
TyA381His) plasmid (bottom row) along with a negative control (top row) 
 
                                                                                                                                                       Chapter 3 
127 
 
3.3.3. Standardising Ty-VLPs purification method 
Ty-VLP purification was performed using three different techniques a) RTB buffer method b) 
Buffer-A method and c) TEN buffer method. Out of these, the RTB buffer method resulted in a 
good yield with minimal impurities. 
Despite previous application of TEN buffer method for the purification of Ty-VLPs from 
various recombinant yeasts, protein yield was not observed in the final stages of purification 
as shown in the Figure 3.14. The whole cell lysate and pellet after removing clarified 
supernatant showed the presence of a 52 kDa protein, but not clarified supernatant. This 
observation suggests the possibility of co-pelleting of Ty-VLPs along with cell debris. The 
protein in the initial stages of purification also appeared to be degraded, and as such this 
method was discontinued. Buffer-A and RTB buffer methods were adapted for Ty-VLP 
purification, which involves the use of mild detergents in their buffers and might help in 
increasing protein solubility. Both methods resulted in TYA381His protein yield in the final 
steps of purification (Figure 3.15 & 3.16). A comparison of the two methods found that the 
RTB buffer method resulted in a higher yield and was used preferentially for rest of the study. 
SDS-PAGE was performed using Ty-VLPs purified by RTB buffer method, which showed the 
purity of the sample (Figure 3.17a). Native SDS-PAGE was also performed to check the 
integrity and size of Ty-VLP particles which showed a band above 12 MDa (Figure 3.17b). As 
Ty -VLPs calculated molecular weight was 14 MDa, the band observed was considered to be 
pure particles.  
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Figure 3. 14. Western blot analysis of S. cerevisiae whole cell lysates at different stages of 
purification of Ty-VLPs by TEN buffer method. 
Lane 1: 0 h copper induction, Lane 2: 4 h copper induction, Lane 3: Cells after lysis with glass 
beads, Lane 4: Pellet remaining after removing clarified supernatant from whole cell lysate by 
centrifugation, Lane 5: clarified supernatant, Lane 6-9: 1 mL fractions from 10-45% sucrose 
gradient loaded with clarified supernatant 
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Figure 3. 15. Western blot analysis of samples at different stages of Ty-VLP purification 
using Buffer-A method. 
Lane 1: Whole cell lysate of TYA381His expressed S. cerevisiae, Lane 2: Clarified supernatant, 
Lane 3: Supernatant on top of ultra-centrifugation, Lane 4: 20% sucrose cushion, Lane 5: 30% 
sucrose cushion, Lane 6: Layer between 30% and 70% sucrose cushions, Lane 7, 8: 70% 
sucrose cushion 
            
.  
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Figure 3. 16. Western blotting of samples at different stages of Ty-VLP purification using RTB 
buffer method. 
Lane 1: Whole cell lysate of TYA381His expressed S. cerevisiae, Lane 2: Crude Ty-VLP pellet 
after first ultra-centrifugation, Lane 3: Supernatant on top of ultra-centrifugation, Lane 4 -9: 
Fraction 1 to fraction 6 respectively 
Note: Fractions 1 to 6 were collected after ultra-centrifugation of 10-50% sucrose gradient 
loaded with crude pellet suspension  
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Figure 3. 17. Gel Analysis of Ty-VLPs purified by RTB buffer method. 
Figure 3.17a. SDS-PAGE, Figure 3.17b. Native SDS-PAGE  
Lane 1 and 2 are concentrated Ty-VLPs purified by the RTB buffer method 
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3.4. Discussion 
3.4.1. Preparation of a yeast construct expressing TYA381His 
The aim of constructing recombinant yeast vector overexpressing the TYA381His monomer 
was to achieve high yields of Ty-VLPs. A recombinant vector overexpressing the truncated 
form of TYA monomer was constructed using pYEX-BX and p416GPD E. coli - S. cerevisiae 
shuttle vectors. Out of these two, the pYEX-BX system resulted in high yield compared to 
p416GPD (data for p416GPD vector system was not shown here).  
pYEX-BX has the advantage of harbouring both auxotrophic URA3 marker allowing easy 
selection of recombinants and a truncated LEU2 marker promoting enhanced replication of 
plasmid and so increasing recombinant gene transcription (Macreadie et al., 1991). Because 
of its advantage over other yeast vectors, it was used previously to express various proteins 
such as nucleoside hydrolase (Miller et al., 2007), and cyanophycin (Steinle et al., 2008). This 
indicates the reason for choosing pYEX-BX vector for TYa monomer overexpression. Truncated 
and full length TYa proteins were expressed in pOGS40 and pMA91-14 vectors respectively 
(Brookman et al., 1995) and were detected using in-house raised monoclonal antibodies and 
it was demonstrated that full length particles were heterogeneous in size compared to 
truncated forms. Production of TYA381 VLPs with an optional C-terminal immunogenic tag 
was demonstrated using pMA5620 recombinant plasmid and can be used as a subunit 
vaccine, and can be detected by antibodies specific to the inserted gene product (Adams et 
al., 1994). As the Ty-VLPs were designed in this study for their future application in DNA 
vaccine delivery, they don’t require an antigenic gene insertion. However for the purpose of 
easy monitoring of particles during purification, a C-terminal 6xHis tag was inserted. 
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The amplified TYA381His gene was successfully cloned into pYEX-BX copper-inducible yeast 
expression vector. Nucleotide sequencing revealed that there are no mutations in the 
inserted gene and an encoded C-terminal 6xHis tag was present.  
3.4.2. Transformation of (pYEX-BX + TYA381His) construct into S. cerevisiae 
Introducing the constructed vector expressing Ty-VLP monomer into yeast is an important 
step for successful protein production. Transformation was achieved using commercial 
transformation kit based on the lithium method (Agatep et al., 1998) and phenotyping was 
performed to identify the genotype of transformant. Stable expression of recombinant 
plasmid in S. cerevisiae was achieved by growing it on selective media based on auxotrophic 
markers (Ura- and Leu-). Even though an auxotroph is grown under strict selective conditions, 
there is a chance of establishing mixed cultures resulting in cross feeding phenomenon 
(Meinander et al., 1997) which subsequently lowers protein expression. This example 
suggests the importance of verifying plasmid stability after constructing any recombinant 
system containing auxotrophic markers (Pronk 2002). This can be performed by phenotypic 
testing using simple plate assays. As the pYEX-BX plasmid contains both URA3 and LEU2 
auxotrophic markers, phenotypic testing was performed to investigate the ability of 
transformants to grown on the selective plates lacking uracil and leucine, on which wild type 
S. cerevisiae W303-1A was not expected to grow. The results from the phenotypic test were 
as expected, indicating the successful stable transformation of (pYEX-BX + TYA381His) vector 
into S. cerevisiae. 
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3.4.3. Optimising parameters for protein expression and standardising purification 
of Ty-VLPs 
The recombinant yeast overexpression vectors harbouring the TYA381His gene in correct 
orientation were transformed into S. cerevisiae W303-1A. Parameters for protein expression 
were optimised and the purification method was standardised successfully. 
3.4.3.1. Optimisation of Western blotting for sensitive protein detection 
Western blotting was optimised for reliable and sensitive protein detection. Western blotting 
of TyA381His protein resulted in faint bands with skim milk as a blocking agent. Skim milk is 
not a compatible blocking agent to use in Western blotting of phosphorylated proteins, as 
milk itself contains a phosphoprotein casein, thus masking the antigen resulting in faint or no 
bands (Mahmood et al., 2012). TyA protein is proline rich and phosphorylated with a slightly 
basic nature (Kingsman et al., 1987). This is a possible explanation for obtaining very faint 
bands for TyA381His immunoprobed with 6xHis anibody using skim milk as a blocking agent. 
BSA was determined to be a suitable blocking agent for detection of the Tya monomer.  
3.4.3.2. Optimisation of copper concentration for inducing protein expression  
Copper-inducible vector is suitable for convenient induction of recombinant proteins which 
can be lethal to yeast (Macreadie et al., 1989). Sub-toxic copper concentrations of 1-3 mM are 
beneficial to yeast cells while upper threshold concentrations of >10 mM may induce 
apoptosis and necrosis in BY4742 strain (Liang et al., 2007). Interruption of transcription by 
retention of transcription factor Cuf1 in cytoplasm at high copper concentrations was 
demonstrated in Schizosaccharomyces pombe (Beaudoin et al., 2006). 
Copper concentrations of 8 mM induced oxidative stress by interupting the glycolytic pathway 
in S. cerevisiae BY4741 (Shanmuganathan et al., 2004). S. cerevisiae S288C strain growth was 
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almost inhibited at 15 mM copper (Yasokawa et al., 2008). Yeast expressed recombinant 
proteins such as tyrosine kinase p60v-src was reported to be lethal to the cell (Boschelli et al., 
1993). These results indicate the importance of investigating a safe copper concentration 
required for inducing protein expression as well as the toxic effect of expressed protein on 
cell growth. The toxicity test in the current study indicated that 0.1-1 mM copper 
concentrations had no effect of yeast cell growth. Thus, minimal copper concentration (0.3 
mM) inducing maximal protein expression was chosen for induction of TYA381His monomer 
in S. cerevisiae W303-1A. The expressed TyA381His protein was found to have no toxic effect 
on yeast growth, indicating that S. cerevisiae is a suitable recombinant host for its expression. 
Ty-VLP purification procedure was standardised by comparing three existing methods, 
allowing for the adoption of the method producing the highest yield. The TEN buffer method 
resulted in co-pelleting of Ty-VLPs along with cell debris during clarification as detected by 
immune blotting. The TyA381His protein has 5 cysteine residues with a possibility of 2 
disulphide bonds formation which might affect protein solubility. Previous studies report the 
use of mercaptans for the reduction of disulphide bonds without influencing the stability or 
structure of the expressed protein (Wall 1971). For this reason, the Buffer-A and RTB buffer 
methods were adapted as they involve the use of DTT and mercaptoethanol respectively. RTB 
buffer method resulted in higher protein yield than Buffer-A method and was therefore 
selected for use in Ty-VLP purification. 
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3.5. Conclusions  
The TyA381His coding gene was amplified successfully from S. cerevisiae whole genomic DNA 
using designed primers. The recombinant vector for the overexpression of the TyA381His 
monomer was constructed by cloning the ampified gene product into a yeast copper-
inducible pYEX-BX plasmid. The presence of the inserted gene was confirmed by nucleotide 
sequencing data analysis and the successful transformation of recombinant vector into yeast 
was achieved. Following this, optimisation of the protein purification was performed to 
achieve high yield. Column chromatography was not required in order to further purify Ty-
VLPs, as significant purity was achieved after the consequent ultra-centrifugation and dialysis 
steps as observed on SDS-PAGE. In conclusion, S. cerevisiae W303-1A strain was utilised for 
the successful overexpression of Ty-VLPs. 
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 CHAPTER 4 
Characterisation of Ty-VLPs and in vitro studies of 
plasmid DNA delivery using Ty-VLPs  
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4.1. Introduction 
DNA vaccines can be categorised among the popular types of vaccines developed in 19th 
century. There are many successful prophylactic and therapeutic DNA vaccines which have 
reached clinical trials, one example being the recent Zika virus vaccine (Morrison 2016). Even 
though naked DNA vaccines demonstrated successful elicitation of immune responses in 
rodents, relatively low foreign gene expression was observed in non-human primates even 
after multiple administrations (Jiao et al., 1992). A safe DNA delivery system crossing all 
barriers might be required to achieve high transfection rate in primates. This observation 
indicates the importance of investigating the effeciency of a DNA vaccine in higher animal 
models. 
Ty-VLPs are true transposition intermediates in yeast, derived from Ty-transposon. Ty 
elements are popular because of their similar life cycle to that of oncogenes, therefore a 
convenient model to study virus-host interactions (Krastanova et al., 2005). Although purified 
Ty-VLPs have been demonstrated as true transposition intermediates by reporting their ability 
to transpose genome carried by them ‘in vitro’ (Eichinger et al., 1988), they were not 
investigated for the application of gene delivery. Ty-VLPs were previously characterised by 
transmission electron microscopy (TEM) within yeast cells (Muller et al., 1987) and also in 
purified form (Adams et al., 1987), and as such the morphology of these particles is well 
known. Cryo-electron microscopic analysis has further been used to elucidate finer details 
such as the trimeric arrangement of monomers and the presence of spikes on the particles 
(Al-Khayat et al., 1999). 
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Work described in the current chapter involves the characterisation of overexpressed protein 
monomer by MALDI-TOF (Matrix Assisted Laser Desorption/Ionization-Time Of Flight) mass 
spectrometry. As MALDI-TOF requires protein monomers, TYA381His was purified by affinity 
column under denaturing conditions. DLS was performed to measure the size of native Ty-
VLPs. The final part of this study involves the formation of plasmid Ty-VLP/DNA complexes 
using a reporter plasmid (pEGFP) to track transfection and expression of a foreign reporter 
gene in vitro.  
The aims of the current chapter include 
1) Characterisation of TYA381His monomer by MALDI-TOF mass spectrometry 
2) Characterisation of the size and morphology of Ty-VLPs by DLS and TEM 
3) Conjugation of plasmid DNA with Ty-VLPs to form complexes 
4) Analysis of the stability of Ty-VLP/DNA complexes 
5) Analysis of cytotoxicity and transfection of Ty-VLP/DNA complexes in vitro using 
murine dendritic cells (DC2.4) 
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4.2. Experimental methods 
This section details the methods used to achieve Ty-VLP characterisation and in vitro studies.  
4.2.1. Experimental protocols for characterising Ty-VLPs and its monomer 
4.2.1.1. Characterisation of TYA381His monomer by MALDI-TOF mass 
spectrometry 
Mass spectrometry is a technique for protein identification and characterisation. MALDI-TOF 
is a very advanced and sensitive type of mass spectrometry used to identify and quantify 
peptides. Tryptic digest of protein monomers was intended to be analysed by MALDI-TOF. 
TYA381His protein can be purified by Ni-NTA sepharose column as it is harbouring C-terminal 
6xHis. Due to the fact that the 6xHis is buried internally within Ty-VLPs the TYA381His protein 
was purified by Ni-NTA column under denaturing conditions, where C-terminal 6xHis can be 
accessible to bind the nickel matrix. Urea (8 M) was used as a denaturing agent in all the steps 
of purification. The steps involved in preparation of the sample for MALDI-TOF are as follows. 
1) Purifying TYA381His protein monomer by denaturing immobilized metal ion affinity 
chromatography (IMAC) 
2) Confirming the expression of 6xHis tagged purified protein by Western blotting 
3) Sample preparation for MALDI-TOF analysis 
4) Analysis by MALDI-TOF 
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4.2.1.1.1. TYA381His purification by IMAC  
Nickel-Nitrilotriacetic acid (Ni-NTA) column is a type of IMAC commonly used for purification 
of 6xHis tagged proteins. A series of steps were followed to purify TyA381His protein as 
detailed below. 
4.2.1.1.1.1. Preparation of Ni-NTA column   
The Ni-NTA column of 1 mL volume was washed with MQH2O and airbubbles trapped beneath 
the filter were removed. The column was then filled approximately with 2 mL sepharose and 
washed with 10 mL MQH2O, allowing it to settle without any air bubbles. The column was 
then charged with 0.2 M nickel sulphate of approximately half the column volume (CV), 
followed by washing with 10 mL MQH2O to remove excess nickel sulphate. The column at this 
stage can be stored in MQH2O at 40C for several days or in 20% ethanol at 40C up to several 
weeks.  
4.2.1.1.1.2. Stripping of nickel sulphate column  
The advantage of gravity based affinity columns is the option of regeneration after use by 
stripping them. The first step was to wash the column with at least 5 CV stripping buffer (50 
mM EDTA, 0.5 M NaCl) to remove attached nickel along with protein impurities. This was 
followed by washing with 5-10 CV of 0.5 M NaCl and 5 CV 1 M NaOH with a MQH2O wash step 
in between. Finally, the column was washed with 70% ethanol. At this stage the column can 
be stored in 20% ethanol at 40C up to several months for further use up to 3 times. 
4.2.1.1.1.3. Preparation of yeast clarified cell lysate 
The recominant yeast harbouring the pYEX-BX+TYA381His plasmid was allowed to express 
TYA381His protein under optimised conditions (section 3.3.2.2.3). The pellet was harvested 
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from 200 mL of culture and used for IMAC each time. The frozen cell pellet was thawed by 
adding 10 mL of lysis buffer (10 mM imidazole, 8 M Urea, 50 mM Tris-HCl and 150 mM NaCl). 
Approximately 1 g of 0.5 mm glass beads were added to each 1 mL screw capped bead beater 
tubes and the cell suspension was aliquoted into them. The sample was then bead beaten for 
15 min (1 min beating and 1 min cooling) at 40C. The lysis time was optimised to achieve 99% 
cell lysis by observing the sample under light microscope. The cell lysate was centrifuged at 
5000 x g for 10 min at 40C. The supernatant was removed carefully and filtered through 0.45 
μm filter before passing through the Ni-NTA column.  
4.2.1.1.1.4. Optimisation of imidazole concentration to elute TYA381His by Ni-NTA 
IMAC 
The Ni-NTA column was pre-equilibrated with 10 CV wash buffer containing 10 mM imidazole. 
Approximately 5 CV of clarified and filtered yeast cell lysate (section 4.2.1.1.1.3) was passed 
through the pre-equilibrated Ni-NTA sepharose column. The wash buffers with an increasing 
concentration of imidazole were used to optimise the maximum elution of TYA381His protein 
with minimal impurities. Approximately 5 CV wash buffers (50 mM NaCl, 50 mM Tris and 8 M 
urea) with an increasing concentration of imidazole (10, 20, 40, 60, 80, 100, 200, 300, 400 and 
500 mM) were passed through the column and each fraction eluted was collected seperately. 
The fractions were analysed by SDS-PAGE and Western blotting using BSA blocking and anti-
6xHis antibodies. The wash buffer resulting in maximum elution of TYA381His protein with no 
impurities was chosen as the elution buffer by considering protein bands visualised by 
Western blotting gel. 
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4.2.1.1.1.5. Concentration of TYA381His protein 
The fractions containing pure TYA381His protein were concentrated and buffer exchanged 
using Amicon Ultra-0.5 Ultracel-30K unit. All the fractions containing TYA381His protein were 
pooled and were applied to an Ultracel-30K device and centrifuged at 2500 x g. After the 
sample reduced to half of the initial volume, it was washed twice with TEN buffer to remove 
salts and small impurities. The sample was then analysed by Western blotting prior to analysis 
by mass spectrometry. 
4.2.1.1.2. Sample preparation for MALDI-TOF analysis 
4.2.1.1.2.1. Pre-processing of sample 
Purified TYA381His protein was separated by SDS-PAGE and stained using AcquaStain. The gel 
was then placed on a sterile glass slab cleaned with 70% ethyl alcohol and the 52 kDa band 
was excised with a sterile scalpel blade. Important measures such as working in the laminar 
flow hood and avoiding latex gloves (may cause protein contamination) were followed. The 
excised gel slice was transferred into a clean Eppendorf tube. Destaining was performed by 
incubating the gel slice in 200 μL destaining solution (50% acetonitrile in 50 mM TEAB) for 1 h 
in a 370C shaker. Then the gel slice was dehydrated with 50 μL of 100% acetonitrile for 10 min 
and allowed to air dry by covering the Eppendorf tube loosely with an aluminium foil. The 
following step was performed to remove any disulphide bonds with the protein and alkylate 
free cysteine residues, allowing easy access of trypsin for digestion. Fifty microliters of freshly 
prepared 50 mM TCEP was added to the dried gel slice, heated for 1 h at 600C and centrifuged 
for 8 sec at 17000 x g. All TCEP was carefully removed and the tubes were cooled to room 
temperature. The alkylation step was performed immediately by adding 50 μL of freshly 
prepared 100 mM Iodoacetamide and incubating at room temperature for 30 min in dark, 
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followed by spinning the sample at 17000 x g for 8 sec. Iodoacetamide was removed and the 
gel slices were washed with destaining solution followed by dehydration with 50 μL 100% 
acetonitrile for 10 min. Once the gel pieces appear opaque, acetonitrile was removed and air 
dried by covering with aluminium foil to perform In-gel tryptic digestion. 
4.2.1.1.2.2. In-gel tryptic digestion  
Approximately 250 ng of trypsin in 10 μL TEAB was added to the gel slice and incubated at 40C 
for 15 min allowing trypsin to diffuse into the dry gel slice. Once the gel hydrated, 20 μL of 50 
mM TEAB was added to ensure sufficient liquid for diffusion of the digested peptides. Then 
the sample was incubated at 370C overnight for trypsin digestion. The clear solution 
containing digested peptides was removed directly into a mass spec vial to analyse using 
Bruker Microflex MALDI-TOF Mass spectrometer. 
4.2.1.1.3. Analysis of MALDI-TOF generated data  
The peptides detected by MALDI-TOF were queried against yeast proteins registered in the 
Mascot database. These peptides were also manually matched with known TYA protein 
sequence to estimate the protein coverage and confirming the presence of 6xHis tag.  
4.2.1.2. Characterisation of Ty-VLP size by DLS 
The Zetasizer Nano ZSTM works on the principle of dynamic light scattering in which the light 
beam hits the particles moving in brownian motion and measures their hydrodynamic 
diameter. Purified Ty-VLP sample was filtered using a 0.2 μm filter before measuring by 
Zetasizer. Approximately a 100 μL of sample diluted in 1 mL TEN buffer in a low volume 
disposable sizing cuvette was used for size measurement at 40C. TEN buffer served as a blank.  
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4.2.1.3. Characterisation of Ty-VLPs by TEM 
 The purified Ty-VLPs were drop casted on to 200 mesh formvar-carbon copper grids by 
floating the grids on 40 μL drops of the sample. The grids were washed twice with freshly 
filtered MQH2O to remove any excess sample. Then the grids were stained with 1% uranyl 
acetate for 30 sec and washed twice with MQH2O. The stained grids were allowed to dry 
overnight before imaging by JEOL1010 TEM at an accelerating voltage of 80 kV. 
4.2.2. Protocols for synthesis and characterisation of Ty-VLP/DNA complexes 
 4.2.2.1. Steps for preparation of Ty-VLP/DNA complexes 
4.2.2.1.1. Removal of RNA from Ty-VLPs 
Ty-VLPs contain natively packed Ty-RNA which acts as transposons in native yeast cell. The 
integrity and shape of Ty-VLPs is not compromised by removal of this RNA (Burns et al., 1992), 
and such removal may create an additional space to accommodate infiltrated plasmid DNA. 
Purified Ty-VLPs were treated with 0.05 mg/ mL RNase-A enzyme at 370C for 5 min to remove 
the packed RNA. Ty-VLPs without RNase-A treatment were used as a control. The samples 
were centrifuged using Ultracel-30K device to separate the Ty-VLPs and digested RNA 
nucleotides. The concentration of nucleotides produced by RNA digestion was measured 
using NanoDrop Lite Spectrophotometer (Thermo Scientific) to ensure the removal of RNA. 
4.2.2.1.2. Conjugation of Ty-VLPs with plasmid DNA 
The subsequent aim of the study is to pack the outside and perhaps the inside of Ty-VLPs with 
plasmid DNA and perform in vitro studies to investigate their transfection efficiency. The eGFP 
plasmid was used as a model DNA vaccine. Ty-VLPs natively contain approximately 15% RNA 
of its weight (Burns et al., 1992). Ty-VLP/DNA complexes of pre-selected ratios 1:1, 1:2, 1:3, 
1:4, 1:5, 1:6, 1:7 and 1:8 were prepared by co-incubation. Calculated amounts of Ty-VLPs and 
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DNA were added to a pre-chilled Eppendorf tube and mixed briefly by a gentle flicking 
followed by incubation at 40C for 2 h. Various ratios of complexes were synthesised to study 
their effect on transfection efficiency.   
4.2.2.2. Characterisation of Ty-VLP/DNA complexes 
Ty-VLP/DNA complexes were characterised to determine their size and aggregation using 
TEM. Agarose gel based assays were performed to analyse integrity of the complexes.  
4.2.2.2.1. TEM characterisation of Ty-VLP/DNA complexes 
4.2.2.2.1.1. Preparation of TEM grids with Ty-VLP/DNA complexes  
The Ty-VLP/DNA complexes were formed by co-incubation (section 4.2.2.1.2). These 
complexes were coated on to 200 mesh formvar-carbon copper grids by directly floating the 
grid on to 50 μL sample drops. The grids were washed twice with MQH2O followed by staining 
with 1% freshly prepared uranyl acetate for 20 sec. Finally, the grids were washed twice with 
MQH2O to remove excess uranyl acetate and allowed to dry overnight before observing by 
TEM.  
4.2.2.2.1.2. Visualisation of complexes by TEM  
The prepared TEM grids were observed at both low and high magnification at an accelerating 
voltage of 80 kV.  
4.2.2.2.2. Agarose gel based assays for characterisation of Ty-VLP/DNA complexes 
4.2.2.2.2.1. Gel retardation assay of complexes  
Various ratios of Ty-VLP/DNA complexes were analysed on 1% agarose gel to estimate their 
integrity. 20 μL of sample along with 5 μL loading dye was loaded on a gel and run for 1 h at 
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100 V. The visualization of Ty-VLP/DNA complexes was facilitated by ethidium bromide 
staining, and the gel image was taken using the Bio-Rad UV gel doc imaging system. 
4.2.2.2.2.2. Benzonase protection assay 
Benzonase® is an endonuclease isolated from Serratia marcescens, which can effectively 
cleave DNA and RNA without proteolytic activity. The inability of this enzyme to enter through 
Ty-VLP pores was previously reported (Burns et al., 1992). Therefore this enzyme can be used 
to detect any infiltrated DNA. Approximately 20 μL of Ty-VLP/DNA sample was treated with 
0.5 μL Benzonase in the presence of 2 mM MgCl2. The mixture was incubated at room 
temperature for 30 min, followed by treatment with 0.075% SDS and analysed on 1% agarose 
gel. 
4.2.3. Protocols for in vitro cellular assays 
The identity of recombinant TYA381His protein was confirmed successfully by MALDI-TOF 
mass spectrometry followed by characterisation of purified Ty-VLPs and Ty-VLP/DNA 
complexes. The most important step in evaluating the efficiency of any DNA vaccine 
formulation is to perform in vitro studies. As dendritic cells are the main antigen presenting 
cells in the mammalian immune system, the murine dendritic cell line DC2.4 was used for all 
in vitro assays. Firstly the cytotoxic effect of Ty-VLP/DNA complexes was studied followed by 
in vitro transfection using various ratios of complexes. The effect of complex incubation time 
on transfection efficiency was also studied.  
4.2.3.1. Cytotoxicity assay of Ty-VLPs on DC2.4 
The cytotoxicity assay was performed by a standard protocol (section 2.13.2) using a 
PrestoBlue® cell viability reagent (Thermo Fisher Scientific, Australia). Briefly, Ty-VLPs of 
various amounts (1-10 μg/mL) were applied to 5 x 104 DC2.4 cells per well in a 6-well tissue 
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culture plate in triplicates. The cytotoxicity was measured at 3 selected time points (24, 48 
and 72 h) and the data obtained was analysed. 
4.2.3.2. In vitro transfection 
Transfection of DC2.4 cells was performed by using a standard procedure (section 2.13.3) 
using various ratios of Ty-VLP/DNA complexes ranging from 1:1 to 1:8 ratios. Transfection 
efficiency was measured by tracking the number of cells expressing GFP protein encoded by 
the reporter plasmid using a BD FACSCanto II flow cytometer.  
4.2.3.3. Effect of complex incubation time on transfection efficiency 
An incubation time of 2 h was used for Ty-VLP/DNA complex formation for the previous 
experiments. The effect of increased incubation time on transfection efficiency was studied 
using 1:1 ratio complexes. This ratio was chosen as an example, as it showed reasonable 
transfection efficiency. 
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4.3. Results 
4.3.1. MALDI-TOF analysis of TYA381His monomer 
4.3.1.1. Optimisation of IMAC for TYA381His protein purification 
IMAC was performed to purify TYA381His monomer for characterisation by mass 
spectrometry. IMAC was performed using Ni-NTA column by applying clarified supernatant of 
recombinant S. cerevisiae expressing TYA381His followed by washing with a series of buffers 
containing various concentrtaions of imidazole. Flow through was collected for each wash and 
analysed on 10% SDS-PAGE (Figure 4.1). This suggests that most of the impurities were 
removed at 10-60 mM imidazole concentration with minor impurities left at 80 mM. No 
traces of the desired 52 kDa protein was observed up to 80 mM imidazole containing buffers 
indicating their suitability as wash buffers. Finally the TYA381His protein of 52 kDa apparent 
molecular weight was eluted in 100 mM and 200 mM imidazole. A faint band was observed 
above the 52 kDa protein in flow through fractions eluted with 100 mM imidazole buffer and 
interestingly its intensity reduced in 200 mM flow through fraction. Based on this data, 200 
mM imidazole containing buffer was selected as elution buffer for repeating TYA381His 
monomer purification.  
4.3.1.2. Optimised protocol for the purification of TYA381His under 8 M Urea 
denaturing conditions  
Approximately 5 mL of clarified cell lysate was applied to pre-equilibrated Ni-NTA column. The 
column was washed with 5 CV of buffers containing 10, 20 and 60 mM imidazole 
concentrations respectively before eluting TYA381His protein with 200 mM imidazole 
containing wash buffer. All the fractions were collected and analysed by Western blotting. 
The fractions containing TYA381His protein were dialysed overnight to remove 8 M urea and 
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other salts present in the elution buffer. The dialysate was then concentrated and buffer 
exchanged using an Ultracel-30K device. The sample was filtered through 0.45 μm filter 
before storing at -20OC for further use. 
4.3.1.3. SDS-PAGE analysis of TYA381His monomer 
The purified TyA381His monomer (4.3.1.2) was analysed by SDS-PAGE followed by Western 
blotting by probing with anti-6xHis. The sample appeared pure without any impurities as 
shown in Figure 4.2. Therefore this sample was used for MALDI-TOF mass spectrometry 
analysis. 
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Figure 4. 1. Optimisation of TYA381His purification by Ni-NTA column. 
Sodium buffers with 10-500 mM imidazole concentration were used for optimising the best 
elution of denatured TYA381His. 1, 2 lanes under each imidazole concentrations represent 
fractions 1 and 2 collected at each step 
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Figure 4. 2. Analysis of concentrated TYA381His purified by Ni-NTA column. 
a) SDS-PAGE gel and b) Western blotting gel of TYA381His protein probed with anti-6xHis 
antibodies 
 -Lane 1: concentrated TYA381His protein       
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4.3.1.4. MASCOT search results  
The summary result from MSDB database indicated that the majority of peptides identified by 
MALDI-TOF matched TYa protein sequence from S. cerevisiae as shown in Figure 4.3. This 
confirms the identity of purified protein as TYa of yeast. The MASCOT search data suggested 
the presence of major metabolic enzymes of S. cerevisiae such as alkaline Phosphatase and 
glucose-6-phosphate isomerase, which might have been co-purified by Ni-NTA column. In 
order to identify sequence coverage, the peptides identified by MALDI-TOF were manually 
matched with known TYA381His sequence. 
4.3.1.5. MALDI-TOF data analysis   
 Manual matching of the peptides identified by MALDI-TOF with TYA381 protein sequence 
resulted in complete coverage of the sequence (Figure 4.4). This data supports the Mascot 
search results confirming the successful expression of TYA381His protein in recombinant 
yeast system. 
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 Figure 4. 3. MALDI-TOF summary report of TYA381His protein in-gel tryptic digested 
sample. 
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Figure 4. 4. Matching of peptides detected by MALDI-TOF from in-gel tryptic digest of 
TYA381His with yeast TYa protein. 
Letters highlighted in red represents the peptides identified by MALDI-TOF mass spectrometry 
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4.3.2. Characterisation of Ty-VLPs by DLS  
The size of Ty-VLPs was measured by DLS after diluting the sample in TEN buffer. The size 
measurement by DLS suggested the presence of 33.48 nm size particles at an intensity of 78% 
(Figure 4.5). The data was clean without any background noise. A sharp peak at 3.6 nm was 
observed along with peak corresponding to Ty-VLPs. A peak of the same size was also 
observed in the blank (data not shown here). Therefore, it can be predicted as soluble salts 
such as NaCl present in the buffer. 
4.3.3. TEM imaging of Ty-VLPs 
Ty-VLPs were observed as spherical particles with a dark electron dense central core 
surrounded by a light ring. The central core represents packed RNA and enzymes required for 
transposition. The size of particles was heterogeneous ranging from 30 nm to 80 nm. The 
majority of particles are of around 30-40 nm size. This data concur with DLS data, as it 
identified that the average size for 76% of the population was around 33 nm. The size of 
around 50 particles was recorded from random fields of electron microscopic grids and a 
graph was plotted as shown in Figure 4.6. The smallest and largest sizes of Ty-VLPs observed 
were 26 nm and 85 nm respectively. Indeed the majority of particles were within the range of 
36-45 nm as expected. The percentage of larger particles was calculated as 2%. This indicates 
the prevalence of medium size range Ty-VLPs.  
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Figure 4. 5. Intensity distribution plot of purified Ty-VLPs measured by Zetasizer Nano ZSTM. 
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Figure 4. 6. Electron microscopy of negatively stained pure Ty-VLP samples on 200 mesh 
carbon formvar copper grids. 
a) and b) are TEM images of purified Ty-VLPs stained with 1% uranyl acetate. The image in the 
inset is Ty-VLP at high magnification showing an electron dense core and c) is Column graph 
showing the number of Ty-VLPs with various size ranges 
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4.3.4. Removal of RNA from Ty-VLPs 
Natively packed RNA was successfully removed from Ty-VLPs. This was confirmed by 
measuring RNA concentration using a Nanodrop and also by TEM imaging.  
 Ty-VLPs treated with RNase-A was centrifuged to pellet the intact particles, thereby leaving 
cleaved RNA nucleotides in the supernatant. The concentration of degraded RNA in the 
supernatant was measured using a Nanodrop. Measurements were taken in duplicate and the 
mean value was calculated. Ty-VLP sample prior to RNase-A treatment have 6.4 ng/μL of RNA, 
and it increased abruptly to 63.8 ng/μL after the treatment (Figure 4.7c). Therefore, this 
indicates the successful removal of RNA from Ty-VLPs.  
Electron microscopic observation of post enzyme treated particles also clearly showed the 
removal of electron dense RNA core from Ty-VLPs (Figure 4.7a & 4.7b). The particles were 
observed to have less rigidity yet retained the spherical shape indicating the intactness of the 
protein shell. The size of particles was in the same range as prior to RNase-A treatment. Both 
these observations together suggest the removal of RNA without affecting the structure of Ty-
VLPs.  
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Figure 4. 7. Characterisation of Ty-VLP/DNA complexes. 
a) and b) are TEM image of Ty-VLPs treated with RNase-A to remove the natively packed RNA, 
c) is a graphical representation of RNA concentration measured by NanoDrop Lite 
Spectrophotometer 
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4.3.4. Characterisation of Ty-VLP/DNA complexes 
The eGFP plasmid DNA was conjugated with Ty-VLPs by incubating calculated amounts of 
both at 40C for 2 h. These complexes were characterised by TEM and agarose gel based assays 
to analyse their integrity, protection of DNA from nucleases and aggregation.  
4.3.4.1. TEM imaging of complexes 
Complexes were applied on to 200 mesh TEM grids and stained with uranyl acetate to 
observe by TEM. The electron microscopic images showed the affinity of Ty-VLPs toward 
pEGFP. Plasmid appeared as floating strands around the particles and some strands were 
projected from Ty-VLPs (Figure 4.8). Even though there was no clear indication of DNA 
packing in the particles, this cannot be discounted. These observations indicate that there 
might have some electrostatic interactions between Ty-VLPs and DNA, as predicted by the 
positive charge of the particles and the negative charge of DNA. So the integrity of complexes 
was further analysed by agarose gel based assays.  
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Figure 4. 8. TEM image of Ty-VLP/DNA complexes. 
The scale bar in the images corresponds to 50 nm. The complexes were stained with 1% uranyl 
acetate, hence DNA can be observed as dark strands 
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4.3.4.2. Gel retardation assay of Ty-VLP/DNA complexes 
The principle of gel retardation assay is that the free DNA move forward in the electric field 
and DNA bound to any other substance will be retarded within the well. The complexes of 
various ratios were run on 1% agarose gel and stained with ethidium bromide before 
observing under UV-light (Figure 4.9a). Free plasmid DNA was used as a control (lane 1), 
where it migrated without any retardation. The excess free DNA was released in all the ratios 
of complexes. The amount of plasmid DNA retarded increased gradually from 1:1 to 1:5 ratios 
of Ty-VLP/DNA complexes and thereafter remained same for 1:6 to 1:8 ratios with a very 
slight increase. This indicates that all the ratios can form complexes with reasonable integrity. 
In comparison, 1:6, 1:7 and 1:8 ratios appeared to hold more amount of DNA.  
4.3.4.3. Benzonase protection assay 
This assay was performed to investigate if any plasmid DNA has entered Ty-VLPs. Benzonase 
enzyme treatment is performed to digest DNA present outside the particles followed by 
treatment with SDS to release DNA inside the particles. All the ratios of complexes including 
control (plain DNA) have no trace of DNA in the wells as shown in Figure 4.9b. This indicates 
that the plasmid DNA is not internalised by Ty-VLPs. However the level of protection of DNA 
cannot be estimated until the transfection was performed.  
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Figure 4. 9. Agarose gel assays of various ratios of Ty-VLP/DNA complexes 
a) Gel retardation assay -Lane 1- Free plasmid DNA, Lane 2- 9 are 1: 1 to 1:8 ratio of Ty-
VLP/DNA complexes. 
b) Benzonase protection assay -Lane 1-Free plasmid DNA treated with Benzonase followed 
by SDS, -Lane 2-9 are 1: 1 to 1:8 ratio of Ty-VLP/DNA complexes treated with Benzonase 
followed by SDS 
 
 
 
 
                                                                                                                                                       Chapter 4 
165 
 
4.3.5. In vitro assays 
4.3.5.1. Cytotoxic effect of Ty-VLPs on DC2.4 cells 
Ty-VLPs of various amounts (1-10 μg/mL) were applied to DC2.4 cells and their effect on cell 
viability was analysed using PrestoBlue® cell viability reagent. The experiment was conducted 
in independent triplicates and the results were represented as mean ± standard deviation. 
The cell viability was calculated by considering cells treated with culture media and Triton-X 
as negative (100% viable) and positive control (0% viable) respectively.  
Cell viability was not reduced significantly within 72 h up to 10 μg/mL Ty-VLPs as seen in the 
column graph (Figure 4.10). Cell viability for some of the time points was maintained above 
100% indicating effective recovery. This indicates the Ty-VLPs up to 10 μg/mL have no effect 
on cell growth and is the maximum safe limit to use in ‘in vitro’ cellular assays.  
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Figure 4. 10. Cytotoxicity assay of various concentrations of Ty-VLPs on DC2.4 cells. 
The x-axis represents the concentration of Ty-VLPs (μg/mL) and the y-axis represents the cell 
viability percentage compared to the positive control 
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4.3.5.2. In vitro transfection of DC2.4 cells with various ratios of complexes 
DC2.4 cells were transfected with freshly prepared Ty-VLP/DNA complexes ranging from 1:1 
to 1:8 ratios to determine the effect of concentration on transfection efficiency. Transfection 
was performed in 6-well cell culture plate seeded with 3 x 105 cells per well. The complexes 
and appropriate control samples were added to cells and incubated in Opti-MEM, a reduced 
serum media for 6 h to allow transfection, followed by 72 h incubation in RPMI 1640 media to 
allow pEGFP expression. The cells at the 72 h time point were acquired to analyse for GFP 
protein expression by flow cytometry. Results were plotted with a mean ± SD values obtained 
from triplicate experiments (Figure 4.11).  
Transfection was observed to increase gradually from 1: 1 to 1:5 ratios of complexes with the 
exception of 1:4. Both 1:5 and 1:6 complexes achieved almost similar transfection rates and 
the level decreased again for 1:7 and 1: 8 ratios. Both positive and negative controls worked 
well as expected. There is a discrepancy observed for Ty-VLP alone transfected sample, which 
showed reasonable transfection rate. This might be due to auto fluorescence. However this 
background noise was subtracted from all the sample values. Ratios of 1:5 and 1:6 were found 
to have the highest rate of transfection relative to other ratios. The transfection efficiency of 
naked plasmid was significantly very low compared to same amount of plasmid complexed 
with Ty-VLPs as shown (Figure 4.12). 
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Figure 4. 11. In vitro transfection of DC2.4 cells with various ratios of Ty-VLP/DNA 
complexes. 
The x-axis represents the sample type used for transfecting DC2.4 cells and the y-axis 
represents the number of cells showing GFP expression. 
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Figure 4. 12. Column graph representing the relative transfection rate of plasmid alone with 
Ty-VLP/DNA complexes. 
The * indicates the p value significance against pEGFP alone, where **** is < 0.0001 
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4.3.5.3. Effect of incubation time of complexes on transfection efficiency 
The effect of incubation time for Ty-VLP/DNA complex formation on transfection efficiency 
was investigated at selected intervals of 1-6 h using 1:1 ratio complexes, as they showed 
reasonable transfection rate. Transfection was performed using a standard protocol (section 
2.13.3) and analysed by flow cytometry.  
The graph plotted with mean values of triplicate transfection against GFP positive cells (Figure 
4.13) showed a gradual increase in transfection rate with an increase in time up to 6 h. Based 
on this experiment, the time of complex incubation for achieving the highest transfection 
efficiency was 6 h.  
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Figure 4. 13. Effect of Ty-VLP/DNA complexes incubation time on transfection efficiency. 
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4.4. Discussion 
4.4.1. TYA381His monomer characterisation by MALDI-TOF Mass spectrometry 
TYA381His monomer was over expressed and its identity was confirmed successfully using 
MALDI-TOF mass spectrometry. Data generated by in-gel tryptic digested monomer showed 
100% identity with TyA protein when matched against the MASCOT database. Presence of 
6xHis tag was also confirmed by manual matching of peptide sequences with known 
sequence. Some types of VLPs were reported as trypsin resistant (Branco et al., 2010). So, to 
overcome this possible limitation, Ty-VLPs were not directly utilised for tryptic digestion. 
MALDI-TOF is an advanced technique of mass spectrometry which has been applied 
previously for characterising denatured VLP monomer (Rhee et al., 2011). A simple technique 
for monitoring recombinant VLP protein was developed for baculovirus/insect cell expression 
system (Franco et al., 2010). Many recent studies used MALDI-TOF to conform the VLP 
monomer identity (Saunders et al., 2015) and detecting influenza virus (Koehorst et al., 2015). 
The purified protein was identified as Tya protein along with yeast metabolic enzymes as 
minor impurities. Though these enzymes have been co-purified with 6xHis tagged protein, 
they have not interfered with Ty-VLP particle assembly. 
4.4.2. Characterisation of purified Ty-VLPs 
Virus-like particles have been utilised in vaccine development for many purposes, such as 
subunit vaccines and gene therapy tools over the last 30 years (Zeltins 2013). Even though 
there are various methods of producing and purifying each type of VLP, the common step 
involved is their characterisation. This is important to ensure their identity before 
employment for downstream applications. Aggregate formation in purified VLP samples can 
be estimated by using size exclusion chromatography (Ladd et al., 2016), DLS and TEM. Size 
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analysis data from DLS and TEM doesn’t concur at all times, as individual particles will be 
measured by TEM and hydrodynamic diameter of aggregates will be measured by DLS (Chuan 
et al., 2008). However for Ty-VLPs DLS size data is in agreement with TEM observations and 
this indicates that Ty-VLPs are homodisperse without any aggregation. The prerequisite for 
current applications is to have intact Ty-VLPs which can hold or infiltrate plasmid DNA. So to 
investigate this, TEM was employed and successfully revealed the intact spherical morphology 
of Ty-VLPs.  
4.4.3. Synthesis and characterisation of Ty-VLP/DNA complexes 
Removal of native RNA packed inside Ty-VLPs was evident by TEM. The eGFP plasmid DNA 
was successfully complexed with Ty-VLPs and showed decent integrity as displayed by gel 
retardation assay, though the method of interaction of DNA with Ty-VLPs was undetectable 
by TEM. The commonly reported mechanisms of VLP-DNA complex formation is by 
encapsulation (Liu et al., 2001), (Zhao et al., 2000), osmotic shock (Barr et al., 1979) and direct 
interaction method (Bousarghin et al., 2002). The encapsulation process involves disassembly 
of VLPs followed by reassembly in the presence of DNA, facilitating its encapsulation. The 
limitations involved in this strategy of packing pEGFP into Ty-VLPs is their inability to 
reassemble back into their native state but forms tubules and double shelled particles (Roth 
2000). The resultant mis-shaped particles cannot be suitable for further applications. 
Therefore, direct incubation method was adapted presuming that either the pores on the 
surface of Ty-VLPs allow DNA infiltration or that the positive charge of TyA protein establishes 
electrostatic interaction with DNA. Even though there is no evidence of encapsulation of DNA, 
most of the strands were adhered to Ty-VLPs as observed by TEM. This observation concurred 
with reasonable strength of complexes by gel retardation assay and considerable transfection 
efficiency.  
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4.4.4. Cytotoxicity assay 
Estimation of cytotoxic effects of any new formulation is mandatory prior to its application in 
the vaccine field. Previous studies demonstrated the importance of conducting this assay 
before evaluating the mechanism of action or immunomodulation of a formulation 
(Maravelias et al., 2000). There are many different approaches to estimate cytotoxic effect of 
a material and is based on cell function or cell number (O'Donovan 2012) and the former is 
most commonly used. A mitochondrial enzyme activity based reagent, PrestoBlue® was used 
in this study as it was reported to be fast and sensitive in comparison to other commonly 
available reagents (Xu et al., 2015). Ty-VLPs of various concentrations ranging from 1-10 
μg/mL had no effect on dendritic cell viability. This indicates the suitability of the DC2.4 cell 
line for evaluating transfection efficiency of Ty-VLP/DNA complexes. 
4.4.5. In vitro transfection  
The eventual fate of a DNA vaccine is to reach their target site allowing expression of an 
immunogenic protein in situ. One of the most commonly used reporter plasmids to evaluate 
this phenomenon in mammalian cells is pEGFP and many recent studies reported its 
suitability to use in vitro in mammalian cells (Mousavi et al., 2016). As Ty-VLPs up to 10 μg/mL 
have no effect on cell viability (Section 4.3.5.1), approximately 3.5 μg/mL Ty-VLPs were 
applied during transfection. Ty-VLP/DNA complexes showed significant transfection efficiency 
compared to plasmid alone. A previous study reported that the probability of a cell to obtain 
none, single or multiple plasmids is the same, although a single plasmid per cell can be 
sufficient to perform its function (Materna et al., 2005). However, the current “proof of 
concept” study requires further experimentation to improve the transfection efficiency of Ty-
VLP/DNA complexes.  
                                                                                                                                                       Chapter 4 
175 
 
4.4.6. Effect of complexes incubation time on transfection efficiency 
The electrostatic interaction of negatively charged DNA with a positively charged surface 
increases with an increase in incubation time (Elaissari et al., 2015). The TyA381His protein is 
slightly basic in nature imparting a net positive charge below its PI value (Kingsman et al., 
1987). This can be the possible reason for the increase in transfection efficiency of 1:10 Ty-
VLP/DNA complexes with incubation time up to 6 hours.  
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4.5. Conclusion 
TYA381His protein purification was optimised by affinity chromatography, and an in-gel 
tryptic digest was analysed by MALDI-TOF which confirmed its identity. Purified Ty-VLPs were 
characterised using various techniques such as DLS and TEM with anticipated morphology and 
size. Ty-VLPs were successfully infiltrated with plasmid DNA and their integrity was adequate 
as observed by gel retardation assays. Further characterisation with TEM revealed the 
successful interaction of DNA with Ty-VLPs. The threshold concentration of Ty-VLPs showing 
no cytotoxic effect on DC2.4 cells was determined. The transfection efficiency of various 
ratios of complexes was analysed in vitro. Furthermore, the effect of incubation time for 
complex formation on transfection efficiency was studied. In conclusion, Ty-VLPs can act as a 
delivery system for plasmid DNA in vitro. However, further research is required to increase 
their transfection efficiency. 
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Solid lipid nanoparticle based DNA delivery system  
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5.1. Introduction 
Vaccines have been vital in the fight against infectious diseases, and over the past hundred 
years have saved millions of lives. The main types of vaccines available are subunit, live 
attenuated, inactivated, conjugate, toxoid and recombinant DNA based vaccines (Tiwle & 
Sanghi., 2014). While effective, each has their own inherent limitations. For example, subunit 
vaccines cannot induce long term immunity, whereas live, attenuated and inactivated 
vaccines can have a limited target range (Abhishek et al., 2016). High production costs make 
recombinant vector based vaccines less available to poor economies (Nascimento et al., 
2012), although WHO became involved with the HBV subunit vaccine making it available in 
poorer countries for USD1 per dose. Toxoid vaccines need multiple doses with adjuvants and 
also cause strong local reactions (Baxter 2007). Even though DNA vaccines have the 
disadvantage of being limited to protein antigens, they offer long term immunity inducing all 
arms of the immune responses (Khan 2013). Most importantly DNA vaccines are effective in 
eliciting immune responses without any side effects. The main drawback of using naked DNA 
vaccines is their difficulty to reach the target site. The main criterion for a successful DNA 
vaccine is to have an efficient delivery system to target cells. For effective DNA vaccination, 
targeting antigen presenting cells is important. The popular DNA vaccine delivery systems 
available are based on viral and non-viral systems. The viral delivery system falls into the live 
vaccine category and has safety limitations, particularly for use in immunocompromised 
individuals. Among the non-viral delivery systems available nanoparticles are gaining 
importance (Taki et al., 2015). However no nanomaterial gene delivery system has been 
approved by the US Food and Drug Administration (FDA) to date (Keles et al., 2016). Solid lipid 
nano particles are well-known among chemically synthesised nanoparticles. They are mainly 
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composed of bio compatible lipids (Neves et al., 2013) and were widely applied in cosmetic, 
food industries, drug delivery and nucleic acid delivery (Naseri et al., 2015). In the current 
study SLNs composed of new combination of cationic lipids were investigated for their ability 
to deliver plasmid DNA in vitro. As there is a demand for new vaccine strategies it is important 
to examine novel non-viral DNA vaccine delivery methods employing SLNs.  
The aims of the work described in the current chapter are to; 
1) Optimise the synthesis of solid lipid nanoparticles  
2)  Synthesise DNA-SLN complexes  
3) Characterise plain SLNs and DNA-SLN complexes 
4) Perform in vitro studies to determine transfection effeciency 
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5.2. Experimental methods 
5.2.1. Preparation and storage of SLNs  
5.2.1.1. SLN preparation 
SLNs were prepared by a modified solvent-emulsification method (Kim et al., 2008). 
Cholesteryl oleate (Sigma, 45% w/w), glyceryl trioleate (Sigma, 3% w/w), DOPE (1,2-Dioleoyl-
sn-glycero-3-phosphoethanolamine, 3-sn-phosphatidylethanolamine (Sigma, 14% w/w), 
cholesterol (Sigma, 10% w/w), and DC-cholesterol (Sapphire biosciences, 28% w/w) were 
dissolved in one volume of a chloroform/methanol mixture (2:1, v/v) and vortexed thoroughly 
after adding 5 volumes of deionised water. The suspension was sonicated on a Qsonica Q1375 
sonicator, operated at a frequency of 20 kHz with 5 sec pulses for a total of 40 cycles. The 
solvent was then removed from the microemulsion using a Heidolph rotary evaporator, at 
55°C. This was followed by freeze drying on an Operon Freeze Dryer. The powdered SLN thus 
formed was stored at 4oC until further use.  
5.2.1.2. Preparation of SLN stock solution 
A stock solution of 10 μg/mL or 15 μg/mL SLN was prepared in MQH2O. Calculated amounts 
of SLN dry powder and 0.45 μm filtered MQH2O were mixed in an Eppendorf tube and 
resuspended vigorously using a vortex mixer for 10 min. Once prepared, the stock solution 
was stored at 4oC until further use. 
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5.2.2. Steps in preparation of DNA-SLN complexes  
5.2.2.1. Amplification of plasmid DNA  
In the current study a mammalian expression plasmid, pEGFP was used as a reporter plasmid 
which contains a CMV promoter and ampicillin resistant genes. This plasmid was propagated 
in E. coli by a standard protocol (section 2.11.1) and purified using a Qiagen plasmid miniprep 
kit following the manufacturer’s instructions. 
5.2.2.2. Preparation of DNA-SLN complexes  
The DNA-SLN complexes were prepared by a co-incubation method. Calculated amounts of 
plasmid DNA and SLNs suspension were briefly vortexed and incubated at room temperature 
for 45 min to obtain different ratios of DNA-SLN complexes, i.e. 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 
1:50 and 1:100. These ratios (DNA:SLN) were selected to study the effect of various 
concentrations of SLNs and DNA on transfection efficiency. These ratios were chosen to have 
an increasing amount of SLNs with a constant DNA amount to determine the DNA holding 
capacity of SLNs. The integrity of these complexes was analysed by TEM and gel retardation 
assays. 
5.2.3. Characterisation of plain SLNs and DNA-SLN complexes 
5.2.3.1. Characterisation by TEM  
The SLNs and complexes formed were characterised for morphology, size and homogeneity 
using TEM. The samples were applied to the TEM grids by direct coating, without any post-
staining. The sample suspensions were dropped onto 200 mesh formvar-carbon copper grids 
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and allowed to dry before visualising under a JOEL 1010 microscope at an accelerating voltage 
of 80 kV. 
5.2.3.2. Determination of particle size and charge by DLS 
The size and charge of cationic SLNs and the complexes formed were determined by laser 
diffraction and light dispersion techniques using a Zetasizer Nano ZS (Malvern, UK), by 
dispersing the sample with distilled water. A 100 μL aliquot of the sample diluted in 1 mL 
distilled water was used for measurement. All the measurements were done at room 
temperature using a disposable clear zeta-cell. 
5.2.3.3. Gel Retardation assay of DNA-SLN complexes  
Various ratios of DNA-SLN complex formulations were analysed on 1% agarose gels. A 20 μl of 
sample along with 5 μL loading dye was loaded on the gel and run for 1 h at 100 V. The 
visualization of DNA-SLN complexes was facilitated with ethidium bromide staining, and the 
gel image was taken under a UV gel doc imaging system (Bio-Rad, USA). 
5.2.3.4. DNase protection study and SDS-induced release assay  
Deoxyribonuclease I (Thermo-Fisher) was added to DNA-SLN complexes to a final 
concentration of 1 U DNase I/2.5 μg DNA, and the mixtures were incubated at 37oC for 30 
min. Thereafter, a sodium dodecyl sulphate (SDS) solution was added to a final concentration 
of 1% to liberate bound DNA from the complexes. All samples were then analysed by agarose 
gel electrophoresis (section 5.2.3.3) and the release pattern was compared to the controls. 
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5.2.4. In vitro cellular assays 
5.2.4.1. Cytotoxicity assay of SLNs and DNA-SLN complexes 
The murine dendritic cell line, DC2.4, was used to study the cytotoxicity effect of different 
concentrations of SLNs and DNA-SLN complexes using PrestoBlue® cell viability reagent in a 
96-well tissue culture plate using a standard protocol (section 2.13.2). Briefly, 5 x 104 cells 
were seeded per well in a 96-well plate and SLNs or DNA-SLN complexes (1, 5, 10, 50, 100 
μg/mL) suspended in 20 μL of sterile PBS were added to a final volume of 120 μL media per 
well. At each timepoint 10 μL of PrestoBlue reagent was added to the wells and incubated for 
60 mins before measuring absorbance using the POLARstar Omega microplate reader. The 
cytotoxic effect was determined at selected timepoints of 24, 48 and 72 h and the data 
obtained were analysed statistically.  
5.2.4.2. ‘In vitro’ transfection 
 Transfection was performed using the standard protocol (section 2.13.3). The safe 
concentration of complexes to apply per well was selected based on cytotoxicity assay data. 
Briefly, 3 x 105 cells were seeded per well in 6-well plates overnight prior to transfection. The 
DNA-SLN complexes (prepared at DNA:SLN ratios of 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:50 and 
1:100) were added and cells were incubated with them in serum-free Opti-MEM media for 6 h 
at 37oC. Then the media was changed to RPMI 1640 and incubated for further 72 h before 
being analysed for GFP positive cells using a BD FACS Canto II instrument. Lipofectamine-
based transfection was used as a reference point to evaluate the in vitro transfection 
efficiency of DNA-SLN complexes.  
                                                                                                                                                       Chapter 5 
184 
 
5.2.4.3. Statistical analysis 
All the experiments were carried out in triplicate and the results were expressed as the mean 
± standard deviation. Student’s unpaired t-test and one-way ANOVA were used to analyse the 
results. 
5.2.5. DNA-SLN uptake analysis by TEM  
The fate of DNA-SLN complexes was studied using ultra-thin TEM sections. DC2.4 cells after 24 
h of transfection were used for conventional TEM sample preparation. Briefly, cells were fixed 
overnight in primary fixative of 2.5% glutaraldehyde, 2% paraformaldehyde in 100 mM 
cacodylate buffer (pH 7.4) followed by washing thrice with 100 mM cacodylate buffer. Then 
the cells were further fixed with 1% osmium tetroxide and 1.5% potassium ferricyanide for 1.5 
h followed by washing thrice with distilled water. Samples were gradually dehydrated with 
increasing gradations of ethanol from 50 to 100% for 15-30 min each time. Following 
dehydration, the cells were vacuum infiltrated and embedded in low viscosity Spurr’s resin 
(Spurr 1969). The samples were sectioned (~90 nm) into thin sections with an ultramicrotome 
and collected on 300 mesh copper grids. The grids were examined with JEOL 1010 
transmission electron microscope at an accelerating voltage of 80 kV. Non-transfected DC2.4 
cells served as a negative control. 
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5.3. Results 
5.3.1. Preparation of SLNs  
 Solid lipid nanoparticles were successfully prepared by a solvent emulsification method and 
DNA–SLN vectors prepared at different mass ratios. Formulation and process parameters such 
as type of lipid, lipid to co-lipid ratio, sonication and stirring time were sequentially optimized. 
5.3.2. Characterisation  
5.3.2.1. Characterisation by electron microscopy  
TEM revealed the spherical morphology of SLNs with a size range of 80-110 nm, with the 
majority of particles in the range of 110 nm. Interestingly, hexagonal and square shaped 
particles were revealed at higher magnification (Figure 5.1). The TEM data for plain SLN size 
concurred with the particle size obtained from DLS experiments. The complexes were self-
assembled as expected. The aggregates comprised of a minimum of four SLNs on average as 
observed at various microscopic fields of sample on TEM grid. The aggregates contained 
visible gaps between the individual SLNs, and might be the result of electrostatic interaction. 
However the integrity of these complexes can be examined with precision by gel retardation 
assays.  
5.3.2.2. Size and zeta potential of the nanoparticles by DLS  
The size, zeta potential (ζ) and polydispersity index (PDI) values are presented in Table 5.1. As 
the sample is polydisperse, intensity distribution data is represented instead of the z-average 
particle size. The mean particle size of plain SLNs is 110 nm with a zeta potential value of 71 
indicating its high stability and a net positive charge. The sizes of DNA-SLN complexes were 
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very high in comparison to plain SLNs indicating the strong electrostatic interaction between 
negatively charged DNA and positively charged SLNs. The size range of 1:1 -1:4 complexes was 
around 700 nm, and 1:5-1:100 complexes were around 400-500 nm. For 1:1 ratio complexes 
the ζ value is less, as the SLN charge might be neutralised by the equal amount of DNA. The ζ 
value increased gradually from the mass ratio 1:2 to 1:100 complexes influenced by the 
increase in positively charged SLNs in the formulations. 
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Table 5. 1. Zetapotential and size of plain SLNs and DNA-SLN complexes.  
The size is in nm and zetapotential is in mV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample name Zeta potential Size (nm) Poly 
dispersity 
index 
(PDI) 
Plain SLNs 71 110 0.545 
1:1 53.1 716.4 0.514 
1:2 72.9 735.9 0.841 
1:3 70.3 741.6 0.572 
1:4 71.9 758.7 0.603 
1:5 75.7 499.6 0.508 
1:10 78.5 480.9 0.595 
1:50 81.4 454.8 0.740 
                                                                                                                                                       Chapter 5 
188 
 
 
 
 
 
Figure 5. 1. Transmission electron micrographs of SLNs and DNA-SLN complexes. 
a) plain SLNs and b) 1:10 ratio DNA-SLN complexes. The inset for image a) is at low 
magnification indicating homogenous dispersion. All the grids were prepared by applying the 
suspension directly and allowing it to dry before observing under TEM 
 
                                                                                                                                                       Chapter 5 
189 
 
5.3.2.3. Agarose gel based assays 
5.3.2.3.1. Gel retardation assay 
 The binding potential of the DNA-SLN complex was detected by a gel retardation assay. The 
principle of this assay is that the free DNA migrates forward within the electric field, whereas 
the DNA interacting with any substance remains in the well. The free plasmid DNA in the lane 
1 (Figure 5.2a) showed complete migration, whereas all the ratios of DNA-SLN complexes 
displayed complete retardation of DNA movement. This indicates the integrity of DNA-SLN 
complexes.  
5.3.2.3.2. DNase protection assay  
A DNase protection assay was performed to analyse the level of protection of SLN bound DNA 
from DNases. The naked plasmid DNA (Figure 5.2b, lane 2) was completely digested by DNase 
in the same time. As shown in Figure 5.2b, the DNA was protected from DNase digestion in all 
ratios of DNA-SLN complexes. Despite a minor amount of DNA appearing to escape from 1:1 
to 1:50 ratio complexes, a significant amount was retarded. Thus the DNA-SLN complexes are 
largely protected against DNases. It is notable in all treatments that the ratio of relaxed 
circular to supercoiled plasmid has increased. 
5.3.2.3.3. SDS induced release assay  
An anionic detergent, SDS, was added to DNase-treated complexes to disrupt the lipid and 
DNA interaction, thereby releasing the protected DNA. This assists the evaluation of 
conformational integrity of the released plasmid. As shown in the Figure 5.2c, most of the 
DNA was released from 1:1 to 1:10 ratio complexes and appeared in its native confirmation. 
However, a very little amount of DNA was released from 1:50 and no DNA release for 1:100 
complexes. This indicates the high level of integrity of 1:50 and 1:100 ratio complexes.  
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5.3.5. Cytotoxicity assay 
 The effect of various concentrations of plain SLNs and DNA-SLN complexes on cell viability 
was studied to identify any shift in cell cytotoxicity after conjugation with DNA. The 1:10 ratio 
was used as an example to compare its cytotoxicity against plain SLNs. The cell viability was 
maintained up to 72 h for 1 and 5 μg/mL concentrations of plain SLNs and DNA-SLN 
complexes as shown in Figure 5.3. A statistically-significant reduction in cell viability was 
observed for 10 μg/mL plain SLNs compared to 10 μg/mL DNA-SLN complexes. The cytotoxic 
effect was clearly seen for 50 and 100 μg/mL plain SLNs and DNA-SLN complexes. Thus the 
maximum safe final concentration of plain SLNs and SLN/DNA complexes which can be used is 
10 μg/mL. A common observation for all the data sets is that there is a gradual increase in cell 
viability at 72 h indicating efficient recovery. In the light of these findings these SLNs can be 
considered non-toxic to cells. 
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Figure 5. 2. Agarose gel assays of various ratios of DNA-SLN complexes. 
Lane M in the above gels has Phage Lambda DNA digested with PstI  
a) Gel retardation assay: lane 1-Plasmid DNA only, 2-SLNs only, 3-10 are 1:1, 1:2, 1:3, 1:4, 1:5, 
1:10, 1:50 & 1:100 ratios of DNA-SLN complexes respectively.  
b) DNase protection assay: lane 1-Plasmid DNA, 2-Plasmid DNA with DNase treatment, 3-10 
are 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:50 & 1:100 ratios of DNA-SLN complexes treated with DNase. 
c) SDS induced release assay: 1-Plasmid DNA, 2-Plasmid DNA with DNase + SDS treatment, 3-
10 are 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:50 & 1:100 ratios of DNA-SLN complexes treated with 
DNase followed by SDS 
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Figure 5. 3. Cytotoxicity assay of a) plain SLNs and b) 1:10 DNA-SLN complexes. 
The * indicates the p value significance difference in the reduction of cytotoxicity between 
the two data sets, where ** is < 0.05 
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5.3.6. ‘In vitro’ transfection  
The transfection efficiency of various mass ratios of DNA-SLN complexes was analysed by 
measuring the GFP fluorescence from the reporter plasmid expression. All ratios of DNA-SLN 
complexes were applied to a final concentration of 7 μg/mL to each well by considering 
cytotoxicity assay observations. As shown in Figure 5.4, the transfection efficiency increased 
gradually from 1:1 to 1:50 weight ratio of DNA-SLN complexes and dropped slightly for 1:100. 
Transfection efficiency of 1:10 to 1:100 ratio complexes was almost comparable to 
lipofectamine. By considering these observations, 1:50 ratio DNA-SLN complexes can be 
utilised to achieve high transfection levels. 
5.3.7. SLNs uptake studies in DC2.4 cells  
In order to explore the uptake mechanism and fate of DNA-SLN complexes incubated with the 
dendritic cell line DC2.4, ultra-thin sections were prepared after 24 h treatment with 
complexes to view under TEM. As the lipids comprising SLNs were already stained with 
osmium tetroxide and potassium ferricyanide during the sample preparation, the particles 
had good contrast without any requirement for post-staining (Rivlin et al., 1987). The cells 
without any exposure to SLNs were used as an untreated control (Figure 5.5a). The electron 
micrograph images showed the internalisation of DNA-SLN complexes by lysosomes (Figure 
5.5b). Endosomal escape of complexes was also observed thus supporting the transfection 
data. 
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Figure 5. 4. Transfection of dendritic cells (DC2.4 cell line) in vitro with various ratios of 
DNA-SLN complexes and controls. 
The * indicates the p value significance against pEGFP alone, where *** is < 0.0001 is and 
**** is < 0.0001 
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Figure 5. 5. TEM image of DNA-SLN complexes uptake by dendritic cells. 
a) TEM image of ultra-thin sections of dendritic cells without transfection. The yellow arrows 
indicate empty lysosomes.  
b) TEM images of dendritic cells transfected with DNA-SLN complexes. Green arrows indicate 
the complex aligned onto the lysosomal membrane ready to escape, whereas the red arrow 
indicates complexes internalised 
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5.4. Discussion 
5.4.1. Synthesis of SLNs 
Solid lipid nanoparticles were previously synthesised utilising techniques such as 
homogenisation, emulsification and microemulsion using various combinations of lipids 
(Mukherjee et al., 2009). The main criterion for using SLNs for DNA vaccine delivery is to have 
a positive charge, small size and biocompatibility. To achieve this aim a modified solvent 
emulsification method was adapted to produce small size SLNs (Garud et al., 2012) in which 
cationic lipids were included along with phospholipids and this formulation was used for 
siRNA delivery successfully (Kim et al., 2008). They have also indicated that due to the 
presence of cholesteryl oleate, the melting point of which is 52°C, the SLNs exhibit a solid core 
at physiological temperature. This provides better stability to the SLNs, thereby making them 
more suited for biological applications than DC-chol/DOPE liposomes and microemulsion 
formulations. Cholesterol is a key component of the animal cell membrane. It is present in 
different proportions and affects the properties of membranes by increasing their mechanical 
strength, affecting membrane elasticity, and increasing the packing density of lipids. 
Therefore, cholesterol being a main constituent offers excellent cell membrane integration 
and uptake properties to SLNs. DOPE, a neutral phospholipid served as a helper lipid and was 
reported to increase the transfection efficiency (Mochizuki et al., 2013). DC-cholesterol was 
used as the charge modifier as the protonated form interacts with the negatively charged 
nucleic acids, thereby promoting the self-assembly of the formulation components.  
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5.4.2. Preparation of DNA-SLN complexes 
These SLNs were conjugated with plasmid DNA at various ratios. The SLN-plasmid DNA 
complexes in combination with other compounds were used for targeted gene therapy to 
lung cancer (Yu et al., 2010) and ocular diseases (Apaolaza et al., 2014) in various cell lines. A 
very similar approach of utilising cationic SLNs to deliver plasmid DNA to liver cancer cells in 
vitro was demonstrated (Bondi et al., 2007). The biocompatibility of SLNs and their effective 
use was further demonstrated in the delivery of anticancer agents to prostate and breast 
cancer cell lines (Radhakrishnan et al., 2016). The main highlight of the current study is 
investigation of transfection efficiency in dendritic cells which are the major antigen 
presenting cells of the mammalian immune system (Steinman 2007). The second highlight is 
investigation of the fate of complexes upon uptake by dendritic cells. These aspects help us to 
understand the efficiency of DNA-SLN complexes in targeting the immune system.  
5.4.3. Characterisation 
TEM and dynamic light scattering (DLS) techniques were used to characterise plain SLNs and 
DNA-SLN complexes. The synthesised plain SLNs showed an average 110 nm hydrodynamic 
size with a PDI of 0.5. DLS was used to measure self-assembly and suspension stability in this 
study. TEM was performed to obtain fine morphological details of the sample. 
Agarose gel based assays indicated the integrity of DNA-SLN complexes formed, and 
protection of DNA from DNase indicating the potential to maintain the integrity of the DNA in 
vivo. The SLN size and positive surface charge obtained are in agreement with previous 
observations and have been attributed to the presence of DC-chol and DOPE (Kim et al., 
2008). Many previous studies indicated that the average indicated diameter of a particle 
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obtained from DLS will be higher than other techniques like TEM and larger than expected 
(Domingos et al., 2009). Self-assembled DNA-SLN complexes were in the range of 200-1000 
nm as measured by DLS. PDI values suggested that the samples are polydisperse, but within 
the acceptable range (Abdellatif et al., 2016). However, the self-assembly is only a probability 
of electrostatic interactions between cationic SLN and anionic DNA (Hotze et al., 2010). A 
cartoon representing the self-assembly of DNA-SLN complexes is shown in the Figure 5.6. This 
scheme is supported by electron microscopy observations as shown in Figure 5.1. However, 
self-assembled forms can be up taken by dendritic cells, although the mechanism of uptake is 
size-dependant (Foged et al., 2005). The size range of all the complexes fits into the 
favourable uptake range by DC2.4 cells (Sharp et al., 2009). This is in good agreement with the 
observed successful transfection by the complexes (Figure 5.4). The observation of square-
shaped SLNs was also demonstrated previously and supports the current study data (Dal 
Pizzol et al., 2014). 
5.4.4. Cytotoxicity assay 
The cytotoxicity of 10 μg/mL DNA-SLN complexes was significantly low as estimated 
statistically compared to plain SLNs over 72 h. The cell viability was more than 100%, 
presumably due to the increase in cell division by lipids available from nanoparticles 
(Savonniere et al., 1996). However the higher doses of 50 and 100 μg/mL were toxic to the 
cells, as expected. This observed toxicity for higher doses of SLNs and DNA-SLN complexes 
might be due to a hormesis effect (Calabrese et al., 1997). 
5.4.5. In vitro transfection of DC2.4 cells with DNA-SLN complexes 
The in vitro transfection results showed a significant increase in transfection rate compared to 
controls. Interestingly the transfection rates of 1:10, 1:50 and 1:100 ratios of complexes were 
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comparable to that of lipofectamine. Even though lipofectamine is an established transfection 
agent in vitro, there is no evidence of its translation in vivo for biological applications and the 
results of this study suggest DNA-SLN may promote transfection comparable to lipofectamine, 
which would be beneficial in vivo. Based on these results the safe concentration of DNA-SLN 
complexes for effective transfection is within the range of 1:10 to 1:100. Hence, 1:10 DNA-
SLN complexes were used for investigation of the uptake mechanism.  
5.4.6. Cell uptake study 
The uptake studies showed the internalisation of complexes by lysosomes and endosomal 
escape. High transfection efficiency and lysosomal uptake suggest the protection of DNA 
allowing GFP expression. These results emphasize the suitability of DNA-SLN complexes for 
application in biological systems.  
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Figure 5. 6. Schematic cross sectional representation of possible self-assembly in DNA-SLN 
complexes. 
Green circles represent eGFP plasmid DNA and pale brown represent SLNs 
 
 
 
 
                                                                                                                                                       Chapter 5 
201 
 
5.5 Conclusions and future directions 
In conclusion, plasmid DNA loaded SLN were prepared and characterized to investigate their 
size, loading efficiency and in vitro transfection and expression. The results revealed that SLNs 
loaded with DNA significantly improves the transfection efficiency compared to naked 
plasmid alone. These results indicate that this system is a promising method for the non-viral 
delivery of DNA that can potentially be a basis for future DNA vaccine delivery. As the current 
SLN system proved to be efficient for plasmid DNA delivery in vitro, further research should 
involve plasmid DNA vaccines encoding antigens to investigate the repeatability of results. 
Once efficacy is demonstrated with a range of DNA vaccines, in vivo trials can be performed to 
understand the antigen presentation pathways and type of immunity elicited. 
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Immunisation by DNA vaccination is a recent invention, and by 2015 only 0.62% of DNA 
vaccine clinical trials proceeded to phase-III, with one of the main problems being cytotoxicity 
(Li et al., 2016). This indicates the importance of developing new formulations and strategies 
for delivering DNA vaccines. Non-viral DNA delivery systems have gained attention as an 
alternative to the viral vectors due to their advantages of being non-immunogenic, non-toxic 
and specific tissue targeting capability (Al-Dosari et al., 2009).  
Several DNA vaccines were commercialized for veterinary use however; they were not 
available for human application (Hasson et al., 2015). The possible barriers for a DNA vaccine 
to be commercialized for human use include safety concerns and failure to elicit an efficient 
immune response in humans (Glenting et al., 2005). More research is still required to boost 
the immune response of DNA vaccines to the levels required by human regulatory 
committees and for commercial application (Li et al., 2012). Hence to contribute to the 
development of new strategies for DNA vaccine delivery, the current study involved the 
investigation of two novel systems, Ty-VLPs and SLNs.   
The primary prerequisite for an efficient DNA vaccine is that the plasmid DNA encoding an 
immunogenic antigen needs to be expressed strongly in mammalian cells, which in turn 
requires a strong promoter (Garmory et al., 2003). A study reported that the GFP protein was 
expressed at higher levels by the CMV promoter than the CKM promoter (Bartlett et al., 
1996). Therefore, the CMV promoter within the reporter plasmid (pEGFP) can result in high 
level expression of GFP protein, making it suitable for validating the potential of delivery 
systems in the current study. 
Nanoparticles are considered suitable as delivery vehicles or adjuvants for DNA vaccines 
(Gregory et al., 2013; Sarei et al., 2013; Zhao et al., 2014), because of their potential to be 
actively up taken by mucosal surfaces (Farris et al., 2016). Therefore the study utilised two 
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delivery systems within the nano size range. Synthesis of SLNs with the desired size can be 
achieved by optimizing the synthesis parameters such as the pulse frequency of sonication 
(Siddiqui et al., 2014). The current study utilized the solvent emulsification/evaporation 
method by applying optimized sonication parameters to achieve SLN mean size of 110 nm. Ty-
VLPs of 40-60 nm size were synthesized using a recombinant construct expressing Tya protein 
up to 381 amino acids. Both Ty-VLPs and SLNs were characterized to ensure their quality and 
dispersity prior to utilizing them for plasmid DNA delivery. However, homogeneity of 
nanoparticles is not necessary for the current application.  
Toxicity of nanoparticles depends on their charge and target cell type (Frohlich 2012). Highly 
cationic polymer based nanoparticles are generally considered as cytotoxic, as they can cause 
significant physical damage to the cell membranes, lysosomes and mitochondria (Frohlich 
2012). In contrast to that, cationic SLNs reconstituted using natural components of protein-
free LDL can be less cytotoxic to cells (Kim et al., 2008). This composition with low toxic lipids 
was adapted to synthesise SLNs in this study, and also the positive charge of SLNs was further 
neutralized by the negative charge of the DNA and hence no cytotoxicity was exhibited up to 
a certain concentration. However, the overall positive charge of complexes facilitated their 
uptake by cells. Cationic peptides containing basic amino acids were reported to form stable 
complexes with DNA and showed efficient immune responses in vitro (Riedl et al., 2006). 
Similarly, the Tya subunit of Ty-VLPs has an overall positive charge, which facilitated adhering 
with DNA and delivering it to dendritic cells in vitro. However the amount of DNA that 
interacted with Ty-VLPs is low compared to that of SLNs as detected by gel retardation assay 
and needs to be further improved. 
Previous studies indicated that flow cytometry is a reliable and sensitive technique to detect 
GFP fluorescence from a reported plasmid (Soboleski et al., 2005). Therefore, the current 
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study utilised flow cytometry to measure expression of pEGFP reported plasmid to estimate 
the DC2.4 cells plasmid uptake efficiency. The transfection efficiency of SLNs was 
demonstrated to be equal to that of lipofectamine, indicating its potential DNA-holding 
capacity and substantial release within the cell for its expression. 
The immune response elicited by the DNA vaccines can be significantly increased by 
improving their uptake by dendritic cells (Kutzler et al., 2004; Tsen et al., 2007). Dendritic cells 
are a main type of professional antigen-presenting cells which have a role in activating naive 
T-cells (Banchereau et al., 1998; Ni et al., 1997; Sprent 1995). Dendritic cells can express 
antigen from DNA vaccines by themselves or respond to antigen produced by other cells 
(cross presentation), which makes them a preferred target for DNA vaccines (Steinman 2013). 
Dendritic cells preferentially uptake particles up to 500 nm size, however larger particle 
uptake can be enhanced by increase in their surface positive charge (Foged et al., 2005). In 
the current study both type of delivery systems utilized were within the preferred size to be 
up taken by dendritic cells with no cytotoxicity; hence the likelihood to translate these 
delivery systems in vivo is good. 
The work conducted in this proof of concept study demonstrated that both the systems (Ty-
VLPs and SLNs) were suitable for plasmid DNA delivery. SLNs demonstrated high transfection 
efficiency compared to that of Ty-VLPs. So, more work needs to be done to improve the DNA 
binding capacity of Ty-VLPs by attaching a cationic peptide to the Tya subunit. The study was 
conducted using a reporter plasmid, pEGFP, and further studies need to be performed by 
employing a DNA vaccine encoding an antigenic part of pathogen in vitro. The future work 
also should comprise investigating the type of immune responses elicited in vivo
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Appendix 1 
 
 
Figure A 1. Phage Lamda DNA digested with PstI 
                                 
The DNA fragments of various sizes were seperated on 1.5% agarose gel electrophoresis and 
the sizes of fragments were as shown. Figure adapted from GENEON product information 
sheeth 
 
 
                                                                                                                                           Appendices                                  
238 
 
 
 
Appendix 2 
 
 
 
a) SDS-PAGE gel staining- Precision Plus Protein™ Unstained Protein Standard (Bio-Rad, USA) 
and b) Western blotting-Precision Plus Protein™ Kaleidoscope™ Prestained Protein Standard 
(BIO-Rad, USA). 
 
  
Figure A 2. Standard protein markers used. 
